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INTRODUCTION
A historical perspective
It seems likely that mycobacterial existence, including its most famous and infamous family 
member,Mycobacterium tuberculosis (MTB), goes back as far as 40,000 years (1). Throughout Egyptian 
dynastic times paintings were made depicting angular spinal deformities characteristic of tuberculous 
spondylitis. In mummies from several Egyptian sites skeletal changes typical of tuberculosis were 
observed, further supporting the notion that the skeletal changes were due to tuberculosis (TB). (2) 
In ancient times TB was known as ‘consumption’ and ‘white plague’. Hippocrates, the ‘father of the 
western medicine’, identified ‘phthisis’ (consumption) as the most widespread and fatal disease of his 
time.
Another important moment in the history of tuberculosis occurred on the evening of 24 March, 1882. 
For the first time the causal agent of tuberculosis was discovered and presented that evening in Berlin. 
Robert Koch described the importance of this discovery: ‘If the importance of a disease for mankind 
is measured by the number of fatalities it causes, then tuberculosis must be considered much more 
important than those most feared infectious diseases, plague, cholera and the like. One in seven of all 
human beings dies from tuberculosis’. For his investigations and discoveries regarding tuberculosis he 
was awarded the Nobel Prize in Physiology or Medicine in 1905. (2) Now, more than 130 years later, 
Robert Koch’s words are, unfortunately, still valid. TB is second only to human immunodeficiency 
virus (HIV) as the most fatal single infectious agent, comprising in 1.3 million deaths in 2012. A third 
of the world’s population is latently infected with MTB, which led to 8.6 million active infections 
in 2012 (3). In Koch’s time there was no way of preventing TB. With his knowledge of the causative 
agent, the means of transmission was identified in the following decades. In addition, breakthroughs 
in immunology research resulted in a vaccine that is still in use. Bacille Calmette Guerin (BCG)was 
first implemented in the 1920s and is now one of the most used vaccines worldwide. It is still widely 
used in high burden countries, leading to an enormous decrease in both MTB-related and unrelated 
infant mortality and morbidity. Unfortunately, this vaccine is not particularly effective at preventing 
the main disease presentation of TB, adult pulmonary TB.
When preventive strategies are lacking, managing the disease becomes even more important. In the case 
of many infectious diseases, to conquer them one needs besides antimicrobial agents a solid immune 
response. The importance of an intact host immune system in fighting TB is underlined in fact that the 
HIV epidemic led to an explosive increase in both incidence and mortality of TB. Additionally, TB risk 
groups in low incidence areas include patients who are deliberately being immunocompromised as an 
(un)intended part of their treatment of other diseases (e.g. transplantation, autoimmune diseases, and 
cancer). The following paragraph will elaborate on the important processes in the immune response 
to MTB.
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Host defence against mycobacteria
Host response to microbial threats comprises of a few vital steps. In order to pose a threat the first 
barrier for microorganisms to overcome is to enter the body. When present in the tissue they will 
come into contact with the immune system, with resident macrophages being among the first types 
of cells. MTB enters the body through the respiratory system, resulting in a major role for the alveolar 
macrophages. The following crucial step is recognition; innate immune cells sense pathogen associated 
molecular patterns (PAMPs) through an array of pattern recognition receptors (PRRs) in and on these 
cells. Recognition leads to activation of that cell, triggering events such as the production and release of 
chemokines and cytokines, phagocytosis and destruction of the pathogen, and attraction of other cells 
to the inflammation site (Figure 1). The monocyte/macrophage is a pivotal cell in the host response to 
MTB as it is involved in phagocytosis and killing of the mycobacteria, as well as in the initiation of the 
adaptive immune response through antigen presentation.
There are a few distinct outcomes possible after that first encounter: the macrophage successfully 
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Figure 1. Schematic overview of host response of macrophages to mycobacteria. Host response to mycobacteria starts 
with recognition of the mycobacterium by PRRs (1), their activation subsequently leads via signalling pathways to the 
following set of actions. Production of cytokines like TNFa and IL12 is initiated through transcription factors that migrate 
to the nucleus (2). Production of IL1β and IL18 need to be cleaved by the inflammasome after transcription before they 
can be secreted. Macrophages will phagocyte mycobacteria (3) and try to degrade them via various mechanisms like 
acidification of phagolysosomes, oxidative stress from reactive nitrogen intermediates, or autophagy. These degraded parts 
of the mycobacteria can be used by macrophages to present them to T cells in order to start the adaptive part of the immune 
response. The activation of T cells leads subsequently to production of cytokines like the vital IFNg. All the cytokines result 
in attraction of other immune cells to the site of inflammation (5).
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kills the mycobacterium in that instance (early clearance) (4); however, mycobacteria possess 
strategies to escape the initial intracellular destruction that will lead to multiplication of the bacteria 
and disruption of the harbouring cell. Outside the cell, mycobacteria can grow even more rapidly, 
resulting in attraction of other monocytes and macrophages that will subsequently be infected (5). 
When thereafter T cells are attracted, the adaptive response to TB starts. When this infection cannot 
be contained, primary TB will occur. Besides monocytes and T cells, B cells, NK cells, and neutrophils 
are attracted to the inflammation site forming a ‘granuloma’ (Figure 2). This granuloma symbolizes an 
equilibrium state for mycobacteria and the immune system, resulting in the hallmark of TB infection: 
its latency. Which way the balance is tipped during life is largely dependent on the quality of the 
immune system, resulting in either postprimary TB or only a detectable adaptive immune response to 
MTB.
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Figure 2. Schematic overview of a granuloma. When macrophages fail to degrade engulfed mycobacteria these 
mycobacteria can multiply in the cells resulting in disruption of the harbouring cell. Attracted to this inflammation site 
immune cells like monocytes, T cells, B cells, NK cells, and neutrophils will try to wall off this potential threat. This 
organised structure of cells surrounding mycobacteria is called a ‘granuloma’. This is an efficient way of trimming down 
the immune response however, it also forms a fertile environment for mycobacteria to grow. This equilibrium state for 
mycobacteria and the immune system can last for several years.
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Essential components of innate immune response to MTB
Macrophages and monocytes are some of the most important cells in the innate immune response to 
MTB. They are the first cell types coming into contact with the mycobacteria and have capabilities of 
phagocytosis and destruction of the pathogen through either acidification of phagolysosomes, oxidative 
stress from reactive nitrogen intermediates, or autophagy (a process in which cytoplasmatic cargo is 
targeted for degradation in specialized structures called autophagosomes). In addition, they produce 
important cytokines: tumour necrosis factor a (TNFa), interleukin 1β (IL1β), interleukin 12 (IL12), 
and interleukin 18 (IL18). The other vital cytokine interferon g (IFNg) is produced by T cells and NK 
cells, enabling macrophages to kill mycobacteria probably partly by inducing autophagy. Autophagy, 
the cellular machinery for targeting intracellular components for lysosomal degradation, has an 
essential role in antimycobacterial host defence (6). Besides inhibiting intracellular mycobacterial 
survival, autophagy facilitates antigen presentation and T cell activation, and modulates production 
of proinflammatory cytokines (6, 7). Although it is considered an essential component of host defence 
against MTB, what drives autophagy and what influences it is not completely known. One cytokine 
can activate autophagy is IFNg that subsequently activates macrophages to kill and eliminate the 
mycobacteria. It also enhances macrophage expression of MHC class II molecules, which results in 
improved antigen presentation to T cells. IFNg is secreted by NK, CD4+, and CD8+ T cells upon release 
of endogenous IL12 and IL18 by macrophages and dendritic cells. The crucial importance of IFNg  for 
human antimycobacterial defence is demonstrated by the increased susceptibility to mycobacterial 
infections in patients with IFNg receptor or IL12 receptor deficiencies (8-10). The importance of other 
cytokines is proved by murine models deprived of these cytokines or signalling pathways (TNFa (11, 
12). IL1β (13, 14)), leading to increased bacterial numbers, defective granuloma formation, and poorer 
survival. Knowing the importance of these cytokines raises the questions of how these cytokines are 
produced, what influences their production, and whether we can identify groups at risk with defects 
in this production.
Therefore, we focus in part one of this thesis on cytokine production, the role of autophagy, and their 
interplay in host response to MTB in order to provide insight in TB pathogenesis and crucial immune 
processes which may eventually translate in TB treatment improvement.
One of the key cytokines in TB infection IL1β (13) is produced in two steps. The transcription results 
in pro-IL1β that needs to be processed to IL1β by caspase-1. Which steps in recognition and signalling 
are vital in MTB-induced IL1β production are not known. In Chapter 2 we therefore investigate the 
mechanisms responsible for IL1β activation and processing in MTB infection in human monocytes and 
alveolar macrophages.
In Chapter 3 we study the effect of autophagy on production of monocyte and T cell-derived 
cytokines induced by MTB. In addition, we examine the impact of two functional single nucleotide 
polymorphisms (SNPs) in autophagy genes on MTB induced cytokine production.
In Chapter 4 we elaborate on autophagy and its role in MTB. We examine twenty-two polymorphisms 
in fourteen autophagy genes in a large cohort of Indonesian TB patients and controls. In these patients 
we furthermore investigate a possible association between these SNPs and the MTB genotype. In 
addition, we search for differences in cytokine production in another cohort that is genotyped for 
14
these SNPs. In Chapter 5 we provide a general overview of the innate immune recognition of MTB, the 
first step in the host response.
Innate memory
All immune responses are divided into an innate part and an adaptive part, and although the influence 
of one on the other is generally recognised, they remain two distinct processes. The innate immune 
system is the first line of defence; it is fast but does not adapt. The adaptive immune cells take a longer 
time but produce an immune response specific to the microbial threat, and are able to remember this.
However, this traditional dichotomy is now being challenged. More and more reports are being 
published lately on the memory properties of innate immune cells, recently termed ‘trained immunity’ 
(15). However, the subject is by no means novel; this phenomenon has been acknowledged in plant and 
invertebrates immune systems (16, 17) for decades, and the first papers on the memory properties of 
innate immune cells in mammals were also written years ago (18, 19). BCG could protect mice deprived 
of functional T and B cells from a subsequent infection with Schistosoma mansoni (18). In addition, 
macrophages were found to have increased functions after BCG exposure, leading in an in vivo model to 
decreased outgrowth of Candida albicans in that infection (19).
Besides these observations in mice, large epidemiological studies showed a survival benefit in children 
vaccinated with BCG beyond the disease burden of TB (20-22). These non-specific effects have been 
described for years; however, without a biological explanation they have been met with scepticism.
Therefore, the aim of the second part of this thesis is to elucidate the biological mechanism of 
nonspecific effects of BCG on the innate immune system.
Trained immunity is a process of improved reaction of innate immune cells after an initial stimulus (for 
example BCG) to reinfection with the same or a different pathogen. In Chapter 6 we aim to describe 
the process of BCG-induced trained immunity in detail. We study monocytes of healthy volunteers 
that have been BCG vaccinated in their response to reinfection in order to describe which receptors 
and intracellular signalling pathways are responsible for this phenomenon. In addition, we decipher 
the involved molecular mechanisms. As this phenomenon has potentially major (clinical) implications, 
its longevity is a key element and consequently is our focus in Chapter 7. Using the same population 
of BCG vaccinated persons as in the previous chapter, we study the described changes over a longer 
period. While the previous chapters focus on monocytes, trained immunity is a description of improved 
responses of innate immune cells, and could therefore potentially occur in all the innate immune cells.
Hence, we question in Chapter 8 what the role of NK cells would be in BCG induced trained immunity. 
Using the same methods as in the previous two chapters, we investigate whether we can extend our 
conclusions about monocytes to other innate immune cells.
In Chapter 9 we give an overview of the available literature on the heterologous effects of vaccines 
centred around the effects of BCG.
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ABSTRACT
Proinflammatory cytokines of the IL1 family play an important role for the anti-mycobacterial host 
defence mechanisms. In the present study we have deciphered the pathways leading from recognition 
of Mycobacterium tuberculosis to the production and release of IL1β, the most important member 
of the IL1 family. By stimulating cells defective in various pattern recognition receptors, we could 
demonstrate that IL1β production is induced by M. tuberculosis through pathways involving TLR2/
TLR6 and NOD2 receptors. In contrast, TLR4, TLR9 and TLR1 receptors are not involved in IL1β 
induction. Recognition of M. tuberculosis by TLR and NOD2 leads to transcription of proIL1β through 
mechanisms involving ERK, p38 and Rip2, but not JNK. Interestingly, although caspase-1 is necessary 
for the processing of proIL1β, activation of caspase-1 is not dependent on the stimulation of cells by M. 
tuberculosis. Monocytes expressed constitutively active caspase-1. The secretion of IL1β is dependent 
on the activation of P2X7-induced pathways by endogenously released ATP. In conclusion, we have 
dissected the molecular mechanisms responsible for IL1β production by M. tuberculosis, and that may 
contribute to a deeper knowledge of the mechanisms of cell activation by M. tuberculosis.
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INTRODUCTION
It is estimated that approximately one-third of the world population is infected with Mycobacterium 
tuberculosis, the agent causing tuberculosis (TB), although only 5% of these individuals will eventually 
develop clinical disease. The WHO estimated that 1.6 million deaths resulted from TB in 2005, equalling 
4400 deaths a day (1). The highest rates of infection and especially the mortality are seen in the 
developing countries, and rates continue to climb in countries where the prevalence of HIV infection 
is high, despite the implementation of TB control programs (2). Furthermore, the increased prevalence 
of multidrug-resistant strains of M. tuberculosis represents a challenge for treatment programmes (3).
The first line of defence against M. tuberculosis is formed by alveolar macrophages, which ingest and 
sequester the bacilli within granulomatous structures. The control and resolution of the infection 
involve the activation of macrophages, in which activated T lymphocytes play a crucial role (4). The 
release of proinflammatory cytokines such as IL1β, TNFa, IL12 or IL18 from monocytes and monocyte-
derived macrophages induces the production of T cell-derived cytokines, most importantly IFNg, 
which in turn will activate macrophages for the killing and elimination of the microorganisms (5,6). 
Patients with defects in receptors for IL12 and IFNg have an increased susceptibility to mycobacterial 
infections (7–9), while the association between low CD4 counts and TB is well-known in HIV-infected 
patients (2).
While most of the research has focused on the mechanisms responsible for the IFNg induction, 
relatively little is known about the mechanisms leading to the production and release of the first wave 
of cytokines that are needed for the activation of T cells. While TNFa is known to be important for 
the integrity of the granuloma, two of the cytokines of the IL1 family, IL1β and IL18, are considered to 
be crucial for the induction of IFNg. IL1-mediated signals have been recently demonstrated to be an 
essential component of the MyD88-dependent innate response to M. tuberculosis infection, while IL18-
dependent pathways seemed to be dispensable (10).
In contrast to other proinflammatory cytokines, IL1β lacks a signal peptide (11). After transcription 
and translation, pro-IL1β is processed by the cysteine protease caspase-1, followed by secretion from 
the cell (12). Activation of caspase-1 requires generation of a protein complex called the inflammasome, 
which recognizes specific ligands such as muramyl dipeptide, ATP or uric acid leading to caspase-1 
activation (13). Detection of the PAMP or danger signals in the inflammasome is achieved by proteins 
of the NOD-like receptor family such as NALP3, NALP1 or IPAF, leading to a conformational change 
and caspase-1 activation (14). Caspase-1 activity is essential in host defence against infection with 
Francisella tularensis (15), Legionella pneumophila (16), Shigella (17) and Pseudomonas aeruginosa (18). The fact 
that IL1β and IFNg play an important role during infection with M. tuberculosis and are regulated by 
caspase-1 activity suggests that inflammasome activation may be important for anti-mycobacterial 
defence mechanisms. In the present study, we investigate the mechanisms responsible for IL1β 
activation by M. tuberculosis in human monocytes and alveolar macrophages, including the receptor 
pathways leading to pro-IL1β mRNA transcription and the mechanisms of caspase-1 activation.
20
MATERIALS AND METHODS
Volunteers
Blood was collected from ten healthy, non-smoking volunteers who had no infectious or inflammatory 
disease at the time of the study. In addition, blood was collected from 74 patients with Crohn’s disease, 
and the presence of the 3020insC NOD2 polymorphism was analyzed by Genescan analysis on an ABI-
Prism 3100 Genetic Analyzer, as previously described (19). Four patients with Crohn’s disease were 
found to be homozygous for the 3020insC mutation, and they were further investigated in the cytokine 
studies. None of the patients with Crohn’s disease used immunosuppressive medication at the time 
of the study. The study was approved by the Ethics Committee of the Radboud University Nijmegen. 
In addition, alveolar macrophages collected from healthy volunteers by bronchoalveaolar lavage were 
suspended to a concentration of 5×106 cells/mL and stimulated for cytokine production.
Microorganisms and reagents
Cultures of M. tuberculosis H37Rv were grown to mid-log phase in Middlebrook 7H9 liquid medium 
supplemented with oleic acid/albumin/dextrose/catalase (Difco, Becton-Dickinson, Palo Alto, CA), 
washed three times in sterile saline, and resuspended in RPMI 1640 medium at various concentrations. 
Separate culture suspensions were sonicated for 10 min on ice, in order to obtain cell lysates. The 
irreversible caspase-1 inhibitor Ac-Tyr-Val-Ala-Asp-2,6 dimethylbenzoyloxymethylketone was 
purchased from AlexisBiochemicals (San Diego, CA). The inhibitor was reconstituted in 10 mM DMSO 
and subsequently diluted to the desired concentration in RPMI. SB202190, p38/Rip2 MAPK inhibitor 
(p38-i); SP600125, JNK1/2/3 inhibitor (JNK-i) and U0126 MEK1/2 inhibitor (Erk-i) were purchased 
from Superarray Bioscience Corporation (Bethesda, MD). In experiments using pharmacological 
inhibitors, control cells were treated with an equivalent concentration of vehicle (0.01–0.1% DMSO).
Isolation of PBMC and stimulation of cytokine production
After informed consent, venous blood was drawn from the cubital vein of patients and healthy 
volunteers into three 10mL EDTA tubes (Monoject, s-Hertogenbosch, Netherlands). Isolation of 
PBMC was performed as described elsewhere (47), with minor modifications. The PBMC fraction 
was obtained by density centrifugation of blood diluted 1:1 in pyrogen-free saline over Ficoll–Paque 
(Pharmacia Biotech, Uppsala, Sweden). Cells were washed twice in saline and suspended in culture 
medium (RPMI 1640 DM) supplemented with 10 μg/mL gentamicin, 10 mM L-glutamine and 10 mM 
pyruvate. The cells were counted in a Coulter counter (Coulter Electronics, Mijdrecht, Netherlands), 
and the number was adjusted to 5×106 cells/mL.
PBMC (5×105) were added in a 100 μL volume to round-bottom 96-well plates (Greiner, Alphen, 
Netherlands), incubated with 100 μL of culture medium (negative control) or M. tuberculosis bacteria 
(1×105 mo/mL), with or without caspase-1 inhibitor at different concentrations. In some blocking 
experiments, PBMC were preincubated for 1 h with the inhibitors p38-i 20 nM, Erk-i 10 nM, or JNK-i 
25 nM, before the stimulation with M. tuberculosis. The role of the endogenous ATP release for the 
stimulation of IL1β was investigated by blocking P2X7 receptors with oxATP (300 μM) during the 
stimulation of cells for 24 h with LPS (20). The stimuli were checked for the contamination with LPS in 
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the Limulus amoebocyte lysate assay and was found to be negative. In addition, alveolar macrophages 
collected from healthy volunteers by bronchoalveaolar lavage were suspended to a concentration of 
5×106 cells/mL and stimulated for cytokine production.
Cytokine production by murine peritoneal macrophages
Resident peritoneal macrophages were harvested from either control mice or mice deficient for the 
various TLR or adaptor molecules. TLR1-/-, TLR2-/-, TLR4-/-, TLR6-/-, TLR9-/- and MyD88-/- mice 
back-crossed to the seventh generation into the C57Bl/6J background were kindly provided by S. 
Akira (Osaka University, Japan). TRIF-defective mice (Lps2 strain) were a kind donation of B. Beutler 
(Scripps Institute, San Diego). After centrifugation and washing, the cells were resuspended in RPMI 
1640 containing 1 mM pyruvate, 2 mM L-glutamine, 100 μg/mL gentamicin and 2% fresh mouse plasma. 
Cells were cultured in 96-well microtiter plates (Greiner) at 1×105 cells/well, in a volume of 100 μL. The 
cells were stimulated with M. tuberculosis (1×105 mo/mL). After 24 h incubation at 37°C, the supernatants 
were collected and stored at −20°C until cytokine assays were performed.
Cytokine and ATP measurements
Human and murine cytokine concentrations were measured by commercial ELISA kits (Pelikine 
Compact, CLB, Amsterdam, Netherlands), according to the instructions of the manufacturer. ATP 
concentrations in the supernatants were assessed using a firefly luciferase assay (ATP determination 
kit, Invitrogen, Carlsbad, CA).
Caspase‐1 colorimetric assay
In order to assess the functional activity of caspase-1, PBMC were incubated for 2 h with either RPMI 
or various stimuli. Cells were lysed and caspase-1 activity was assessed using a commercial colorimetric 
assay (R&D Systems, Minneapolis, MN).
Western blot assays
After stimulation with either RPMI or M. tuberculosis for 2 h, PBMC (107 cells/well in a total volume of 
1 mL) were lysed in 100 μL lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 10% 
glycerol, 1% Triton X-100, 40 mM glycerophosphate, 50 mM sodium fluoride, 200 μM sodium vanadate, 
10 μg/mL leupeptin, 10 μg/mL aprotinin, 1 μM pepstatin A and 1 mM phenylmethylsulfonyl fluoride). 
Following centrifugation (10  rpm, 5 min), the protein content was determined by BCA protein assay 
(Pierce) and equal amounts of protein were loaded on 12% SDS-PAGE and transferred onto nitrocellulose 
membranes. For caspase-1 quantitations, membranes were incubated with specific caspase-1 p10 
polyclonal antiserum (1/500) and procaspase-1 polyclonal antiserum (1/500) (Santa Cruz). β-actin was 
quantified as an internal control using specific anti-β-actin polyclonal antiserum (1/1000) (Santa Cruz). 
Blots were washed and incubated with peroxidase-conjugated goat anti-rabbit IgG (1/1000 dilution). 
After washing the blots three times with TBS-T the blots where developed with hyperECL according 
to manufacturer’s instructions (GE Healthcare). In addition, supernatants of PBMC stimulated for 24 h 
with either RPMI or M. tuberculosis and were assessed for the presence of pro-IL1β and IL1β. Membranes 
were incubated with anti-(pro)I1β polyclonal antibody (1/1000 dilution) (Cell Signaling), while the rest 
of the procedure was similar with that employed for caspase-1 Western blots.
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Quantitative PCR
PBMC were stimulated as described under the section Isolation of PBMC. After 4 h, the supernatant 
was removed and the cells were resuspended in 200 μL RNAzolB RNA isolation solvent (Campro 
Scientific) and stored at −80°C. mRNA was isolated following the manufacturer’s protocol. 
The amount and quality of mRNA were determined using a NanoDrop® ND-1000 UV–Vis 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). cDNA was synthesized from using 
Superscript Reverse Transcriptase (Invitrogen). Relative mRNA levels were determined using the 
Biorad I-Cycler and SYBR Green method (Invitrogen) The following primers were used: IL1β forward 
(5′-TGGCCCAGGCAGTCAGA-3′), and reverse (5′-GGTTTGCTACAACATGGGCTACA-3′); β2 M 
forward (5′-ATGAGTATGCCTGCCGTGTG-3′) and reverse (5′-CCAAATGCGGCATCTTCAAAC-3′) 
(Biolegio, Malden, Netherlands).
Statistical analysis
The differences between groups were analyzed by the Mann–Whitney U test, and where appropriate 
by the Wilcoxon rank test to determine differences between groups where p <0.05. All experiments 
were performed at least twice, and the data presented as the cumulative result of all experiments 
performed. Data are given as means ±SD.
RESULTS
M. tuberculosis induces IL1β production through caspase‐1‐dependent mechanisms
PBMC produced significant amounts of IL1β when stimulated with TLR2 (Pam3Cys) and TLR4 (LPS) 
stimuli, as well as with M. tuberculosis (Figure 1A). Both heat-killed and live M. tuberculosis stimulated 
comparable amounts of IL1β. Primary alveolar macrophages isolated from healthy volunteers also 
released IL1β after stimulation with M. tuberculosis (Figure 1B). The transcription of pro-IL1β mRNA 
was stimulated by mycobacteria (Figure 1C), and this resulted in the release of active IL1β in the 
supernatant (Figure 1D). The release of the mature form of IL1β from the cell was dependent on 
caspase-1 (Figure 1E).
Both TLR2/TLR6 and NOD2 pathways mediate induction of IL1β by M. tuberculosis
When murine macrophages isolated from the various mouse knock-out strains were stimulated with 
M. tuberculosis, cells from TLR2-/- and TLR6-/- mice released significantly less IL1β compared with wild-
type controls (Figure 2A and B), similar to stimulation induced by the specific TLR2 agonist Pam3Cys 
(not shown). In contrast, macrophages from TLR4-/- and TLR1-/- mice released normal amounts of 
IL1β (Figure 2C and D). TLR9 had no role in the stimulation of IL1β after challenge with M. tuberculosis 
(Figure 2E). LPS and CpG induced cytokine production only in wild-type macrophages, but not 
in cells isolated from TLR4-/- or TLR9-/- mice, respectively. Interestingly, PBMC from individuals 
defective in NOD2 function (Crohn’s disease patients homozygous for the 3020insC NOD2 mutation) 
(19) stimulated with M. tuberculosis released significantly less IL1β than either healthy volunteers or 
Crohn’s disease patients homozygous for the wild-type NOD2 allele (Figure 2F).
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Figure 1. M. tuberculosis induces IL1β production through caspase‐1‐dependent mechanisms. (A) Human PBMC were 
stimulated with Pam3Cys (1 μg/mL), LPS (10 ng/mL), heat-killed, or live M. tuberculosis (1×105 mo/mL) for 24 h at 37°C. IL1β 
in supernatant was measured by ELISA. (B) Human primary alveolar macrophages isolated from healthy volunteers were 
stimulated with M. tuberculosis (1×105 mo/mL) for 24 h at 37°C. IL1β in supernatant was measured by ELISA. (C) Human 
PBMC were stimulated with M. tuberculosis (1×105 mo/mL) for 4 h at 37°C. The transcription of pro-IL1β mRNA was assessed 
by RT-PCR. (D) Western blot for pro-IL1β and IL1β of the supernatants of PBMC stimulated for 24 h with either RPMI 
or M. tuberculosis (1×105 mo/mL). (E) Human PBMC were stimulated with M. tuberculosis (1×105 mo/mL), in the presence or 
absence of a caspase-1 inhibitor (10 mM) for 24 h at 37°C. IL1β and IL6 in the supernatant were measured by ELISA (n=10, 
mean±SEM, *p<0.05 by Wilcoxon signed rank test
The intracellular pathways leading to IL1β mRNA transcription involve MyD88 and ERK/
p38 kinases
To assess the role of the intracellular pathways involved in the induction of IL-1β by M. tuberculosis, 
cells from MyD88-/- and TRIF-defective mice were stimulated with the microorganisms for 24 h. IL1β 
production was strongly dependent on MyD88, but not on TRIF (Figure 3). In addition, stimulation of 
IL1β in PBMC by M. tuberculosis was mediated by the ERK, as well as p38 and/or Rip2 kinases, but not 
by JNK (Figure 4A). Quantitative PCR analysis demonstrated that p38 and ERK inhibitors decreased 
IL1β mRNA expression (Figure 4B). In line with these data, pro-IL1β intracellular concentrations 
were decreased by 55–70% by addition of p38 and/or ERK inhibitors (not shown). Similar effects 
were observed for the induction of IL6 production. In contrast, the induction of TNFa was regulated 
through ERK and JNK-dependent pathways, while blockade of p38 had no effect (Figure 4A).
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Figure 2. The role of TLR and NOD2 pathways for the induction of IL1β by M. tuberculosis. Murine macrophages 
isolated from TLR2-/- (A), TLR6-/- (B), TLR4-/- (C), TLR1-/- (D) and TLR9-/- (E) mice were stimulated for 24 h at 37°C 
with 1×105 mo/mL M. tuberculosis. The experiments were performed in twice with ten mice/group. IL1β and TNFa in the 
supernatant were measured by ELISA. (F) PBMC from individuals defective in NOD2 function (n=4, NOD2 def, white 
bars), Crohn’s disease patients with wild-type NOD2 (n=4, NOD2wt, gray bars) and healthy volunteers (n=10, black bars) 
were stimulated for 24 h at 37°C with 1×105 mo/mL M. tuberculosis (mean±SEM, *p<0.05 by Wilcoxon signed rank test).
Figure 3. The role of MyD88 and TRIF pathways for the induction of IL1β by M. tuberculosis. Murine macrophages 
isolated from MyD88-/-(A) and TRIF-/- (B) mice were stimulated for 24 h at 37°C with 1×105 mo/mL M. tuberculosis. IL1β and 
TNFa in the supernatant were measured by ELISA (n=10, means ±SEM, *p <0.05 by Wilcoxon signed rank test).
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Figure 4. The role of intracellular kinase pathways for the induction of IL1β by M. tuberculosis. (A) PBMC were 
preincubated for 1 h with the inhibitors for the kinases p38 (20 nM), Erk (10 nM), or JNK (25 M), before the stimulation for 
24 h at 37°C with M. tuberculosis (1×105 mo/mL). IL1β, IL6 and TNFa in the supernatant were measured by ELISA (n=6, means 
±SEM, *p <0.05 by Wilcoxon signed rank test). (B) Inhibitors of p38 and ERK kinases decreased the expression of IL1β 
mRNA after 4 h stimulation of PBMC with M. tuberculosis, as assessed by quantitative PCR (one representative experiments 
out of three performed).
Figure 5. Mechanisms involved in the processing and secretion of IL1β. (A) Western blots of the inactive (p45) 
and active (p10) caspase-1 fragments in monocytes isolated from healthy volunteers, either not stimulated (RPMI), or 
stimulated with LPS or M. tuberculosis (MTB). One representative experiment out of three experiments is presented. (B) The 
role of the endogenous ATP release for the stimulation of IL1β was investigated by blocking P2X7 receptors with oxATP 
(300 μM) during the stimulation of cells for 24 h with M. tuberculosis. Mature IL1β concentrations were measured by ELISA 
in both PBMC lysates and supernatants. (n=6, means ±SEM, *p <0.05 by Wilcoxon signed rank test). (C) Diagram depicting 
the pathways leading to IL1β production and release induced by M. tuberculosis.
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Posttranslational mechanisms involved in the processing and secretion of IL1β
Active caspase-1 is important for the processing and release of IL1β. Surprisingly, unstimulated 
monocytes expressed both the inactive (p45) and the active forms of caspase-1 (p10) even before 
stimulation, while LPS and M. tuberculosis had little additional activating effects (Figure 5A). These 
data were supported using a functional colorimetric assay that showed that in contrast to control 
medium alone (11±3 conventional units/mL), lysates of freshly isolated PBMC contained 91±15 units/
mL caspase-1. The secretion of IL1β has been reported to be mediated by the interaction between 
endogenous ATP and P2X7 receptor (20). This was also the case for the induction of IL1β by M. 
tuberculosis, as intracellular IL1β was present in high concentrations in PBMC stimulated with 
mycobacteria (2780±765 versus 20±10 pg/mL in unstimulated cells, p<0.01), while blockade of P2X7 
with oxATP significantly inhibited the IL1β release (Figure 5B). This suggested that endogenous ATP 
was present in the supernatants: indeed, endogenous ATP was released in the supernatants by primary 
human monocytes (3.5±0.7 nM).
DISCUSSION
Cytokines of the IL1 family play an important role for the anti-mycobacterial host defence mechanisms. 
In the present study we have deciphered the pathways leading from recognition of M. tuberculosis to the 
production and release of IL1β, one of the most important proinflammatory cytokines. By stimulating 
cells defective in various pattern recognition receptors, we demonstrate that IL1β production is 
induced by M. tuberculosis through pathways involving TLR2/TLR6 and NOD2 receptors. This leads 
to transcription of IL1β through mechanisms involving ERK, p38 and Rip2. Interestingly, although an 
active caspase-1 is required for the release of active IL1β, its activation was only moderately dependent 
on the stimulation of cells by M. tuberculosis, due to the presence of constitutively active caspase-1 in 
human primary monocytes.
The importance of understanding the mechanisms responsible for IL1β production by M. tuberculosis is 
underlined by the fact that an intact IL1-mediated signal is an essential component of the host defence 
to mycobacteria (10,21,22). Aerogenic infection with M. tuberculosis proved fatal for IL-1RI-/- mice, 
resulting in a mycobacterial load increased by 2 logs in the lungs and necrotizing pneumonia (21,22). 
Defective granuloma formation was seen, and splenocytes of IL-1RI-/- mice produced less IFNg (21). 
These data are in contradiction with a recent study by Master et al., suggesting that M. tuberculosis 
prevents inflammasome activation and IL1β secretion (23): if mycobacteria would not induce IL1β 
secretion and this pathway would be absent during the anti-mycobacterial host defence, IL1-deficient 
mice could not be more susceptible to TB (21,22). Our study also clearly demonstrates the capacity 
of M. tuberculosis, either alive or heat-killed, to stimulate IL1β synthesis in human and murine primary 
monocytes or macrophages. In contrast, the study of Master et al. has shown defective IL1β production 
only in the murine macrophage cell-lines RAW 264.7 and J774A (23). This demonstrates the importance 
of using primary cells when the inflammasome activation and IL1β induction is investigated.
Production and release of IL1β are regulated at several levels: the transcription of the gene, processing 
from the inactive 31 kDa pro-IL1β into the active 17 kDa IL1β form, and secretion from the cells (24). 
The transcription of the genes encoding proinflammatory cytokines is under control of signals induced 
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by pattern recognition receptors on the immune cells. TLRs have been shown to be pivotal in the 
recognition of M. tuberculosis and the induction of proinflammatory cytokines (25). In our study, the 
induction of IL1β by M. tuberculosis is mediated by pathways involving TLR2 and TLR6. These 
data are in line with the studies involving TLR2 for the recognition of mycobacteria (26,27), and the 
increased susceptibility to M. tuberculosis infection of TLR2-/- mice (28). TLR2 is a receptor for bacterial 
lipopeptides, which are recognized by TLR2/TLR1 or TLR2/TLR6 heterodimers (29,30). Cooperation 
of TLR2 and TLR6 has been described to be involved in recognition of mycobacterial components 
(31). In line with this, IL1β production induced by M. tuberculosis was dependent on TLR2 and TLR6, 
but not TLR1 (Figure 2). Moreover, TLR4 also does not seem to mediate the induction of IL1β by 
M. tuberculosis, although it is involved in the general recognition of mycobacteria. Differences in the 
transcription mechanisms responsible for the induction of TNFa and IL1β are well known, and this 
may be one of the factors explaining why TLR4 does not modulate induction of IL1β, while influencing 
other proinflammatory cytokines (26,32). Alternatively, other pathways apart of TLR4 (e.g. TLR2/
TLR6) may be sufficient for redundant induction of IL1β by M. tuberculosis. TLR9 was not significantly 
engaged in the induction of IL1β. TLR9-/- mice have shown only minor defects in pathogen clearance, 
while enhancing the effects of TLR2 deficiency (33).
Interesting new information is the involvement of NOD2 as a receptor mediating IL1β production by 
M. tuberculosis. NOD2 is a receptor of bacterial peptidoglycans (34) and only recently we demonstrated 
its role in the recognition of mycobacteria (35,36). It has also been recently shown that common 
polymorphisms of NOD2 are strongly associated with TB in African-American patients (37). These 
data argue that TLRs and NOD2 collaborate for an effective recognition of M. tuberculosis and induction 
of IL1β production.
We further investigated the mechanism of IL1β production by identifying the signalling pathways 
leading to transcription of the IL1β gene. TLR2 induces intracellular signals through Mal/MyD88, 
while TLR4 is able to activate a secondary TRIF/TRAM-dependent pathway. In line with the data 
obtained in the various TLR knock-out mice, IL1β induction was dependent on MyD88, but not on 
TRIF. MyD88-/- mice are also known to be more susceptible to mycobacterial infection (38,39). The 
distal intracellular pathways induced by TLR involve the MAPK ERK, JNK and p38. Recently, it has 
been shown that the blockade of LPS-induced p38 kinase activation inhibits the IL1β production in 
rat pulmonary interstitial macrophages (40), but no data on the role of MAPK on IL1β induction by 
mycobacteria are available. Our data show that both the ERK and p38 and/or Rip2 pathways are part 
of the intracellular pathway of IL1β gene activation induced by M. tuberculosis. The pharmacological 
inhibitors available cannot discern between the TLR/p38 pathways and the NOD2/Rip2-mediated 
pathways, and future experiments are needed to determine the relative importance of these two 
mechanisms. In contrast, no role for the JNK kinases for the induction of IL1β by M. tuberculosis has 
been observed.
The processing of IL1β is assumed to be mediated by caspase-1 activation by a protein complex formed 
mainly by receptors of the NOD-like receptor family, called the inflammasome. Several inflammasomes 
activate IL1β during bacterial infections, such as the NALP3 inflammasome that recognizes bacterial 
ligands including muramyl dipeptide (41), the NALP1b inflammasome that recognizes anthrax lethal 
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toxin (42), and the Salmonella-induced Ipaf inflammasome (42). Although M. tuberculosis contains 
peptidoglycans, the bacterial structures containing muramyl dipeptide, it is not known whether 
inflammasome components recognize and are activated by mycobacterial PAMP. We have shown 
that IL1β production by human monocytes stimulated with M. tuberculosis is caspase-1 dependent. 
When we assessed the capacity of M. tuberculosis to activate caspase-1, we observed that caspase-1 was 
already present in its active form in freshly isolated human PBMC, and only moderately upregulated 
by stimulation with mycobacteria. These data were supported by the demonstration of functional 
caspase-1 in human primary monocytes using a functional colorimetric assay. This implies that in 
human primary monocytes the inflammasome is constitutively active, and bacterial products are able 
only to moderately increase caspase-1 activation and the processing of pro-IL1β. Therefore, although 
inflammasome components such as NALP3 and ASC are central for caspase-1 activation, this process 
does not necessarily require activation by microbial products in human monocytes. This is in contrast 
with the literature from which the concept was proposed that inflammasome activation by danger 
molecules (either bacterial or not) is an essential step for the induction of IL1β production (43). 
However, this concept has been built upon a body of evidence derived from monocyte/macrophage 
cell-lines (e.g. THP-1 cells) or murine cells, and not from primary cells (41,44). Important differences 
between THP-1 cells (no active caspase-1) and primary human monocytes (constitutively active 
caspase-1) for the activation of caspase-1 have been recently demonstrated by our group (45). Thus, 
the present study cautions against the extrapolation of data obtained in cell-lines with the physiology 
of human primary cells.
The release of IL1β from the cells was dependent on endogenous ATP production from the monocytes 
(46), and the blockade of the P2X7 receptor with oxATP significantly reduced IL1β production.
IL1β is one of the important proinflammatory cytokines with anti-mycobacterial activities, and in this 
study we show that M. tuberculosis is a potent inducer of IL1β secretion from human primary PBMC 
and alveolar macrophages. Interestingly, the main regulatory step of IL1β production is at the level of 
transcription, and PBMC contain constitutively active caspase-1. These data question the necessity 
for inflammasome activation during recognition of mycobacteria by these cells. Upon recognition 
of M. tuberculosis, TLR2/TLR6 and NOD2 receptors induce IL1β transcription through pathways 
involving Erk, p38 and Rip2 (Figure 5C). In conclusion, we have dissected the molecular mechanisms 
responsible for IL1β production by M. tuberculosis, and this contributes to a better understanding of the 
mechanisms leading to host cell activation by mycobacteria.
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ABSTRACT
Both autophagy and proinflammatory cytokines are involved in the host defence against mycobacteria, 
but little is known regarding the effect of autophagy on Mycobacterium tuberculosis (MTB)-induced 
cytokine production. In the present study, we assessed the effect of autophagy on production of 
monocyte and T cell derived cytokines, and examined whether two functional polymorphisms in 
autophagy genes led to altered cytokine production. Blocking autophagy inhibited TNFa production, 
while enhancing IL1β production in peripheral blood mononuclear cells stimulated with MTB. 
Induction of autophagy by starvation or interferong had the opposite effect. The modulation of both 
TNFa and IL1β production by autophagy was induced at the level of gene transcription. Functional 
polymorphisms in the autophagy genes ATG16L1 and IRGM did not have a major impact on MTB-
induced cytokine production in healthy volunteers, although a moderate effect was observed on IFNg 
production by the ATG16L1 T300A polymorphism. These data demonstrate the interplay between 
autophagy and inflammation during host defence against mycobacteria, and future studies to 
investigate the clinical implications of these effects for the susceptibility to tuberculosis are warranted.
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INTRODUCTION 
Tuberculosis (TB) is a major health problem with 10 million new cases diagnosed each year, causing a 
death toll of nearly 2 million victims [1]. However, from the estimated 2 billion individuals that have 
been initially infected with Mycobacterium tuberculosis (MTB), most develop asymptomatic infection, 
also called ‘latent tuberculosis’. The pathogen is often not eliminated and may persist for years 
inside macrophages, due to its capacity to evade the host immune response. This persistence allows 
progression to active tuberculosis either as the primary disease or, years later, as reactivation when 
cellular immunity fails. 
The interaction between MTB and cells of both the innate and adaptive immune system results in 
secretion of proinflammatory cytokines such as tumour necrosis factora (TNFa), interleukin (IL)1β, 
IL18, IL12 and IFNg.  TNFa, produced by mononuclear cells, is crucial for host defence as TNFa 
deficient mice succumb rapidly after MTB infection, with significantly higher mycobacterial outgrowth 
in different organs compared to wild-type animals [2]. TNF is important for formation of granuloma, 
a mechanism for containing and restricting the replication of the bacilli [2, 3]. The crucial role played 
by TNFa in human TB is also demonstrated by the increased susceptibility to TB in patients treated 
with anti-TNFa therapy [4]. 
IL1β is an essential component of the host defence to mycobacteria [5-7]. MTB infected IL1 receptor 
type 1 knock-out mice exhibit lower production of IFNg, defective granuloma formation, and 
decreased survival [6]. IFNg is secreted by natural killer (NK), CD4+, and CD8+ T cells upon release 
of endogenous IL12 and IL18 by macrophages and dendritic cells. IFNg activates macrophages to 
kill and eliminate the mycobacteria. It also enhances their expression of major histocompatibility 
complex (MHC) class II molecules, which results in improved antigen presentation to T cells. The 
crucial importance of IFNg for human anti-mycobacterial defence is demonstrated by the increased 
susceptibility to mycobacterial infections in patients with IFNg receptor or IL12 receptor deficiencies 
[8-10]. As cytokines are therefore crucial for host defence against MTB, it is essential to understand the 
molecular pathway of the MTB-induced cytokine production. 
Autophagy is a pathway through which cytoplasmic components, including organelles and 
intracellular pathogens, are sequestered in a double-membrane-bound autophagosome and delivered 
to the lysosome for degradation [11, 12]. Elimination of dysfunctional cell components is one of the 
main roles of autophagy, besides the recycling of cytoplasmic material, allowing the cell to maintain 
macromolecular synthesis and energy homeostatis during starvation and other stressful conditions. 
In addition to its role in cell survival, autophagy is also involved in host defence, with important 
effects on both innate and adaptive immune system [13, 14]. Autophagy has an essential role for anti-
mycobacterial host defence by fusing the autophagosomes containing mycobacteria with lysosomes 
[15, 16], leading to antigen presentation and T cell activation [17, 18]. Recent experiments in mice 
suggest that autophagy also modulates cytokine production: macrophages from ATG16L1 knockout 
mice with no functional autophagy exhibit elevated IL1β production, suggesting an inhibitory role 
of autophagy on the production of this cytokine [19]. However, so far this has not been studied in 
humans: although both autophagy and proinflammatory cytokines have an important role in host 
defence against mycobacteria, there are no reported data regarding the effect of autophagy on MTB-
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induced cytokine production. Therefore, in the present study, we assessed the effect of autophagy on 
production of monocyte and T cell derived cytokines induced by MTB, and examined if two functional 
polymorphisms lead to altered MTB-induced cytokine production. 
MATERIAL AND METHODS
PBMC stimulation assays
After obtaining informed consent, venous blood was drawn from the cubital vein of healthy 
volunteers into 10 ml EDTA tubes (Monoject). The mononuclear cell fraction was isolated by density 
centrifugation of blood, diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, PA, 
USA). Cells were washed twice in saline and resuspended in culture medium (RPMI, Invitrogen, 
CA, USA) supplemented with gentamicin 10 μg/ml, L-glutamine 10 mM, and pyruvate 10 mM. Cells 
were counted in a Coulter counter (Coulter Electronics) and the number was adjusted to 5x106 
cells/ml. A total of 5 x 105 mononuclear cells in a 100μl volume was added to round-bottom 96-wells 
plates (Greiner) in duplicate. Cells were incubated with either RPMI or increasing doses of 3-methyl 
adenine (3-MA, Sigma) ranging from 1-10 mM for 24, 48 hours or 7 days at 37°C (incubation time was 
dependent on the cytokines measured). Cytokine concentrations were assessed in the supernatants 
using enzyme-linked immunosorbent assay (ELISA).
For autophagy inhibition and induction experiments, cells were pre-incubated for 1 hour at 37°C 
in RPMI or in the presence of 3MA (10mM) or IFNg (400IE/ml, Immukine, Boehringer Ingelheim), 
respectively. After pre-treatment, 100 μl of RPMI (negative control) or sonicated MTB H37Rv (1μg/ml 
end concentration) was added to the cells. Cells were incubated for 24 hours and cytokine production 
was measured in supernatant using ELISA.  
Autophagy was also induced by incubation of PBMCs in starvation medium (Earle’s Balanced Salt 
Solution, EBSS, Invitrogen, Carlsbad, CA, USA). In some wells, PBMCs were pre-incubated for 1 hour 
at 37°C in the presence of 3MA (10 mM), to block the induction of autophagy. Subsequently, cells were 
stimulated for 3 hours with sonicated MTB H37Rv (1μg/ml). Thereafter, supernatants were discarded 
and TRIzol reagent was added to the cells, after which they were stored at -80°C until analyzed. 
To investigate the effect of 3MA on the ATP-dependent IL1β release, PBMCs were pre-treated for 1 
hour with either RPMI or 3MA (10mM). Subsequently, cells were stimulated with RPMI or MTB 
H37Rv (1μg/ml) for 3 hours. After stimulation, supernatants were discarded and refreshed with 
RPMI containing 1 mM ATP, after which the cells were incubated for another 15 minutes. The ATP-
dependent IL1β secretion after the additional 15 minutes was assessed in the supernatant.
Inhibition of autophagy by siRNA
As a complementary approach to inhibit the autophagy PBMC’s were transfected with control 
(scrambled) or ATG7 siRNA with nucleofector kit using an Amaxa electroporation chamber  (Lonza, 
Basel). After 24h incubation at 37°C, cells stimulated with MTB H37Rv (1μg/ml), and after an additional 
incubation of 24h supernatants were collected and stored at -80°C until analysis. 
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Cytokine measurements
Cytokine measurements of TNFa, IL1β, IL6, IFNg, IL10, IL22 and IL23 were performed in the 
supernatants using commercial ELISA kits (R&DSystems, MN, USA (TNFa, IL1β, IL22), Sanquin, 
Amsterdam, The Netherlands (IL6, IL10, IFNg) or E-Bioscience, San Diego, USA (IL23)).
Real‐Time PCR for IL‐1β, TNFa and ATG7
RNA purification was performed from TRIzol according to manufacturer’s instructions.Isolated 
RNA was transcribed into complementary DNA using iScript cDNA Synthesis Kit (Bio-Rad, 
CA, USA) followed by quantitative PCR using SYBR Green (Applied Biosystems, CA, USA). 
Following primers were used: IL1β forward 5’-GCCCTAAACAGATGAAGTGCTC-3’ and 
reverse 5’-GAACCAGCATCTTCCTCAG-3’, TNFa forward 5’- TGGCCCAGGCAGTCAGA-3’ 
and reverse 5’-GGTTTGCTACAACATGGGCTACA -3’ and ATG7 forward 
5’-CAGTTTGCCCCTTTTAGTAGTGC-3’and reverse 5’-CCTTAATGTCCTTGGGAGCTTCA-3’. 
Data were corrected for expression of the housekeeping gene β2-microglobulin, for which the primers 
forward 5’-ATGAGTATGCCTGCCGTGTG-3’ and reverse 5’-CCAAATGCGGCATCTTCAAAC-3’ 
were used.
Genotyping for ATG16L1 Thr300Ala and IRGM polymorphisms
DNA was isolated from whole blood by using the Puregene isolation kit (Gentra Sytems, MN, USA), 
according to the manufacturer’s protocol. Genotyping for the presence of the ATG16L1 Thr300Ala 
(rs2241880),and IRGM promoter polymorphisms rs4958847 and rs13361189 polymorphisms was 
performed using TaqMan single nucleotide polymorphism (SNP) assay C_9095577_20, C_1398968_10 
and C_31986315_10 respectively, on the 7300 ABI Real-Time polymerase chain reaction system (Applied 
Biosystems, CA, USA). These genotyping assays were performed in a 25 μL total reaction volume, 
containing 2 μL of genomic DNA as well as primers, two specific probes (with either VIC or FAM 
label) and Universal PCR 2x Master mix (Applied Biosystems). Cycling conditions were 2 min at 50°C 
and 10 min at 95°C followed by 40 cycli of 95°C for 15 sec and 1 min at 60°C. Fluorescence intensities 
were corrected using a post-read / pre-read method for 1 min at 60°C before and after the amplification. 
The software automatically plotted genotypes based on a two-parameter plot with an overall success 
rate of >95%. Intermediate samples were excluded from the analysis.
Two cohorts of healthy volunteers without known TB contact have been assessed (N=73 and N=104), 
consisting of foresters from the ‘Geldersch Landschap’  and ‘Kroondomein’ departments in the 
Netherlands. The individuals were between 23-73 years old, and 77% were male. All volunteers gave 
written informed consent, and the study was approved by the Ethical Committee of the Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands. The cytokine production induced 
by sonicated MTB H37Rv in cells isolated from volunteers bearing various ATG16L1 and IRGM genetic 
variants was compared.
Statistical analysis
Differences were analyzed using the Wilcoxon signed rank test or Friedman test for paired samples 
and Mann-Whitney or Kruskal-Wallis test for unrelated samples. P<0.05 was considered statistical 
significant. Data are shown as cumulative results of level obtained in all volunteers (means + SEM).
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RESULTS
Inhibition of autophagy enhances MTB‐induced production of IL1β and IL6, but decreases 
production of TNFa.
Inhibition of autophagy with 3MA (a blocker of the Beclin1 complex that is crucial for the initiation of 
autophagy) decreased TNFa production induced by MTB H37Rv (Friedman test p=0.003). In contrast, 
autophagy inhibition increased the production of IL1β and IL6 (Friedman test p=0.017 and p=0.035 
respectively) in a dose dependent manner (Figure 1). No changes were observed in the induction of 
IL10 (range 46-50 pg/ml) or IL18 (range 2-4 pg/ml) production when autophagy was inhibited (data 
Figure 1. The effect of the autophagy inhibitor 3MA on MTB‐induced cytokine production. Freshly isolated human 
PBMCs were pre-incubated with increasing doses of 3MA (1, 2, 5, or 10mM) for 1 hour at 37°C in culture medium and 
subsequently stimulated with sonicated MTB H37Rv (1μg/ml). After 24 hours of incubation, TNFa (A), IL1β (B) and IL6 
(C) were measured in the supernatant using specific ELISA. Data are presented as means +SEM, n=4 *p<0.05 compared to 
RPMI.
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not shown). The T cell derived cytokines IFNg, IL17, IL22 and IL23 levels were not detectable when 
cells were stimulated with MTB H37Rv, most likely due to the naïve TB status of the individuals tested.
Induction of autophagy enhances TNFa production.
In line with the experiments showing that inhibition of autophagy leads to decreased production of 
TNFa, induction of autophagy with IFNg enhanced TNFa production in MTB stimulated PBMCs. 
This effect was abolished when autophagy was inhibited by 3MA (p<0.01), suggesting that normal 
autophagy is necessary for the effects of IFNg on TNFa production (Figure 2a). In contrast, treatment 
of PBMCs with IFNg did not significantly modify IL1β production (Figure 2b).
Figure 2. Modulation of inflammatory cytokine production by inhibition and induction of autophagy.  PBMCs were 
pre-incubated for 1 hour with RPMI (negative control), 3MA 10mM (inhibition of autophagy), IFNg (400IE/ml; induction 
of autophagy) or both 3MA and IFNg at 37°C. Thereafter, cells were stimulated for 24h at 37°C with either RPMI or 
sonicated MTB (1μg/ml). TNFa (A) and IL1β (B) concentrations were measured in the supernatant using specific ELISA. 
Data are presented as means +SEM, n=6, **p<0.01.
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Inhibition of autophagy using siRNA against ATG7 influences both TNFa and IL1β 
production.
Figure 3 shows inhibition of autophagy with siRNA against ATG7.  In line with experiments using a 
pharmacological agent (3MA) to inhibit autophagy, inhibition of autophagy by ATG7 siRNA showed 
the same trends of diminished production of TNFa (Figure 3a) and increased production of IL1β 
(Figure 3b).
Modulation of IL1β and TNFa production is regulated at the transcriptional level.
In the following set of experiments we assessed the level at which autophagy regulates cytokine 
production. Both induction (with starvation medium EBSS) and inhibition (with 3MA) of autophagy 
modulated the transcription of proinflammatory cytokines. TNFa mRNA levels significantly increased 
Figure 3. Modulation of inflammatory cytokine production by inhibition of autophagy with siRNA against ATG7. 
PBMC’s were transfected with siRNA ATG7 or scrambled siRNA after 24 hours stimulated with sonicated MTB (1μg/ml). 
After another 24 hours incubation TNFa (A) and IL1β (B) concentrations were measured in the supernatant using specific 
ELISA. Data are presented as means +SEM, n=6.
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Figure 4. The modulatory effect of autophagy on cytokine production is exerted at a transcriptional level. Cells 
pre-treated for 1 hour with RPMI or starvation medium, in the presence or absence of 3MA (10mM), were stimulated for 
3 hours with sonicated MTB (1μg/ml). RT-PCR was performed and relative levels of TNFa (A, C) and IL1β (B, D) mRNA 
were determined. Data are presented as fold change, n=6, *p<0.05, **p<0.01.
Separately, PBMCs were pre-incubated for 1 hour in the presence or absence of 3MA (10mM) and were stimulated for 3 
hours with MTB (1μg/ml) at 37°C. After the stimulation, supernatants were discarded and refreshed with RPMI or RPMI 
containing 1mM ATP, and cell were incubated for additional 15 minutes. ATP-dependent IL1β production was measured 
with ELISA (E). Data are presented as means +SEM, n=6.
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when incubating stimulated PBMCs in starvation medium (EBSS) (Figure 4a), while induction of 
autophagy seemed to decrease IL1β mRNA (Figure 4b). The opposite effect was exerted by autophagy 
inhibition through 3MA: TNFa mRNA was decreased (Figure 4c), while a trend towards an increase 
in IL1β mRNA was observed (Figure 4d). In contrast, inhibition of autophagy had no effect on IL1β 
processing and release induced by the inflammasome activation with ATP [20] (Figure 4e). 
Figure 5. ATG16L1 polymorphisms and MTB‐induced cytokine production. Cytokine production capacity of TNFa (A), 
IL1β (B) and IFNg (C) by PBMCs obtained from healthy volunteers after stimulation for 24 hours (TNFa and IL1β) or 48 
hours (IFNg) with sonicated MTB stratified for ATG16L1 Thr300Ala genotype (A allele equals 300Thr allele, G allele equals 
300Ala allele). Data are presented as means + SEM, n=73 (13 AA, 37 AG, 23 GG).
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Figure 6. IRGM1 polymorphisms and MTB‐induced cytokine production. Cytokine production capacity of TNFa (A, 
D), IL1β (B, E) and IFNg (C, F) by PBMCs obtained from healthy volunteers after stimulation for 24 hours (TNFa and IL1β) 
or 48 hours (IFNg) with sonicated MTB stratified for IRGM genotypes. Data are presented as means +SEM. n=104 (2 AA, 25 
GA, 77 GG for rs4958847, and 2 CC, 17 TC, 83 TT for rs13361189).
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Autophagy gene polymorphisms and cytokine production induced by MTB
Polymorphisms in two genes involved in the process of autophagy, ATG16L1 and IRGM, have 
been associated with auto inflammatory disorders [21-23], and IRGM polymorphisms also with 
susceptibility to tuberculosis [24-26]. Considering the possible role of autophagy in modulating 
cytokine production induced by MTB, we examined if ATG16L1 and IRGM polymorphisms lead 
to altered cytokine production. However, no statistically significant differences in MTB-induced 
cytokine production were observed when PBMCs were used from healthy volunteers with different 
ATG16L1 genotypes, although PBMCs from individuals bearing the ATG16L1 300G variant tended to 
produce less IFNg (Figure 5). In addition, no significant differences in cytokine production were 
observed between individuals bearing the different IRGM alleles (Figure 6). Although the cohorts 
were relatively large (57-104 subjects), only one (in the case of TNFa and IFNg) or two (in the case of 
IL1β)  individuals were homozygous for the IRGM rs4958847 AA and rs13361189 CC allele, precluding 
a definitive conclusion regarding the effect of these two IRGM SNPs on cytokine production.
DISCUSSION
Autophagy is essential for host defence against MTB [15, 16, 24]. In the present study, we show that 
autophagy modulates pro-inflammatory cytokine production after stimulation with MTB. Autophagy 
showed differential effects on MTB-induced cytokine production; autophagy stimulated TNFa 
production and inhibited IL1β and IL6 production. These effects of autophagy on MTB-induced 
proinflammatory cytokines were exerted at the transcriptional level. 
Activation of autophagy resulted in opposite effects on TNFa and IL1β, exerting an increase of TNFa 
production and a decrease in IL1β production. This is an important, yet puzzling, effect considering 
the role of both TNFa and IL1β in host defence against MTB [11, 12, 15, 16, 27, 28]. On the one hand, the 
increase in the production of TNFa is likely to increase anti-mycobacterial innate immunity. On the 
other hand, one may speculate that the decrease in the production of IL1β may result in decreased Th17 
responses [29], and thus indirectly shifting the response towards protective Th1 cellular immunity, as 
Th1 and Th17 are known to negatively regulate each other [30]. We were not able to study directly the 
effect of autophagy on Th17 responses for two reasons. Inhibition of autophagy through 3MA inhibited 
T cell proliferation, while prolonged incubation of cells, necessary for optimal Th17 responses, led to 
cell death when cells were kept for long periods of time in the EBSS (starvation) medium. Another 
mechanism that might influence cytokine levels in these experiments is IFNg-induced TLR2 and 
NOD2 expression [31, 32], which in turn can lead to more cytokine production. However, induction of 
autophagy with starvation medium instead of IFNg led to similar results, while the effects of IFNg on 
cytokine production were abolished when 3MA was added. Therefore, the effects of IFNg on cytokine 
production are at least partly mediated through autophagy.
In a separate set of experiments, we investigated the level at which the effects of autophagy on MTB-
induced cytokines are exerted. Autophagy clearly influenced transcription of both TNFa and IL1β, while 
no post-transcriptional effect was observed for modulation of IL1β synthesis. However, a different effect 
was seen on TNFa versus IL1β transcription. There are several pathways that induce pro-inflammatory 
cytokines after MTB stimulation. The most important receptors involved in MTB recognition and 
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subsequent induction of cytokine responses are TLRs (TLR2 in combination with TLR1 or TLR6, TLR4 
and TLR9) and NOD2. We have previously shown that NOD2- but not TLR-responses are modulated 
by autophagy [33]. TNFa and IL1β transcription are differently regulated, with IL1β transcription being 
mediated by ERK and p38, but not JNK kinase. In contrast, TNFa transcription is mediated through 
ERK and JNK-dependent pathways, with little effects through p38 kinase [34]. Our data therefore 
suggest that differential modulation of the MAP kinase transcriptional pathways by autophagy may be 
responsible for the differences in TNFa and IL1β production, although this remains to be confirmed in 
future studies. 
IL1β is processed and secreted after activation of a protein complex called the inflammasome, leading to 
activation of caspase-1 and processing of inactive pro-IL1β into the active cytokine. ATP acting on the 
P2X7 receptor is a known activator of the inflammasome. No effect of autophagy on the IL1β processing 
and secretion induced by ATP was observed, providing an additional argument that autophagy 
modulates cytokine production in humans at the transcriptional, rather than the post-transcriptional 
level [33]. This is in contrast to studies in murine cells, in which inhibition of the inflammasome by 
autophagy seems to play an important role [19, 35]. This argues that important differences exist between 
the effects of autophagy in mice and humans. 
Single nucleotide polymorphisms in the autophagy genes ATG16L1 and IRGM have been associated 
with Crohn’s disease [21-23], and an association of IRGM SNPs and TB has also been reported [24-26]. 
ATG16L1 is a component of a large protein complex formed together with ATG5 and ATG12 that is 
essential for autophagosome formation. IRGM is a downstream effector of IFNg and has been implicated 
in the process of autophagy induction in macrophages [16]. Subsequently, reduction in IRGM1 levels 
are associated with decreased autophagy [24]. However, these polymorphisms did not influence the 
induction of TNFa or IL1β production by cells isolated from healthy volunteers and stimulated with 
MTB. While the T300A ATG16L1 polymorphism has been shown to modulated NOD2-induced IL1β 
production, it does not affect TLR-induced cytokine synthesis [33]. Although we should be careful 
interpreting these data, given the small number of subjects with carrying the functional SNPs, this 
suggests that modulation of cytokine production by NOD2 ligands in MTB may be compensated by 
the unaffected TLR-dependent induction. Interestingly, a trend towards lower IFNg production was 
observed in cells isolated from individuals homozygous for the 300A allele of ATG16L1, and this may 
affect anti-mycobacterial host defence in the patients. Whether the T300A ATG16L1 polymorphism also 
modulates susceptibility to TB remains unclear. The effects of this ATG16L1 SNP may be exerted not 
only though IFNg production, but also through modulation of antigen presentation at the level of MHC 
class II, a process known to be influenced by autophagy [17, 18]. 
Our findings might have been strengthened by examination of M. tuberculosis genotype in relation to host 
genotype. Another SNP in the IRGM gene, -261T, has been shown to be associated with protection from 
certain MTB genotypes but not with protection against Mycobacterium africanum [25]. This supports the 
concept of co-evolution of M. tuberculosis and the human immune system, similar to a previous study [36]. 
In this study we looked at the relation between host genotype and autophagy-mediated modulation of 
cytokine production, but in future patient studies we hope to investigate whether there is a relation 
between certain autophagy host-genotypes and M. tuberculosis  genotypes 
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In conclusion, the process of autophagy influences cytokine production induced in human peripheral 
blood mononuclear cells by MTB. These effects are different on TNFa versus IL1β induction, and are 
induced at the transcriptional level. The next step will be to relate these effects on cytokine production 
to the direct anti-mycobacterial defence mechanisms in macrophages. Finally, an assessment of the 
clinical implications of this autophagy-inflammation interaction is needed, with the important question 
whether (partial) defects in autophagy may increase susceptibility to TB.
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ABSTRACT
Recent data suggest that autophagy is important for intracellular killing of Mycobacterium tuberculosis, 
and polymorphisms in the autophagy gene IRGM have been linked with susceptibility to tuberculosis 
(TB) among African-Americans, and with TB caused by particular M. tuberculosis genotypes in Ghana. 
We compared 22 polymorphisms of 14 autophagy genes between 1022 Indonesian TB patients and 
952 matched controls, and between patients infected with different M. tuberculosis genotypes, as 
determined by spoligotyping. The same autophagy polymorphisms were studied in correlation with 
ex-vivo production of TNFa, IL1β, IL6, IL8, IFNg and IL17 in healthy volunteers.
No association was found between TB and polymorphisms in the genes ATG10, ATG16L2, ATG2B, 
ATG5, ATG9B, IRGM, LAMP1, LAMP3, P2RX7, WIPI1, MTOR and ATG4C. Associations were found 
between polymorphisms in LAMP1 (p=0.02) and MTOR (p=0.02) and infection with the successful M. 
tuberculosis Beijing genotype. The polymorphisms examined were not associated with M. tuberculosis 
induced cytokines, except for a polymorphism in ATG10, which was linked with IL8 production 
(p=0.04). All associations found lost statistical significance after correction for multiple testing. This 
first examination of a broad set of polymorphisms in autophagy genes fails to show a clear association 
with TB, with M. tuberculosis Beijing genotype infection or with ex vivo proinflammatory cytokine 
production. 
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INTRODUCTION
Mycobacterium tuberculosis (M. tuberculosis), the main cause of tuberculosis (TB) worldwide, is an 
intracellular pathogen that primarily infects macrophages (1, 2). This pathogen resides and multiplies 
within a host-derived phagosome where it persists through interference with phagosome-lysosome 
biogenesis (3, 4). Recent studies suggest that autophagy, a homeostatic process involved in nutrient 
regeneration and immune responses, is involved in intracellular killing of M. tuberculosis (3, 5, 6), and 
that physiological or pharmacological induction of this process in vitro (i.e.: with ATP, IFNg, vitamin 
D3) promotes fusion of phagosomes containing M. tuberculosis with lysosomes and subsequent killing 
of the pathogen in autophagic characteristic double-membrane autolysosomes (1, 3, 7). In addition, 
intracellular survival of M. tuberculosis was shown to depend on its ability to escape or inhibit autophagy 
(5, 8), and a study by Kumar et al. found that genes that regulate intracellular survival of M. tuberculosis, 
regardless of its genotype, are in the autophagy pathway itself or in pathways that affect autophagy 
(9).
Susceptibility to TB is partly genetically determined and variations in genes involved in the autophagic 
pathway may affect the host response to M. tuberculosis infection. Indeed, mice deficient in autophagy 
and autophagy related genes were found to be more susceptible to infection with M. tuberculosis (10, 
11) and human mononuclear cells with certain polymorphisms in autophagy related genes displayed 
an impaired ability to control M. tuberculosis growth (12, 13), thus suggesting that polymorphisms 
in autophagy and autophagy related genes may be associated with TB. This appears to be the case 
as various polymorphisms in one autophagy gene IRGM, a downstream effector of IFNg, have been 
associated with increased protection against M. tuberculosis infection in African-American (14) and 
Chinese individuals (15) and infection by particular M. tuberculosis genotypes in Ghana (16). In addition, 
polymorphisms in a number of genes which affect autophagy, such as P2RX7, have also been associated 
with TB (17, 18). However, to our knowledge, besides IRGM no other gene of the autophagy pathway 
itself has been examined in TB patients. We have therefore examined a selection of autophagy genes in 
a large cohort of TB patients and healthy controls in Indonesia. Since susceptibility to TB may depend 
on the interplay between host and mycobacterial genotype (2, 9, 19), we also grouped patients’ M. 
tuberculosis isolates into W-Beijing genotype strains, which account for one-third of all M. tuberculosis 
infections in Indonesia (20, 21), and non-W-Beijing genotypes. Furthermore, in a Caucasian cohort that 
was genotyped for the 22 SNPs, we measured cytokine production in peripheral blood mononuclear 
cells (PBMCs) stimulated with M. tuberculosis.
MATERIAL AND METHODS
Subject recruitment
We previously recruited consecutive TB patients diagnosed in two outpatient clinics and two hospitals 
in Jakarta and Bandung (Indonesia) from January 2001 to December 2006, for a series of genetic studies 
examining host susceptibility to TB (19, 22, 23).
Diagnosis of pulmonary TB (PTB) was done according to World Health Organization criteria by clinical 
presentation and chest radiograph examination, followed by confirmation with microscopic detection 
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of acid-fast bacilli in Ziehl-Neelsen-stained sputum smears and positive culture of M. tuberculosis on 3% 
Ogawa medium. For M. tuberculosis genotype analysis, mycobacterial DNA was extracted by bringing 2 
loops of bacterial mass from an M. tuberculosis culture in saline solution and subsequently heating it at 
95ºC for 5 min. M. tuberculosis genotype was determined by using a commercially available Spoligotyping 
kit (Isogen Bioscience, Maarssen, The Netherlands) as previously described (20). M. tuberculosis Beijing 
genotype was defined as a spoligo-pattern showing hybridization to at least 3 of the 9 spacers 35–43 
and absence of hybridization to spacers 1–34. Spoligotyping was done at the Hasan Sadikin Hospital, 
Bandung, Indonesia. In addition, for quality control purposes, spoligotyping of 10% of the isolates and 
of all isolates lacking hybridization were also done at Gelre Hospital, Apeldoorn, The Netherlands.
We excluded from the genetic studies patients with a confirmed diagnosis of extra-pulmonary TB 
(n=93), diabetes mellitus (fasting blood glucose > 126mg/dL) (n=139) and HIV-positive subjects (n=10). 
Standard regimen for treatment of TB consisted of isoniazid, rifampin, pyrazinamide, and ethambutol 
(2HRZE/4H3R3) was administered free of charge to all patients according to the Indonesian National 
TB program.
During the above mentioned period we also recruited 1000 randomly selected age and gender matched, 
but genetically unrelated control subjects from the same, mostly poor and densily populated areas 
where TB is abundant. All control individuals were subjected to the same physical examination, blood 
tests and chest radiography as the TB patients. A total of 952 control subjects were enrolled in the 
study after excluding individuals with symptoms or chest X-ray abnormalities suggesting active TB 
or a history of TB.
A structured questionnaire was used for patients and control subjects to record clinical information, 
age, gender, self and parental ethnicity, socio-economic status and concurrent medical history. 
Ethics statement
All individuals recruited signed a written informed consent. The study protocol was reviewed and 
approved by the local institutional review boards of the medical faculty of university of Indonesia, the 
Eijkman institute for molecular biology in Jakarta in Indonesia and the Medical Ethical Committee 
Arnhem-Nijmegen in The Netherlands. 
Genotyping
Using NCBI SNP database we selected SNPs in autophagy genes previously associated with TB 
(P2RX7- rs2393799 [17]), other diseases (ATG16L1- rs2241880 (24, 25), ATG5- rs2245214 (26) IRGM 
rs72553867 (27) rs4958847 (28) or with a minor allele frequency of at least 5% (Table 1). 
Blood samples were obtained by venapuncture. Genomic DNA was isolated from EDTA blood of 
patients, controls and a cohort of healthy volunteers using standard methods, and 5 ng of DNA was used 
for genotyping. Multiplex assays were designed using Mass ARRAY Designer Software (Sequenom) 
and genotypes were determined using Sequenom MALDI-TOF MS according to manufacturer’s 
instructions (Sequenom Inc., San Diego, CA, USA). Briefly, the SNP region was amplified by a locus-
specific PCR reaction. After amplification a single base extension from a primer adjacent to the SNP 
was performed to introduce mass differences between alleles. This was followed by salt removal 
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and product spotting onto a target chip with 384 patches containing matrix. MALDI-TOF MS was 
then used to detect mass differences and genotypes were assigned real-time using Typer 4 software 
(Sequenom Inc. San Diego, CA, USA). As quality control, 5% of samples were genotyped in duplicate 
and each 384-well plate also contained at least 8 positive and 8 negative controls, no inconsistencies 
were observed. DNA samples of which half or more of the SNPs failed (N=90) were excluded from 
analyses. Variants with call-rates below 90% were also excluded from further analyses (n=0).  
For quality control purposes the genotype of at least two samples for each homozygous genotype 
were confirmed by sequencing using Sanger method with Big Dye Terminator version 3 (Applied 
Biosystems). After the cycle sequence reaction, the samples were purified by ethanol precipitation and 
analysed on a 3730 Sequence Analyzer (Applied Biosystems). 
Previously polymorphisms in various genes were genotyped on a two-stage genome-wide association 
study (GWAS) using Illumina’s GoldenGate Assay according to manufacturer instructions, aiming 
to discover genes relevant in pulmonary TB susceptibility in the same Indonesian cohort involved in 
the current study (29). Among the SNPs studied, five were in autophagy genes and were included in 
our data analysis (Table 1). The overlap of study subjects between the current study and the GWAS 
is shown in Figure 1. 
Cytokine production by M. tuberculosis stimulated PBMC
Cells isolated from healthy Caucasian volunteers bearing various genotypes were examined for cytokine 
production induced by sonicated M. tuberculosis H37Rv (n=67). These individuals were aged 23-73 years, 
77% was male and none had a known TB contact. All gave written informed consent, and the study was 
approved by the Ethical Committee of the Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands. 
Blood samples were obtained by venapuncture. The mononuclear cell fraction was isolated from blood 
by density centrifugation of blood, diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia 
Biotech, PA, USA). Cells were washed twice in saline and resuspended in culture medium (RPMI, 
Invitrogen, CA, USA) supplemented with gentamicin 10 μg/ml, L-glutamine 10 mM, and pyruvate 10 
mM. Cells were counted in a Coulter counter (Coulter Electronics) and the number was adjusted to 
5x106 cells/ml. A total of 5 x 105 mononuclear cells in a 100 μl volume of RPMI was added to round-
bottom 96-wells plates (Greiner) with or without sonicated M. tuberculosis H37Rv (final concentration: 
1 μg/ml). After 24 hours, 48 hours 
(both without serum) or 7 days of incubation (in the presence of 10% serum), supernatants were 
stored at -20°C. Cytokine concentrations were assessed in the supernatants using enzyme-linked 
immunosorbent assay (ELISA).
Cytokine measurements of TNFa, IL1β, IL6, IL8 (after 24 hours incubation); IFNg (after 48 hours 
incubation), and IL17 (7 days incubation) were performed in the supernatants using commercial 
ELISAs from R&D Systems, MN, USA (TNFa, IL1β, IL8, and IL17) or Sanquin, Amsterdam, The 
Netherlands (IL6 and IFNg).
56
Table 1. Polymorphisms in autophagy genes studied
Gene Gene ID SNP
Heterozygositya
Disease associated
Asiansb
All 
populations
ATG10 83734
rs1864183 19% 49% N.A.
rs3734114 38% 25% N.A.
ATG16L1 55054 rs2241880 47% 48%
Inflammatory bowel disease (24) 
and Crohn`s disease (25)
ATG16L2 89849 rs11235604 N.D. 18% N.A.
ATG2A 23130
rs77228473 N.D. N.D. N.A.
rs77833427 8%c 0.5% N.A.
ATG2B 55102
rs3759601 29% 42% N.A.
rs9323945 42% 16% N.A.
rs74719094 N.D. 0.3% N.A.
ATG5 9474 rs2245214 62% 50%
Systemic lupus erythematosus 
(26)
ATG9B 285973 rs61733329 17%c 4% N.A.
IRGM 345611
rs72553867 29%c 22% Crohn's disease (27)
rs4958847 33% 48 Crohn's disease (28)
LAMP1 3916 rs9577229 17%c 16% N.A.
LAMP3 27074 rs482912 42% 51% N.A.
P2RX7 5027 rs2393799 48%c 48% Tuberculosis [17]
WIPI1 55062 rs883541 49% 35% N.A.
GWAS
MTOR
 
2475 rs6701524 21% 30% N.A.
rs10492975 18% 20% N.A.
ATG4C 84938
rs10493328 5% 15% N.A.
rs10493327 40% 48% N.A.
rs10493329 4% 19% N.A.
adata from dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/, bdata from  HapMap-HCB (Han Chinese from 
Beijing), cdata from low coverage pilot panel CHB+JPT (Han Chinese from Beijing and Japanese from Tokyo), 
N.D. = no data available, N.A. = no known association 
Statistical analysis
All data collected from the questionnaires and genotyping were analysed using SPSS version 17.0 (SPSS 
Inc., Chicago, IL, USA). The Hardy-Weinberg equilibrium (HWE) was checked for each SNP using 
the program HWE Version 1.10 (Rockefeller University, New York). The program Conting was used 
to calculate the χ2 and the associated values for a contingency table. Patient data were stratified for the 
M. tuberculosis genotype with which they were infected; Beijing or non-Beijing strains and the χ2 was 
calculated with SPSS. Differences in cytokine production were analyzed using the Wilcoxon signed 
rank test. All statistical analyses were 2-sided, and P< 0.05 was considered to be statistically significant.
The available number of study subjects allowed us to observe a 5% allele difference between patients 
and controls for the SNP in IRGM (rs4958847), based on previously reported allele distribution in the 
general population, a power (β) of 0.80 and a significance level (a) of 0.05.
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RESULTS 
Study subjects 
A total number of 1022 confirmed pulmonary TB patients and 952 age- and gender matched community 
controls were included in the data analysis. As shown in Table 2, 78% of patients and control  subjects 
were Javanese (a population group with relatively low genetic variance in Indonesia (30)) with similar 
age, gender  distribution, and likelihood of having a BCG scar. Furthermore, both groups also had 
a similar socioeconomic status (not shown) and previous analysis in this cohort (29) showed that 
population stratification was minimal.
Table 2. Demographic information of the study population
TB patients controls p value
Mean age (years) 33 33 0.7
Gender male (%) 53.4 53.2 0.6
Self reported ethnicity 0.9
Javanese 78.5% 78.3%
Mixed (either parent Javanese) 11.1% 11.8%
Non-Javanese 8.1% 8.2%
unknown 2.3% 1.7%
BCG scar present 44% 49% 0.07
Association between polymorphisms in autophagy genes and susceptibility to TB
Polymorphisms rs11235604 (in ATG16L2), rs77228473 and rs77833427 (in ATG2A), rs74719094 
(in ATG2B), rs72553867 (in IRGM), rs10493328 and rs10493329 (in ATG4C) were rare in the study 
subjects. With the exception of the SNP rs3759601 in ATG2B (HWE: 2p = 0.034), all polymorphisms 
were in Hardy–Weinberg equilibrium in the healthy controls. The distribution of the alleles for all 
polymorphisms analyzed in the current study is presented in Table 3. After Chi-square testing we did 
not detect significant associations between any genetic polymorphism and susceptibility to TB. This 
was also the case when the largest group (Javanese) was analysed separately (data not shown).
Figure 1: The overlap of study subjects between the current study (n=1974) and the previous genome‐wide association 
study (GWAS, n=1139) (29).
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Table 3. Distribution of polymorphism allele frequencies in cases and controls
Gene SNP Allele Frequency in cases 
(%) 
Frequency in controls 
(%) 
P value 
Autophagy specific genes
ATG10 rs1864183 A 
G 
AA 
GA 
GG 
1450 (86) 
236 (14) 
625 (74.1) 
200 (23.7) 
18 (2.1) 
1400 (83.3) 
280 (16.7) 
583 (69.4) 
234 (27.9) 
23 (2.7) 
0.094 
rs3734114 C 
T 
CC 
TC 
TT 
491 (29.2) 
1189 (70.8) 
71 (8.5) 
349 (41.5) 
420 (50) 
502 (29.8) 
1180 (70.2) 
84 (10) 
334 (39.7) 
423 (50.3) 
0.489 
ATG16L1 rs2241880 C 
T 
CC 
TC 
TT 
449 (26.6) 
1237 (73.4) 
62 (7.4) 
325 (38.6) 
456 (54.1) 
453 (26.8) 
1235 (73.2) 
59 (7) 
335 (39.7) 
450 (53.3) 
0.876 
ATG16L2 rs11235604 CC 
TC 
835 (99) 
9 (1) 
839 (99.2) 
6 (0.8) 
n.a. 
ATG2A rs77228473 C 1676 (100) 1680 (100) n .a. 
rs77833427 CC 
TC 
837 (99.9) 
1 (0.1) 
843 (99.9) 
1 (0.1) 
n.a. 
ATG2B rs9323945 
rs74719094 
C 
T 
CC 
TC 
TT 
TT 
TG 
1240 (74) 
436 (26) 
464 (55.4) 
312 (37.2) 
62 (7.4) 
842 (99.8) 
2 (0.2) 
1267 (75.6) 
409 (24.4) 
485 (57.4) 
297 (35.4) 
56 (7.2) 
844 (100) 
0.566 
n.a. 
ATG5 rs2245214 C 
G 
CC 
GC 
GG 
1017 (59.3) 
697 (40.7) 
294 (35.9) 
395 (46.8) 
145 (17.3) 
1006 (60.1) 
668 (39.9) 
300 (35.8) 
406 (48.5) 
131 (15.7) 
0.632 
ATG9B rs61733329 C 
T 
CC 
TC/TT 
1542 (91.4) 
146 (8.6) 
706 (83.6) 
138 (16.4) 
1513 (89.4) 
179 (10.6) 
676 (79.9) 
170 (20.1) 
0.046 
Association between polymorphisms in autophagy genes and M. tuberculosis genotype
To examine a possible association between host and mycobacterial genotype, autophagy gene 
polymorphisms were compared between patients infected with M. tuberculosis Beijing genotype and 
other M. tuberculosis genotypes. One hundred and sixty-one patients (33%) were infected with M. 
tuberculosis Beijing genotype strains, 322 with a non-Beijing strain, while no strain information was 
available for the remainder (n=540). Patients infected with M. tuberculosis Beijing and non-Beijing strains 
were not significantly different in terms of age, sex, or history of previous tuberculosis treatment. The 
distribution of the alleles for all polymorphisms among patients infected with M. tuberculosis Beijing 
and non-Beijing strains is shown in Table 4. The polymorphism in LAMP1 (rs9577229) showed an 
association with TB caused by M. tuberculosis Beijing strains, when the TC was combined with the low
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Gene SNP Allele Frequency in cases 
(%) 
Frequency in controls 
(%) 
P value 
Autophagy specific genes
IRGM rs72553867 A 
C 
AA/CA 
CC
83 (4.9) 
1605 (95.1) 
82 (9.7) 
762 (90.3)
95 (5.6) 
1742 (94.4) 
93 (11) 
753 (89)
0.389
rs4958847 A 
G 
AA 
GA 
GG 
661 (39.4) 
1017 (60.6) 
131 (15.6) 
399 (47.6) 
309 (36.8) 
664 (39.6) 
1014 (60.4) 
128 (15.3) 
408 (48.6) 
303 (36.1) 
0.908 
LAMP1 rs9577229 C 
T 
CC 
TC 
TT 
1349 (80.9) 
319 (19.1) 
538 (64.5) 
273 (32.7) 
23 (2.8) 
1382 (82.3) 
298 (17.7) 
567 (67.5) 
248 (29.5) 
25 (3.0) 
0.364 
LAMP3 rs482912 A 
G 
AA 
GA 
GG 
762 (45.3) 
920 (54.7) 
166 (19.7) 
430 (51.1) 
245 (29.1) 
774 (46.1) 
906 (53.9) 
170 (20.2) 
434 (51.7) 
236 (28.1) 
0.89 
P2RX7 rs2393799 C 
T 
CC 
TC 
TT 
775 (46) 
909 (54) 
181 (21.5) 
413 (49) 
248 (29.5) 
766 (45.4) 
922 (54.6) 
177 (20.6) 
412 (49.9) 
255 (29.5) 
0.932 
WIPI1 rs883541 A 
G 
AA 
GA 
GG 
655 (38.9) 
1027 (61.1) 
120 (14.7) 
415 (49.4) 
306 (36.0) 
669 (39.8) 
1011 (60.2) 
125 (14.9) 
419 (49.9) 
296 (35.2) 
0.866 
GWAS
MTOR rs6701524 A 
G 
AA 
AG 
GG 
1092 (92.5) 
88 (7.5) 
505 (85.6) 
82 (13.9) 
3 (0.5) 
988 (91.5) 
92 (8.5) 
453 (83.9) 
82 (15.2) 
5 (0.9) 
0.57 
rs10492975 A 
G 
AA 
AG 
GG 
1059 (89.7) 
121 (10.3) 
477 (80.8) 
105 (17.8) 
8 (1.4) 
951 (88.1) 
129 (11.9) 
417 (77.2) 
117 (21.7) 
6 (1.1) 
0.25 
ATG4C rs10493328 A 
G 
58 (4.9) 
1122 (95.1) 
32 (3) 
1048 (97) 
0.09 
rs10493327 
rs10493329 
A 
G 
AA 
AG 
GG 
A 
G 
805 (68.2) 
375 (31.8) 
273 (46.3) 
259 (43.9) 
58 (9.8) 
1124 (95.1) 
58 (4.9) 
765 (70.8) 
315 (29.2) 
272 (50.4) 
221 (40.9) 
47 (8.7) 
1034 (96.8) 
34 (3.2) 
0.37 
0.15 
n.a. not analysed; SNP not polymorphous in this population
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Table 4. Polymorphism in autophagy genes according to M. tuberculosis genotypes strain
Gene SNP Allele Frequency in Beijing 
(%) 
Frequency in non-Beijing 
(%) 
P value 
Autophagy specific genes
ATG10 rs1864183 A 
G 
AA 
GA 
GG 
285 (88) 
39 (12) 
125 (77.2) 
35 (21.6) 
2 (1.2) 
553 (84) 
105 (16) 
232 (70.5) 
89 (27.1) 
8 (2.4) 
0.260 
rs3734114 C 
T 
CC 
TC 
TT 
87 (27) 
235 (73) 
9 (5.6) 
69 (42.9) 
83 (51.6) 
206 (31.2) 
454 (68.8) 
33 (10) 
140 (42.4) 
157 (47.6) 
0.245 
ATG16L1 rs2241880 C 
T 
CC 
TC 
TT 
89 (27.5) 
235 (72.5) 
14 (8.7) 
61 (37.7) 
87 (53.7) 
163 (24.7) 
497 (75.3) 
19 (5.8) 
125 (37.8) 
186 (56.4) 
0.475 
ATG16L2 rs11235604 CC 
TC 
158 (97.5) 
4 (2.5) 
326 (98.8) 
4 (1.2) 
0.300 
ATG2B rs3759601 
rs9323945 
C 
G 
CC 
GC/GG 
C 
T 
CC 
TC 
TT 
285 (88.5) 
37 (11.5) 
127 (78.9) 
34 (21.1) 
273 (72.6) 
103 (27.4) 
100 (53.2) 
73 (38.8) 
15 (8) 
602 (91.5) 
56 (8.5) 
274 (83.3) 
55 (16.7) 
574 (75.1) 
190 (24.9) 
218 (56.8) 
138 (36.3) 
26 (6.9) 
0.235 
0.661 
ATG5 rs2245214 C 
G 
CC 
GC 
GG 
182 (56.5) 
140 (43.5) 
51 (31.7) 
80 (49.7) 
30 (18.6) 
393 (60.5) 
257 (39.5) 
122 (37.5) 
149 (45.8) 
54 (16.6) 
0.443 
ATG9B rs61733329 C 
T 
CC 
TC/TT 
300 (92.9) 
24 (7.1) 
139 (85.8) 
23 (14.2) 
597 (90.5) 
63 (9.5) 
269 (81.5) 
61 (18.5) 
0.235 
IRGM rs72553867 CA 
CC 
19 (11.7) 
143 (88.3) 
30 (9.1) 
300 (90.9) 
0.359 
rs4958847 A 
G 
AA 
GA 
GG 
136 (42) 
188 (58) 
24 (14.8) 
88 (54.3) 
50 (30.9) 
251 (38.3) 
405 (61.7) 
53 (16.2) 
145 (44.2) 
130 (39.6) 
0.094 
LAMP1 rs9577229 C 
T 
CC 
TC/TT 
313 (83.7) 
61 (16.3) 
128 (68.4) 
59 (31.6) 
587 (77.2) 
173 (22.8) 
226 (59.5) 
154(40.5) 
0.020 
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Gene SNP Allele Frequency in Beijing 
(%) 
Frequency in non-Beijing 
(%) 
P value 
Autophagy specific genes
LAMP3 rs482912 A 
G 
AA 
GA 
GG
149 (46.3) 
163 (50.6) 
32 (19.9) 
85 (52.8) 
44 (27.3)
309 (47) 
349 (53) 
72 (21.9) 
165 (50.2) 
92 (28)
0.831
P2RX7 rs2393799 C 
T 
CC 
TC 
TT 
170 (52.5) 
154 (47.5) 
46 (28.4) 
78 (48.1) 
38 (23.5) 
301 (45.9) 
355 (54.1) 
74 (22.6) 
153 (46.6) 
101 (30.8) 
0.164 
WIPI1 rs883541 A 
G 
AA 
GA 
GG 
124 (38.3) 
200 (61.7) 
24 (14.8) 
76 (46.9) 
62 (38.3) 
265 (40.3) 
393 (59.7) 
47 (14.3) 
171 (52) 
111 (33.7) 
0.547 
GWAS
MTOR rs6701524 A 219 (95.2) 417 (91) 0.023
G 
AA 
AG/GG 
11 (4.8) 
105 (91.3) 
10 (8.7) 
41 (9) 
188 (82.1) 
41 (17.9) 
rs10492975 A 
G 
AA 
AG 
GG 
205 (89.1) 
25 (10.9) 
92 (80) 
21 (18.3) 
2 (1.7) 
416 (90.6) 
44 (9.4) 
189 (82.5) 
37 (16.2) 
3 (1.3) 
0.84 
ATG4C rs10493328 A 
G 
10 (4.3) 
220 (95.7) 
22 (4.8) 
436 (91.7) 
0.85 
rs10493327 
rs10493329
A 
G 
AA 
AG 
GG 
A 
G 
158 (68.7) 
72 (31.3) 
53 (46.1) 
52 (45.2) 
10 (8.7) 
220 (95.7) 
10 (4.3) 
307 (67) 
151 (33) 
103 (45) 
101 (44.1) 
25 (10.9) 
432 (95.2) 
22 (4.8) 
0.81 
0.84 
n.a.= not analysed; SNP not polymorphous in this population
prevalent TT genotype (p=0.02). The same was true for the polymorphism in MTOR (rs6701524); 
when combining the AG with the low prevalent GG genotype, MTOR was significantly associated 
with infection with M. tuberculosis Beijing strains (p=0.02). However, both associations lost statistical 
significance after correction for multiple testing. 
Polymorphisms in autophagy genes and M. tuberculosis induced cytokine production
Association between host genotype and M. tuberculosis induced cytokine production by PBMC was 
examined in healthy Caucasian individuals. Table 5 shows the difference in M. tuberculosis induced 
production of TNFa, IL1β, IL6, IL8, IFNg and IL17 by PBMC isolated from individuals stratified for 
different genotype of autophagy related genes. Six of these polymorphisms showed no polymorphic 
distribution in the Caucasian individuals and could therefore not be analysed. With the exception of 
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ATG10 (rs1864183), for which a significant difference was found in IL8 production between individuals 
with an AA and GG genotype (p=0.04), no associations were observed between the investigated 
cytokines and the autophagy related polymorphisms. Figure 2 presents scatter plots of TNFa, IFNg, and 
IL17 stratified for genotypes of both investigated polymorphisms in IRGM which was previously linked 
with susceptibility to TB.
Table 5. Variation in cytokine level associated with polymorphisms in autophagy genes
Gene SNP IL1βa IL6a IL8a IL17a TNFaa IFNga
ATG10 rs1864183 1.4 1.2 1.2b 2.1 1.1 1.4
rs3734114 1.4 1.1 1.1 2.6 1.8 1.2
ATG16L1 rs2241880 1.3 1.1 1.1 1.7 1.4 3.3
ATG16L2 rs11235604 n.a. n.a. n.a. n.a. n.a. n.a.
ATG2A rs77228473 n.a. n.a. n.a. n.a. n.a. n.a.
rs77833427 n.a. n.a. n.a. n.a. n.a. n.a.
ATG2B rs9323945 1.1 1.4 1.2 2.5 1.0 3.1
rs74719094 n.a. n.a. n.a. n.a. n.a. n.a.
ATG5 rs2245214 1.2 1.3 1.0 1.3 1.4 1.9
ATG9B rs61733329 n.a. n.a. n.a. n.a. n.a. n.a.
IRGM rs72553867 1.7 1.0 1.4 2.4 2.2 1.7
rs4958847 1.3 1.7 1.8 2.9 2.3 2.1
LAMP1 rs9577229 n.a. n.a. n.a. n.a. n.a. n.a.
LAMP3 rs482912 1.2 1.2 1.1 1.6 3.3 3.4
P2RX7 rs2393799 1.2 1.1 1.1 1.8 1.3 2.9
WIPI1 rs883541 1.4 1.1 1.2 2.9 2.0 4.5
a Values are expressed as the ratio of cytokine production associated with different genotypes (median for all 
individuals bearing the same genotype), using the genotype groups with the highest and lowest cytokine production.
b Significantly differences (P<0.05) in genotype groups with highest and lowest cytokine production calculated by 
Wilcoxon signed rank test.
n.a. not analysed; SNP not polymorphous in this population
DISCUSSION
In vitro data strongly support a role for autophagy in control of M. tuberculosis, and a study involving 
2010 patients with pulmonary TB and 2346 control subjects from Ghana has previously reported an 
association between a polymorphism in the autophagy gene IRGM and TB (16). To further explore a 
role of autophagy in TB we examined polymorphisms in a number of autophagy genes in TB patients 
and matched controls from Indonesia. Among almost 2000 subjects, no association was found 
between TB and 22 SNPs in 14 different autophagy and autophagy related genes, including IRGM 
and P2RX7 which were previously associated with TB. When TB patients were stratified according 
to M. tuberculosis genotype,  associations were observed between SNPs in LAMP1, MTOR and infection 
with M. tuberculosis Beijing genotype, but statistical significance was lost after correction for multiple 
testing. No significant correlation was found between M. tuberculosis induced cytokine production and 
genotype of autophagy related genes in a separate cohort of healthy Caucasian volunteers. 
IRGM, a downstream effector protein of IFNg, induces autophagy and subsequent generation of 
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large autolysosomal organelles as a mechanism for the elimination of intracellular M. tuberculosis (31). 
In a cohort of 2010 Ghanaian patients and 2346 controls a polymorphism (rs9637876) in IRGM was 
associated with decreased susceptibility to TB caused by M. tuberculosis Euro-American (EUAM) 
lineage, although not for M. tuberculosis East-African-Indian (EAI), Beijing, Delhi, M. africanum and M. 
bovis lineages (16). In a study in the US, a polymorphism in IRGM (rs10065172) was more common in 
370 African-American TB patients compared to controls, but not in 177 Caucasian patients compared 
to 110 Caucasian controls (14). We did not find an association between TB, which in Indonesia is 
mainly caused by the M. tuberculosis Beijing lineage, and two different polymorphisms in IRGM. 
P2RX7 is an autophagy related gene. It encodes for the P
2
X
7 
receptor, a plasma membrane receptor 
which mediates ATP-induced autophagy and subsequent intracellular killing of M. tuberculosis upon 
upregulation in mature macrophages (32-34). P2RX7 displays a high genetic heterogeneity (12), and 
a polymorphism with a C allele at position -762 in the P2RX7 promoter region was found to have a 
protective effect against TB in over 300 TB patients and 160 ethnically matched controls subjects from 
The Gambia (18). However, no association was found between the same polymorphism and TB in 
our cohort of Indonesian subjects. It is noteworthy that the protective effect of this polymorphism in 
Gambian subjects was weak and that it did not correlate with altered receptor expression or activity, 
suggesting the effect of this SNP might be influenced by other host and pathogen factors (18). In 
addition, the relative importance of the role of P
2
X
7
 receptor in the control of M. tuberculosis growth is 
still debated since mice deficient for P
2
X
7
 receptor displayed a similar ability to control pulmonary M. 
tuberculosis infection compared to wild-type mice (35). Unfortunately, studies on the effect of P2RX7 
polymorphisms in susceptibility to pulmonary TB in humans have not yet been done either in vivo or 
in other ethnic groups. 
Polymorphisms in various genes have been associated with TB, but only polymorphisms in VDR (36-
38), NRAMP1 (39, 40) and MBL (41, 42) were found to be associated with TB in different geographic 
regions and ethnic groups. However, the effect of SNPs in these genes varies among racial groups. 
SNPs in NRAMP1 were associated with an increased risk of PTB in Gambians (39) but were found to 
have a protective effect in Cambodians (40), polymorphisms in MBL were associated with protection 
against TB in South Africans (41) but in South Indians increased susceptibility to this disease (42), 
while SNPs in VDR were found to increase susceptibility to PTB in three African countries (36) but 
to have no effect in Cambodians (40). As suggested by Fernando et al, these contrasting findings 
between different ethnic groups may be due to differences in allele frequencies (17). In addition, the 
phylogeography of mycobacteria implies that M. tuberculosis lineages have become differentially adapted 
to genetic variations among racial groups (2).
The development of TB is the result of a complex interaction between the host and pathogen influenced 
by environmental factors (43). After stratification according to M. tuberculosis genotype, we found a 
suggestive association between TB caused by M. tuberculosis Beijing genotype and a polymorphism 
in LAMP1, similar to what we have previously shown for polymorphisms in SLC11A/NRAMP1 (19). 
However, nine major M. tuberculosis genotypes have been previously identified in Indonesia (20) 
and some polymorphisms analysed here may be associated with TB caused by other genotypes not 
identified in this study. 
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LAMP1 and LAMP2 are two major protein components of late endosome and lysosome membranes, 
thought to form a protective barrier against degradation by hydrolytic enzymes (44, 45). Mice lacking 
Lamp2 display impaired autophagy and lysosome biogenesis, while deletion of both Lamp1 and Lamp2 
is embryonically lethal (44). However, the contribution of these two lysosomal membrane proteins to 
phagosomal maturation and killing of intracellular pathogens still needs to be clarified.
Our group recently showed that inhibition of autophagy (genetically or with either siRNA or 3MA) 
increased IL1β production (46-48). However, with the exception of a SNP in ATG10 and IL8, no 
differences in cytokine production were observed in M. tuberculosis stimulated PBMCs of healthy 
volunteers stratified for genotype of autophagy related genes. 
Our paper has several limitations. First and most importantly, no tuberculin skin testing was performed 
in the control population. However, exposure to tuberculosis must be common in this group, as the 
majority of controls lived in households of tuberculosis patients, who mostly had a productive cough 
(98%) for a median of 3 months before first presentation at the TB clinic (49). Especially because of 
the high incidence of TB in Indonesia, 128 per 100.000 in 2005 (50). Second, as we powered our study 
on an expected 5% difference in allele frequency between the groups the study lacks power to exclude 
any association amongst SNPs that are below this frequency.
This is the first paper to investigate the relation of different SNPs in a broad set 14 autophagy genes 
with susceptibility to TB, as well as with the infecting M. tuberculosis genotype and ex vivo cytokine 
production. These data further supports the belief that susceptibility to TB has a polygenic nature and 
polymorphisms in more than one gene may be required to render individuals more or less susceptible 
to develop active disease.
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Figure 2: Scatter plots of TNFa, IFNg, and IL17 produced after stimulation of PBMC with M. tuberculosis stratified 
for genotypes of both investigated polymorphisms in IRGM.
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ABSTRACT
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a major health problem, with 10 
million new cases diagnosed each year. Innate immunity plays an important role in the host defense 
against M. tuberculosis, and the first step in this process is recognition of MTB by cells of the innate 
immune system. Several classes of pattern recognition receptors (PPRs) are involved in the recognition 
of M. tuberculosis, including Toll-like receptors (TLRs), C-Type lectins (CLRs), and Nod-like receptors 
(NLRs).  Among the TLR family, TLR2, TLR4, and TLR9 and their adaptor molecule MyD88 play the 
most prominent roles in the initiation of the immune response against tuberculosis. In addition to 
TLRs, other PRRs such as NOD2, Dectin-1, Mannose receptor and DC-SIGN are also involved in the 
recognition of M. tuberculosis. Human epidemiological studies revealed that genetic variation in genes 
encoding for PRRs and downstream signalling products influence disease susceptibility, severity and 
outcome. More insight into PRRs and the recognition of mycobacteria, combined with immunogenetic 
studies in TB patients, does not only lead to a better understanding of the pathogenesis of tuberculosis, 
but may also contribute to the design of novel immunotherapeutic strategies.
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Tuberculosis (TB) is a major public health problem, with 10 million new cases diagnosed each year, 
causing a death toll of 2 million victims. However, form the estimated 2 billion persons individuals 
that have been initially infected with Mycobacterium tuberculosis, only 5 to 10% develop symptomatic TB. 
The reason why some infected individuals develop active disease while others do not, is not yet entirely 
understood. The role of inborn variability in susceptibility to tuberculosis has been accidentally 
proven by an episode that occurred almost a century ago, when in 1926 newborn infants from the town 
of Lübeck  in Germany received live Mycobacterium tuberculosis (MTB) instead of the vaccine bacillus 
Calmette-Guérin (BCG). Some of the children became gravely ill, while others were unaffected [1]. 
This finding indicates that at least some individuals display an effective immune response to MTB 
and that this plays an important part in determining the outcome of the infection. In addition, this 
episode in young infants known to have immature adaptive immunity also suggests that the innate 
host defense is an important arm of anti-mycobacterial host defence. 
Much has been learned during the last decade on the mechanisms through which the immune response 
to MTB is initiated. The first step is recognition of mycobacteria as invading pathogens, followed 
by activation of innate host defence responses, and the subsequent initiation of adaptive immune 
responses. Knowledge about these processes is crucial for understanding the pathophysiology of 
tuberculosis on the one hand, and for the development of novel strategies of vaccination and treatment 
such as immunotherapy on the other hand. This review focuses on the first step of the immune 
response, the recognition of mycobacteria by cells of the innate immune system.
Initiation of the innate immune response starts with pattern recognition of microbial structures called 
pathogen-associated molecular patterns (PAMPs). Recognition of PAMPs is performed by germline-
encoded receptors expressed mainly on immune cells termed pattern recognition receptors (PRRs) 
[2]. The first step in understanding the mechanisms of recognition of pathogenic bacteria is a solid 
knowledge of the structure of the cell wall of the microorganism, which is the first structure to come 
in contact and to be recognized by the cells of the immune system. 
The mycobacterial cell wall
MTB is a slow-growing intracellular pathogen that can survive inside the macrophage of the host. 
MTB is an acid-fast bacterium due to the fact that the cell wall mainly consists of hydrophobic mycolic 
acids. This is a specific component of mycobacterial cell wall and makes up 50% of its dry weight. 
Due to this thick layer of mycolic acids, the entry of nutrients is impaired, which causes slow growth 
of mycobacteria, but  it also increases cellular resistance to degradation through lysosomal enzymes 
[3]. The mycolic acids are distributed as a thick layer mostly at the external portions of the cell wall, 
while the internal layers of mycobacteria consist mostly of arabinogalactan, phosphalidyl-myo-inositol 
mannosides (PIMs), and peptidoglycans (Figure 1) [4]. Next to the mycolic acid layer, other components 
include mannose-containing biomolecules including mannose-capped lipoarabinomannan (Man-
LAM), the related lipomannan (LM), and manno-glycoproteins [4] . Mannan and arabinomannan are 
present on the surface and form the outer capsule of this bacterium. Man-LAM, LM and PIMs all 
share a conserved mannosyl-phosphatidyl-myo-inositol (MPI) domain that presumably anchors the 
structures into the plasma membrane [5]. 
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Man-LAM, one of the most abundant mannans present on the cell surface, is an important virulence 
factor of MTB [6]. Man-LAM is a heterogeneous lipoglycan with a characteristic tripartite structure 
of a carbohydrate core, the MPI anchor and various mannose-capping motifs. These mannose-
capped motifs are characteristic for all pathogenic mycobacteria, and they are not present on fast-
growing mycobacterial strains which are significantly less pathogenic. These strains have either 
uncapped LM or have phospho-myo-inositol caps (PILAM), which are known to display more robust 
immunostimulatory effects. PIMs can be divided into two groups dependent on the mannose content, 
which determines its immunogenic effect [7,8]. Also present on the cell surface are the manno-
glycoproteins, which can also be secreted during growth.
Innate immunity and host defence
After the inhalation of infected aerosols into the lungs of the host, the first encounter of mycobacteria is 
with alveolar resident macrophages. Mycobacteria that escape the initial intracellular destruction can 
multiply and disrupt the macrophage, after which chemokines are released, attracting monocytes and 
other inflammatory cells to the lung. Inflammatory monocytes will differentiate into macrophages which 
readily ingest but do not destroy the mycobacteria [9]. In this stage of the infection the mycobacteria 
grow logarithmically and blood-derived macrophages accumulate, but little tissue damage occurs. 
Two to three weeks after infection, T cell immunity develops and antigen-specific T lymphocytes 
arrive, proliferate within the early lesions or tubercles, and release proinflammatory cytokines such as 
interferon g (IFNg) that will activate macrophages to kill the intracellular mycobacteria. Subsequently, 
cell membrane 
peptidoglycan 
 PIM 
  arabinogalactan 
mycolic acids 
porins 
lipomannan 
mannan-caps 
manno-
glycoproteins 
Figure 1. The structure of the Mycobacterium tuberculosis cell wall. This figure shows schematic the major components 
of the cell wall and their distributions. The inner layer is composted of peptidoglycan which is covalently linked to 
arabinogalactan layer. The outer membrane contains mycolic acids, glycolipids like (mannose-capped) lipomannan, and 
manno-glycoproteins.
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the early logarithmic bacillary growth stops, and central solid necrosis in these primary lesions or 
granuloma inhibits extracellular growth of mycobacteria. Several scenarios may follow, with infection 
becoming stationary or dormant in some individuals, or progressive in the lung or with hematogenous 
dissemination in a minority of patients. In addition, reactivation can occur months or years afterwards, 
under conditions of failing immune surveillance [9]. Granuloma often contain central caseous necrotic 
tissue which gives rise to cavities, and aerogenic spread of mycobacteria.
The macrophage is a pivotal cell in these events, as it is involved in phagocytosis and killing of 
mycobacteria as well as in the initiation of adaptive T cell immunity. Phagocytosis of MTB involves 
different receptors such as the scavenger receptors, the mannose receptor (MR) and complement 
receptors [10-13]. Phagocytosis can involve both uptake of the bacilli after opsonization with 
complement factors, or it can be initiated as a non-opsonic event. In vitro experiments have shown 
that complement receptor 3 (CR3) mediates approximately 80% of complement-opsonized MTB 
phagocytosis [12]. Non-opsonic phagocytosis is an important process in the primary infection of the 
lung, because complement factors are largely absent in the alveolar space [14]. 
Macrophages can eliminate mycobacteria through different mechanisms, such as production of 
reactive oxygen and nitrogen species, acidification of the phagosome, and phagosome fusion with 
the lysosomes [9]. The fate of intracellular mycobacteria is also influenced by autophagy, a cellular 
process though which cytoplasmic components, including organelles and intracellular pathogens, 
are sequestered in a double-membrane-bound autophagosome and delivered to the lysosome for 
degradation [15]. Activation of autophagy leads to phagosome maturation, an increased acidification in 
the phagosome, and killing of mycobacteria in macrophages [16]. However, once inside the cell, MTB 
often evades destruction by the innate microbial machinery [17], one of the main mechanisms being the 
inhibition of phagosome-lysosome fusion [18]. 
The interaction between MTB and cells of both the innate and adaptive immune system results in the 
secretion of chemokines and cytokines, the most important being tumor necrosis factor a (TNFa), 
cytokines of the interleukin 1 family (IL1β, IL18), IL12 and IFNg. TNFa deficient mice succumb 
rapidly after MTB infection, with significantly higher mycobacterial outgrowth in different organs 
compared to wild type animals [19]. TNFa is also important for formation of granuloma, an important 
mechanism for containing and restricting the replication of the bacilli [19,20]. The importance of IL1β 
production is underlined by the fact that an intact IL1-mediated signals are an essential component of 
the host defence to mycobacteria [21-23]. Infection of IL1 receptor type 1 knock-out mice with MTB 
is associated with lower production of IFNg, defective granuloma formation, and lower survival [22].
IFNg activates macrophages to kill and eliminate the mycobacteria. It also enhances their expression of 
MHC class II molecules, which results in improved antigen presentation to T cells. IFNg is secreted by 
NK, CD4+, and CD8+ T cells upon release of endogenous IL12 and IL18 by macrophages and dendritic 
cells. The crucial importance of IFNg for human anti-mycobacterial defence is demonstrated by the 
increased susceptibility to mycobacterial infections in patients with IFNg receptor or IL12 receptor 
deficiencies [24-26]. 
Various macrophages subsets have been identified with different potential functions. For example 
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alveolar macrophages, usually the first encounter with the mycobacterium, have an immune suppressive 
and poor antigen presenting ability [27,28]. Two main subtypes are described; the classical and the 
non-classical or alternative phenotypes. The classical route of differentiation induced by microbial 
products or IFNg leads to induction of antimicrobial effects and production of proinflammatory 
cytokines as TNFa, IL1β and IL12(p40) and IL23 [29,30]. This in contrast to the nonclassical 
macrophages subsets, which lack antimicrobial activity and production of IL12. These subsets have a 
poor antigen presenting capacity and can suppress cellular immunity by production of IL10 [30]. The 
macrophages subset polarization may determine the outcome of the host response in skewing the pro 
and anti-inflammatory immune response and subsequently in elimination of mycobacteria.
The first step in the activation of innate host defence begins with the pattern recognition of the 
pathogen. The PAMPs of MTB are sensed by specific PRRs, which in turn trigger production of 
proinflammatory cytokines and chemokines, phagocytosis and killing of the mycobacteria, and 
antigen presentation. This review focuses on the role of the PRRs and downstream signalling for the 
recognition of MTB, including the intracellular mechanisms activated by PRRs. First, we will review 
specific evidence from in vitro studies and animal research. Then, we will discuss the human genetic 
studies done to assess the role of variation in PRR genes for the susceptibility to tuberculosis .
RECOGNITION OF MYCOBACTERIUM TUBERCULOSIS – 
EXPERIMENTAL STUDIES
The interaction between MTB and host cells is complex and, although extensively studied, not yet 
completely elucidated. Here we will focus on the PRRs that recognize specific PAMPs of mycobacteria 
and induce intracellular signals leading to cytokine production and initiation of adaptive immunity. 
A schematic representation is presented in Figure 2. Host receptors which are mainly involved in 
bacterial phagocytosis rather than immune recognition, such as complement receptors and scavenger 
receptors, go beyond the scope of this review. 
Toll‐like receptors
Toll-like receptors (TLRs) are a family of PRRs consisting of 12 members in mammals. TLRs are 
expressed on the surface of the cell membrane or on the membrane of endocytic vesicles of mainly 
immune cells including macrophages and dendritic cells (DCs). Although the interaction of MTB 
with TLRs leads to phagocyte activation, the interaction itself does not lead to immediate ingestion 
of the mycobacteria. After the interaction of specific mycobacterial structures with TLRs, signalling 
pathways are triggered in which adaptor molecule myeloid differentiation primary response protein 
88 (MyD88) plays an important role [31]. Subsequently, IL1 receptor associated kinases (IRAK), 
TNF receptor associated factor (TRAF) 6, TGFb-activated protein kinase 1 (TAK1) and mitogen-
activated protein (MAP) kinase are recruited in a signalling cascade leading to activation and nuclear 
translocation of transcription factors such as the nuclear transcription factor (NF)-κb [32]. This 
leads to the transcription of genes involved in the activation of the innate host defence, mainly the 
production of proinflammatory cytokines as TNFa, IL1β and I-12 and nitric oxide [33]. 
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MyD88 plays a central role in the activation of the innate immune response to M. tuberculosis; compared 
to wild-type mice, MyD88 knockout mice are more susceptible to infection [21]. In addition to MyD88, 
TLR4 can induce intracellular signals through a second pathway, which is mediated by the adaptor 
molecule Toll/IL-1R (TIR) domain-containing adapter inducing interferon (IFN) β (TRIF). Recently, 
this MyD88-independent, TRIF-dependent TLR4 signalling cascade was shown to be involved in the 
LPS-induced autophagy [34]. As the TLR4-induced activation of autophagy plays an important role in 
the phagosome-lysosome fusion, a process counteracted by MTB [34], it is tempting to speculate that 
the interaction between TRIF and autophagy is an important component of the innate host defence 
to mycobacteria.
The TLRs known to be involved in recognition of MTB are TLR2, TLR4, TLR9, and possibly TLR8 [35-
40]. TLR2 forms heterodimers with either TLR1 or TLR6. These heterodimers have been implicated 
in recognition of mycobacterial cell wall glycolipids like LAM, LM, 38-kDa and 19-kD mycobacterial 
glycoprotein, and phosphatidylinositol mannoside (PIM), and triacylated (TLR2/TLR1) or diacylated 
(TLR2/TLR6) lipoproteins [39,41,42]. TLR2 is believed to be important in the initiation of innate 
host defence through its stimulatory effects on TNFa production in macrophages [31,38]. In turn, an 
important role for TLR2 and TLR6, but not TLR4 or TLR9, was found for the stimulation of IL1β 
production [43]. TLR2 is also important for IL12 release in macrophages, but not in DCs [44]. TLR2-
/- mice show defective granuloma formation, and when infected with high doses of MTB, they have a 
greatly enhanced susceptibility to infection compared to the WT mice [45,46]. In addition, TLR2-/- 
mice display defects in controlling chronic infection with MTB [46].
TLR4 is activated by heat shock protein 60/65 [37,47], a protein that is secreted by a variety of MTB 
species. Studies with TLR4 transfected CHO cells and murine macrophages showed the importance 
of TLR4 in recognition of MTB [36,39]. Macrophages of TLR4 deficient mice showed less, but not 
completely abolished TNFa production. In vivo murine studies on the role of TLR4 in the recognition of 
MTB have shown conflicting results, even when the same mouse strain was used. Reiling et al showed 
that TLR4 deficient mice, in contrast to TLR2 deficient mice, showed similar susceptibility to MTB 
infection compared to wild-type animals [45]. In contrast, Abel et al reported higher mycobacterial 
outgrowth in lungs, spleen and liver, and a lower survival following infection compared to wild type 
animals [48]. More studies are necessary to elucidate the source of these discrepancies, and the role of 
TLR4 for MTB infection.
TLR9 recognizes unmethylated CpG motifs in bacterial DNA. In vitro studies showed that MTB-
induced IL12 release in dendritic cells was TLR9-dependent [38,44]. In vivo experiments showed that 
when mice were infected with a high infectious dose of MTB, animals lacking TLR9 succumb earlier 
to infection than wild type animals [38].
TLR8 is able to recognize single stranded RNA from pathogens such as RNA viruses. Interestingly, 
Davila et. al. demonstrated upregulation of TLR8 protein expression in macrophages after infection 
with BCG [40]. Until now, this is the only study addressing a potential role of TLR8, but the mechanism 
through which TLR8 recognizes MTB and signals intracellular remains unknown.
A partially redundant role of TLRs for the host defence against mycobacteria has been suggested, and it 
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has been hypothesized that defects in multiple TLRs are necessary to unveil the role of these receptors 
for antimycobacterial defence. Indeed, TLR2 and TLR9 double knock-out mice display greater defects 
of IL12 and IFNg production in comparison with both single TLR knock-out mice, and they succumb 
earlier to infection, even when infected with a low inoculum of MTB [38].
NOD like receptors
The NOD like receptors (NLR) family of proteins highly resembles the family of plant R (resistance) 
proteins, which have a crucial role in the defence against plant pathogens. The mammalian NLR family 
consists out of more than twenty members with a conserved structure. The core of the molecule is 
formed by the nucleotide-binding domain, named NACHT (NAIP, CIITA, HET-E, TP-1 [49]) or NOD 
(nucleotide oligomerization domain) domain. The C-terminal part consists of a series of leucin-rich 
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Figure 2. Pattern recognition receptors in the recognition of mycobacteria and downstream signaling pathways. 
Mycobacteria can be recognized through different pattern recognition receptors (PRRs) of the host. Both intracellular and 
extracellular receptors are involved in this process. After recognition of mycobacteria, intracellular signalling cascades are 
activation which eventually will lead to the activation of transcription of NF-κB. After transcription, production of pro- 
and anti-inflammatory cytokines and chemokines is induced. The type of signalling cascade induced depends mainly on the 
type of PRR that recognizes (components of) MTB.
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repeats, which are thought to recognize the PAMPs of the pathogen and initiate activation of the 
molecule. The N-terminal portion of the molecule contains an effector domain of CARD (caspase 
activation and recruitment domain), PYRIN, or BIR (baculovirus inhibitor of apoptosis repeat domain) 
[50]. CARD-containing NLRs such as NOD1 and NOD2 are thought to form oligomers and then to 
recruit receptor-interacting protein 2 (RIP2) (or CARD containing kinase - RICK) through CARD-
CARD interactions, which leads to the recruitment of NF-κb [51].  
A major signalling pathway for the activation of the antimycobacterial host defence is represented by 
the inflammasome, that through activation of caspase-1 leads to processing of pro-cytokines of the 
IL1 family into the bioactive IL1β and IL18. Several PYRIN-domain containing NLRs (NALPs) can 
form different variants of the inflammasome containing either NLRP1, NLRP3 (cryopyrin) or NLRC4 
(Ipaf) [52], as well as the adaptor protein ASC [53,54]. A fourth type of inflammasome formed by the 
intracellular protein AIM2 is activated by intracytoplasmic DNA [55]. A recent study has shown that 
induction of IL1β production by MTB is mediated by TLR2/TLR6 and NOD2 receptors, while caspase-1 
is constitutively activated in human primary monocytes [43]. This is in contrast with the study of 
Master et al. that suggested that MTB inhibits inflammasome activation and IL1β production [56]. 
However, these studies are not completely comparable as the latter study has used murine macrophage 
cell-lines, in contrast to the human primary cells used by the former study. In addition, if MTB would 
inhibit IL1β production even in normal hosts, that could not explain the increased susceptibility to 
infection of IL1R-deficient mice [22].
NOD2 is an intracellular receptor mediating stimulation of proinflammatory cytokine production by 
MTB. NOD2 is a receptor for bacterial peptidoglycans [57] and recently we demonstrated its role 
in the recognition of mycobacteria [58,59]. NOD2 deficient mice  showed impaired production of 
proinflammatory cytokines and nitric oxide when infected with MTB. However, the susceptibility to 
MTB infection of NOD2-deficient mice is variable [60,61].
C‐type lectins
C-type lectins are a family of PRRs involved in the recognition of polysaccharide structures of 
pathogens. The mannose receptor (MR, CD206) consists of eight linked carbohydrate recognition 
domains and one cystein rich domain. MR is highly expressed on alveolar macrophages [62]. 
Mycobacterial stimulation through MR leads to production of the antiinflammatory cytokines IL4 
and IL13, inhibition of IL12 production, and failure to activate oxidative responses [63,64]. Man-LAM 
and other major components of the MTB cell wall like PIMs are natural mycobacterial ligands for MR. 
In addition, binding of MTB to MR induces phagocytosis, but phagosome-lysosome fusion is limited 
[65-67]. 
Differences at the level of mannosylation between MTB strains may also contribute to recognition 
by C-type lectins. Torrelles et al. showed that differences in virulence between MTB strains could 
be related to expression of Man-LAM on the cell wall [4]. Virulent MTB strains with less surface 
mannosylation do not use MR for phagocytosis, but rely primarily for recognition and phagocytosis 
on CR3 after opsonisation. These strains are virulent because they display more other cell envelope 
components (like phenolic glycolipids and triacylglycerols) [68,69]. These cell components regulate 
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the cytokine response, and demonstrate rapid intracellular growth and marked tissue damage [70,71]. 
On the contrary, heavily mannosylated MTB strains such as the laboratory strain H37Rv use the MR 
receptor during invasion of the cell and are associated with a higher survival within the macrophage 
and an anti-inflammatory cytokine response. It is speculated that this type of recognition might lead 
to a latent stage of infection [4]. This might not be the case for all mycobacterial species; a mutant 
Mycobacterium bovis strain, which entirely lacked surface mannose shown a comparable cytokine profile 
as the non mutant did [72].
DC‐SIGN
Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN, CD209) 
plays an important role in MTB-DC interaction. This receptor is mainly expressed on DCs and serves as 
both a PRR and an adhesion receptor, due to its functions in DC migration and DC-T-cell interactions 
[73,74]. The carbohydrate recognition domain of DC-SIGN recognizes Man-LAM and lipomannans 
and the amount of Man-LAM determines the binding strength [64]. Recently it was shown that 
a-glucan (a dominant capsular polysaccharide) is also a ligand for DC-SIGN [75]. After engagement of 
mycobacterial structures, DC-SIGN promotes an anti-inflammatory immune response by maturation 
of infected DCs and induction of IL10 production [64]. Later, it was shown that DC-SIGN exerts its 
immunosuppressive effects through induction of acetylation of the NF-kb subunit p65 via Raf-1, but 
only in the presence of simultaneous TLR stimulation [76]. 
Dectin‐1 
Dectin-1 is a receptor with an extracellular carbohydrate recognition domain and an intracellular 
ITAM domain. This receptor is mainly expressed on macrophages, DCs, neutrophils and a subset of 
T cells. Dectin-1 mainly recognizes β-glucans present in fungal pathogens, but it has been suggested 
to play an important role in MTB recognition as well. The precise PAMP that leads to the recognition 
through dectin-1 is not known, although some species of MTB express a-glucan on the cell surface 
[77]  as a ligand for dectin-1. Murine bone-marrow derived macrophages infected with either virulent 
or avirulent mycobacteria produce TNFa and IL6 in a dectin-1-independent or dectin-1-dependent 
manner, respectively [78]. A study with DCs isolated from spleens showed that dectin-1 triggers the 
production of IL12 [79]. Several studies have shown synergistic effects between TLR2 and dectin-1 
for the recognition of fungal pathogens [80,81], but this remains to be demonstrated in case of 
mycobacteria. Finally, a recent report showed that dectin-1, independent of TLR2 recognition, is 
important for the innate immunity recognition of MTB  and for inducing Th1 and Th17 responses [82]. 
RECOGNITION OF MYCOBACTERIUM TUBERCULOSIS - HUMAN 
GENETIC STUDIES
In order to have a complete picture of the role of PRRs for the host defence to MTB, the results of 
in vitro and animal studies need to be corroborated with studies in patients. The association of host 
genetic factors with susceptibility or resistance to TB has been studied extensively with candidate 
gene approaches and genome-wide association studies. These analyses have revealed several important 
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candidate genes for susceptibility to TB [83,84]. For the scope of this review this section is limited to 
PRRs and their signalling pathways only. Table 1 shows an overview of investigated SNPs with or 
without association with TB.
Table 1. SNPs associated with susceptibility to tuberculosis
receptor/signalling 
pathway
gene amino acid association no association
TLR1 1805T>G Lle602Ser [101] [121]
816T>C Asn199Asn
TLR2 2258G>A Arg753Gln [86] [121]
196to174I/D* - [99] [87,89,91]
TLR4 13843A>G Asp299Gly [103,104] [105,121]
1196C>T Thr399Ile [103,121]
TLR6 1083G>C Thr361Thr [102]
745C>T Ser249Pro [102] [121]
TLR8
4959C>G - [40]
2921A>G - [40]
3943A>G - [40]
5088A>G Met1Val [40]
TLR9 588A>G Lys196Lys [99]
411C>T His137His [99]
TIRAP 539C>T Ser180Leu [106] [107]
DC‐SIGN
336A>G - [108,110] [109,122]
601C>T - [108,109]
871G>C - [108] [109]
939C>T - [108,109]
Neck region 
length
- [108,109,122]
* I/D insertion/deletion 
Toll like receptors
The TLR2 gene is located on chromosome 4q32 and is composed of two non-coding exons and 
one coding exon [85]. More than 175 SNPs for the human TLR2 have been reported. In a Turkish 
cohort an association between Arg753Gln and susceptibility to TB [86] was reported, while this 
was not confirmed in two Asian cohorts due to the absence of this particular polymorphism in these 
populations [87,88]. Arg753Gln seems to be present only in Caucasian populations, with percentages 
ranging from 0 to 0,49% in East Asian populations [87,89-91]. In a Tunisian cohort Arg677Trp showed 
an association with susceptibility to TB [92], but these results were put in doubt by the discovery of a 
pseudogene on which this SNP seems to be located [93].
The TLR2 genotype 597CC has been correlated with susceptibility to TB, especially with disseminated 
forms of the infection (miliary and meningitis) caused by a particular MTB genotype family (“the Beijing 
genotype”), in a cohort of patients from Vietnam [94,95]. A highly polymorphic guanine-thymine 
repeat, located 100 base pairs upstream of the TLR2 translation start site in intron 2, was correlated 
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with promoter activity and the expression of TLR2 on CD14+ PBMCs (the shorter the repeat, the 
weaker the promoter activity and the lower the expression of TLR2) for both tuberculosis and non-
tuberculosis mycobacterial lung infections in a Korean cohort [96,97]. However, these data could not 
be reproduced in a Taiwanese population [98]. Another variation in genotype that seems to influence 
TLR2 expression is -196 to -174 insertion/deletion, with a recent study displaying an association with 
TB, while another study showed a possible effect on development of systemic symptoms [98,99]. Many 
other polymorphisms in human TLR2 are examined for their association with enhanced susceptibility 
to TB, but this requires further confirmation [99]. 
Since TLR1 and 6 form heterodimers with TLR2, SNPs in these receptors might influence TLR2 
signalling as well. One example is Ile602Ser SNP in TLR1, which leads to aberrant TLR1 cell trafficking, 
no functional TLR1 on the cell surface, and which might influence the mycobacterial recognition 
[100]. The 602I variant is over expressed in African-Americans infected with TB [101]. In addition, an 
association between the TLR6 SNPs Ser249Pro and Thr361Thr and MTB-induced cytokine production 
has been shown [102].
Immunogenetic studies have reported in two other TLR genes: TLR4 and TLR8. In these genes the 
genetic variation associated with susceptibility to TB seems to be less pronounced. 
TLR4 Asp299Gly SNP showed an association with TB in HIV positive Caucasians and Tanzanians, but 
not in a Gambian population [103-105]. TLR8 has always been linked with recognition of viral PAMPs, 
but in an immunogenetic study in Indonesia, the TLR8 gene, which is located on the X chromosome, 
was the only gene showing an association with TB. This finding was confirmed in a second much larger 
cohort from Russia, and supported by functional data, as discussed above [40]. Further studies are 
needed to confirm these findings.
Besides the PRR receptor polymorphisms, SNPs in the TLR signalling pathways may also influence 
susceptibility to MTB.  Khor et al. proposed that the Ser180Leu SNP in the gene coding for TIR domain 
containing adaptor protein (TIRAP) was associated with a higher susceptibility to TB in a cohort from 
West-Africa [106], although the frequency of the mutant allele was very rare. However, this association 
could not be confirmed in a study involving 9000 individuals from Ghana, Russia and Indonesia [107]. 
Regarding the other PRRs important for MTB recognition, the 871G and 336A variants located in the 
promoter region of DC-SIGN were associated with protection against tuberculosis in a South-African 
cohort of patients [108]. This finding was however not confirmed in a Tunisian cohort [109], while 
a later study even showed an association in opposite direction (a protective effect of 336G) [110]. 
Furthermore, genetic variation of the neck-region of DC-SIGN (which supports the carbohydrate 
recognition domain) failed to show an association with tuberculosis susceptibility [109,111].
CONCLUSIONS AND FUTURE RESEARCH
Pattern recognition of MTB is a complex process in which a multitude of receptors recognize specific 
PAMPs of the microorganism. Recognition by specific receptors is followed by different intracellular 
signalling pathways, in order to integrate and induce an efficient activation of the innate host defence 
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mechanisms. While activation through TLRs, NLRs and dectin-1 initiates essentially a proinflammatory 
response, signalling through the C-type lectins DC-SIGN or MR have mainly a modulatory function. 
The interplay between these pathways lead to finely tuned response of the immune system during the 
encounter with MTB.
One has to acknowledge that both in vitro and in vivo studies suffer from specific limitations, which 
may at least partly explain some discrepancies between experimental and immunogenetic studies 
in TB patients. In vitro studies use various cell types, murine macrophages (bone-marrow derived 
or alveolar), DCs or PBMCs. This can influence the outcome due to the preferential expression of 
specific receptors on different cell types.  A second limitation is that in most in-vitro studies only a 
single receptor is examined, isolated from its physiological environment, while the interplay between 
different pathways is probably one of the most relevant aspects of pathogen recognition. The role of 
the innate immune receptors involved in MTB recognition has often been studied in transfected cell 
lines, while animal models deficient of specific receptors show that these receptors can compensate for 
each other and sometimes display redundant roles [112-114].
In vivo animal studies have the disadvantage that the most commonly used murine models do not 
represent human TB; granuloma are not formed in these models, which is a crucial step in the latency 
of this disease. Rabbit and monkey models which are more similar with human TB are rarely used. 
Even human genetic studies have limitations, in terms that these studies often lack the translation at 
the level of protein function, while in other situations an important gene is highly conserved and lacks 
functionally-relevant genetic variants that can be assessed. 
While pattern recognition is an important component of the host response to infection with MTB, 
other factors are relevant as well, including the intrinsic capacity of macrophages to kill MTB, the 
distribution and function of different T cell subsets, and regenerative and fibrotic tissue responses. 
These particular aspects were beyond the scope of this review.
Humans and MTB have co-evolved for millennia, and it is likely that a close relationship exist at the 
genomic level. Indeed, two studies have shown a direct association between the genetic characteristics 
of patients with tuberculosis and their mycobacterial isolates [95,115]. Both. Polymorphisms in 
respectively TLR2 and SLC11A1 (NRAMP1) were associated with higher change of be infected with 
strains belonging to the evolutionary successful M. tuberculosis Beijing genotype. Globally, M. tuberculosis 
shows strong geographical differences [116,117], and this might be triggered by evolutionary pressure 
from the innate immune system (‘co-evolution’). Besides M. tuberculosis also host immune gene 
polymorphisms show strong geographical differences. The studies of Caws et. al and van Crevel et. 
al [95,115] provide support for the hypothesis that evolutionary adaptation of particular M. tuberculosis 
lineages to certain human populations. For instance, in the case of TLR2 in the study of Caws, a certain 
M. tuberculosis genotype family might have a higher or lower affinity for TLR2 expressed in individuals 
with a particular TLR2 genotype, leading to differences in downstream signalling and subsequent 
events after recognition of M. tuberculosis. Clearly, this concept needs to be investigated in terms of 
innate immune recognition by examining a number of PRR genes in TB patients in relation to their 
infective M. tuberculosis genotypes. Comparing host-mycobacterial genotype relationships of more 
successful M. tuberculosis genotypes like the Beijing family and less successful genotypes will help 
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increase the understanding of the concept of ‘co-evolution’, virulence and innate host defence to M. 
tuberculosis. 
Other important new areas of research related to innate immunity have been initiated recently, and 
their relationship with tuberculosis remains to be answered. One of the important cellular responses 
associated with antimycobacterial defence has been suggested to be the process of autophagy. 
Autophagy has been also shown to modulate the inflammation [118], especially through its interaction 
with the peptidoglycan receptor NOD2 [119,120]. One important question to be answered is whether 
there is a role for autophagy in the induction of an inflammatory response by MTB? What is the 
explanation for the apparent redundancy in the pattern recognition, and which PRR is most important 
in which stage of the disease? Answers to these questions are needed in order to develop rational 
immunotherapeutic interventions like addition of TLR-agonists to candidate vaccines. 
More can also be learned from studies in human patients. For instance: patients with advanced HIV-
infection have virtually no T cell immunity. However, even in settings which are hyperendemic for 
TB, some HIV-infected patients will never develop TB. Certainly, these individuals must have a very 
effective innate host response against MTB. A pivotal approach will be to combine genetic with 
functional studies; what does a SNP associated with susceptibility to TB mean in terms of the function 
of the immune response? 
Another suggestion is to study an increased number of SNPs in more PRRs in the same population, 
and to assess the cumulative effects of various combinations of SNPs to obtain a stronger association 
with disease. A striking observation is that only loss-of-function mutations are investigated. Could 
it be that gain-of-function mutations of PRRs might influence the immune response to MTB as well?
Finally, one of the most important challenges for the coming years is to translate the knowledge gained 
in the basic science of immune responses to mycobacteria into improved or novel immune-based 
treatment strategies, ranging from a better vaccine to immunotherapy.
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ABSTRACT 
Adaptive features of innate immunity, recently described as ‘trained immunity’, have been documented 
in plants, invertebrate animals and mice, but not yet in humans. Here we show that Bacillus Calmette-
Guérin (BCG) vaccination in healthy volunteers leads to phenotypic changes in circulating monocytes, 
that persist for at least three months after vaccination. Monocytes of BCG-vaccinated individuals 
display increased activation markers, and produce higher amounts of proinflammatory cytokines 
in response to unrelated bacterial and fungal pathogens. These training effects are induced through 
NOD2 and are mediated by increased histone methylation. In experimental studies, BCG vaccination 
induced T and B lymphocyte-independent protection of SCID mice from disseminated candidiasis. 
In conclusion, BCG induces trained immunity and non-specific protection to infections through 
epigenetic reprogramming of innate immune cells.
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INTRODUCTION
The general perception in immunology is that innate immunity, as opposed to adaptive immunity, 
is static and does not adapt to an enhanced functional state. There is, however, an increasing body 
of scientific literature indicating enhanced non-specific protection against infections after previous 
exposure to certain microbial components in plants (1), invertebrates (2, 3), as well as mice (4). In 
our recent review of the relevant literature we have proposed the term ‘trained immunity’ for this effect 
(5). Prominent microbial components that are able to induce this enhanced effector function are 
mycobacterial components such as Bacillus Calmette-Guérin (BCG), complete Freund’s adjuvant and 
muramyl dipeptide (6-9). 
BCG, the live attenuated vaccine against tuberculosis (TB) is one of the world’s most widely used 
vaccine (10). It is usually given to newborns protecting them especially against severe forms of TB 
(e.g. TB meningitis, disseminated TB) (11). Soon after its introduction in the 1930’s, epidemiological 
studies surprisingly demonstrated that BCG also protects against childhood mortality independent of 
its effect on TB (12-15). Recent studies corroborated these findings and suggested a reduction of the 
burden of infection other than TB (16-20). For example, in a case-control study in Brazil, BCG reduced 
the risk of death from pneumonia by 50% (17). Little is known about the mechanisms responsible for 
these protective effects of BCG, although macrophages from BCG-vaccinated mice displayed a higher 
release of oxygen radicals and intracellular fungal killing (8), suggesting an important role of innate 
immune mechanisms. 
In the present paper, we explored the mechanisms of the enhanced immune function induced by BCG 
both in vitro and in vivo. 
MATERIALS AND METHODS
Subjects
Subjects (age range 20-36 years) who were scheduled to receive a BCG vaccination at the public health 
service, because of travel or work in TB-endemic countries, were asked to participate in this trial. 
Twenty healthy individuals were included between August and November 2010. Blood was drawn 
before the vaccination, two weeks after, and three months after the BCG vaccination. The study was 
approved by the Arnhem-Nijmegen Ethical Committee. 
In vitro cytokine stimulation experiments were performed with PBMCs isolated from buffy coats 
obtained from healthy volunteers (Sanquin Bloodbank, Nijmegen, the Netherlands).
PBMC stimulation assays
The mononuclear cell fraction was isolated from blood by density centrifugation of blood, diluted 1:1 in 
pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, PA, USA). Cells were washed twice in saline 
and resuspended in culture medium (RPMI, Invitrogen, CA, USA) supplemented with gentamicin 10 
μg/ml, L-glutamine 10 mM, and pyruvate 10 mM. Cells were counted in a Coulter counter (Coulter 
Electronics) and the number was adjusted to 5x106 cells/ml. A total of 5 x 105 mononuclear cells in 
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a 100μl volume was added to round-bottom 96-wells plates (Greiner) with RPMI or with sonicated 
MTB H37Rv (1μg/ml end concentration), heat-killed Candida albicans, heat-killed Candida albicans 
hyphae 1x106 microorganisms/ml strain UC820), Staphylococcus aureus (1x106 microorganisms/ml), or E. 
coli lipopolysaccharide (LPS, Sigma-Aldrich, 1ng/ml). After 24 hours or 48 hours, supernatants were 
stored at -20°C. Cytokine concentrations were assessed in the supernatants using enzyme-linked 
immunosorbent assay (ELISA). 
For ChIP analysis, adherent monocytes from the subjects were obtained in 6 wells plate by incubating 
15 x106 PBMCs for 1 hour. Then, adherent monocytes were collected before further treatment for 
chromatin immunoprecipitation.
Buffy coats of blood from anonymous blood donors were used for the in vitro ‘training’ experiments. For 
the isolation of PBMCs the same procedure was used as described above. Monocytes were used after 
adherence for one hour in flat-bottom 96-wells plates. For the training of monocytes, RPMI, BCG (1μg/
ml, BCG vaccin SSI from the Netherlands vaccine institute ), MDP (10 μg/ml), Pam3Cys (10 μg/ml) or 
LPS (1 ng/ml) were added for 24h incubation at 37°C. Thereafter, supernatant was discarded and fresh 
RPMI with 10% serum was replaced. After 7 days at 37°C, supernatants was discarded and the cells 
were stimulated with either E. coli LPS (10ng/ml), sonicated MTB H37Rv (1μg/ml), Staphylococcus aureus 
(1x106 microorganisms/ml) or RPMI as a control for an additional 24h. Subsequently, supernatants 
were stored at -20°C until ELISA was performed. In some representative experiments, the final cell 
number after initial training with either control medium, BCG or MDP was assessed using Hoechst 
33342 Fluorescent Stain and showed little variation. The normalized cytokine levels based on the 
number of cells actually present in the well showed the same trend as the non-normalized cytokines 
levels.  
In the “inhibition” experiments, before the priming with BCG, the adherent monocytes were pre-
incubated for 1 hour with the inhibitors: Bartonella LPS (1μg/ml), anti-TLR2 antibody and anti-IgG 
(10 μg/ml, eBioscience), Rip2/p38 inhibitor (1μM, Sigma-RBI), Pargyline (3μM, Sigma-Aldrich), MTA 
(1mM, Sigma-Aldrich). 
Cytokine measurements
Cytokine measurements of TNFa, IL1β and IFNg were performed in the supernatants using commercial 
ELISA kits from R&DSystems, MN, USA (TNFa and IL1β) or Sanquin, Amsterdam, The Netherlands 
(IL6 and IFNg). In a small proportion of baseline samples in which cytokine concentrations were 
beyond the detection limit, these outliers were excluded from the analysis.
FACS analysis
Cells were phenotypically analyzed by ten-colour and five-colour flow cytometry using a Coulter 
Navios and Coulter Cytomics FC 500 respectively (Beckman Coulter, Fullerton, FL) and evaluated 
using Kaluza 1.1 software (Beckman Coulter). Cells were washed with PBS with 1% bovine serum 
albumin before being labeled with fluorochrome-conjugated mAbs. After incubation for 30 min 
at 4°C in the dark, cells were washed twice to remove unbound antibodies and analyzed. For cell 
surface staining, the following mAbs were used: CD11b (IM25814), CD14-ECD (IM2707U), CD45-PC7 
(IM3548) (all from Beckman Coulter Corporation), CD284-PE (TLR 4) (312806), CD206-PE (321106) 
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and CX
3
CR1-FITC (341606) (all form Biolegend), CD282-APC ((558319 BD biosciences) and dectin-1-
APC ((FAB1859A) R&D systems).  
Quantitative reverse‐transcription PCR
For qRT- PCR, adherent monocytes were primed with either culture medium or b-glucan and subjected 
after 7 days to a second stimulation with LPS 10ng/ml, Pam3Cys 10μg/ml, or heat-killed C. albicans 1x105/
mL for 4 hours. Samples were treated with TRIzol Reagent (Invitrogen) and total RNA purification 
was performed. Isolated RNA was reverse-transcribed into complementary DNA using iScript cDNA 
Synthesis Kit (Bio-Rad). Quantitative PCR was performed using the SYBR Green method. The following 
primers were used in the reaction (5’-3’): TNFa forward: TGGCCCAGGCAGTCAGA and TNFa reverse: 
GGTTTGCTACAACATGGGCTACA, IL1β forward: GCCCTAAACAGATGAAGTGCTC and IL1β 
reverse: GAACCAGCATCTTCCTCAG, β
2
-microglobulin forward ATGAGTATGCCTGCCGTGTG 
and β
2
-microglobulin reverse CCAAATGCGGCATCTTCAAAC (Biolegio). Each sample was analyzed 
following a relative quantification model with efficiency correction, and β
2
-microglobulin was used as 
housekeeping gene. The mRNA expression level of non-primed and non-stimulated sample was used 
as reference. The results are presented as the ratios of mRNA production by β-glucan in primed vs. 
non-primed monocytes.
Chromatin immunoprecipitation
For Chromatin immunoprecipitation (ChIP), adherent monocytes were cultured as described 
above (cf. “Stimulation experiments”). ChIP was performed using antibodies against H3K4me3 
(Diagenode). ChIPed DNA was further processed for qPCR analysis. The following primers were 
used in the reaction (5’-3’): TNFa forward: CAGGCAGGTTCTCTTCCTCT and TNFa reverse: 
GCTTTCAGTGCTCATGGTGT, IL6 forward: TCGTGCATGACTTCAGCTTT and IL6 reverse: 
GCGCTAAGAAGCAGAACCAC, TLR4 forward: GTCCCTGCTCTGCTACCTTG and TLR4 
reverse: TTGAAAGGAGCAGGGTGACT, myoglobin forward: AGCATGGTGCCACTGTGCT and 
myoglobin reverse: GGCTTAATCTCTGCCTCATGAT.
Mouse experiments
PrkdcSCID mice (abbreviated SCID) were obtained from Charles River Wiga (Sulzfeld, Germany). 
Female mice between 6 and 8 weeks of age were used. The mice were fed with sterilized laboratory 
chow (Hope Farms, Woerden, The Netherlands) and water ad libitum. Mice were housed in a pathogen-
free facility. The experiments were approved by the Ethics Committee on Animal Experiments of the 
Radboud University, Nijmegen. Mice were first injected with BCG vaccine SSI (750μg/mouse) in a 
100μL volume of sterile pyrogen-free phosphate-buffered saline (PBS) or with PBS alone. 14 days later, 
mice were infected intravenously with a lethal dose of C. albicans blastoconidia (1×104 CFU/mouse). 
Survival was then monitored and kidney fungal burden was assessed 3 and 14 days after the C. albicans 
injection. To assess cytokine production, splenocytes from BCG or vehicle- vaccinated mice were 
retrieved 7 days after the intravenous infection with C. albicans and stimulated in vitro with LPS (10 ng/
ml). The measurement of cytokines concentrations was performed using a specific radioimmunoassay, 
as described previously (21) in supernatants collected after 48 hours of incubation at 37°C in 5% CO
2
 
in a 48-well plate.
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Statistical analysis
Differences were analyzed using the Wilcoxon signed rank test or Friedman test for paired samples. 
P<0.05 was considered statistically significant. Otherwise stated, data are shown as cumulative results 
of level obtained in all volunteers (means + SEM).
RESULTS
Monocyte phenotype is modified upon BCG vaccination.
In the first series of experiments, blood was collected from twenty naïve (non-exposed) volunteers, 
before and after (2 weeks and 3 months) vaccination with BCG (Figure 1A).
 As expected, two weeks after BCG vaccination, IFNg production induced by MTB was seven-fold 
higher than the production before vaccination, and this effect remained present after at least three 
months (Figure 1B). Surprisingly however, IFNg production was also significantly increased when 
cells were exposed to unrelated pathogens such as yeasts (7.7-fold increase, Figure 1B) or hyphae 
(5.2-fold increase, Figure S1A) of C. albicans, and S. aureus (3.5-fold induction, Figure 1B). Exposure of 
PBMC to LPS induced production of IFNg in very low amounts that did not differ before and after BCG 
vaccination (Figure S1B).  
Interestingly, in the same series of experiments, the production of the proinflammatory cytokines 
TNFa and IL1β was also found to be enhanced when cells isolated from the volunteers after BCG 
vaccination were exposed to mycobacterial and non-mycobacterial stimuli (Figure 1C,D). Of note, 
the increased production of cytokines remained present 3 months after the BCG vaccination (Figure 
1B‐D). 
These data demonstrate that BCG alters the functional state of circulating mononuclear cells. To further 
explore this, we investigated the expression of known cell surface activation markers of monocytes. We 
observed a slight increase in the population of CD14+ monocytes after BCG vaccination (Figure 2A), 
which all express the differentiation markers CX
3
CR1 and CD11b (Figure S2C, D, E). Interestingly, 
the proportion of CD14+ monocytes expressing TLR4 changed significantly after vaccination (Figure 
S2B). In addition, the expression of CD14 (Figure S2A), TLR4 (Figure 2B‐D) and CD11b (Figure 
2E, F) was enhanced on monocytes isolated 2 weeks and 3 months after BCG vaccination, compared 
with their expression before vaccination. The mean fluorescence intensity of the CX
3
CR1 marker was 
not changed (Figure S2F). No changes could be observed in the proportion or expression of pattern 
recognition receptors such as dectin-1, TLR2 or mannose receptor (Figure S2G‐K). These observations 
show that BCG vaccination can induce long-term changes in the phenotype of circulating monocytes, 
in line with the higher proinflammatory cytokine production after BCG. To examine the level at which 
the enhanced monocyte function is exerted, we assessed whether the increased cytokine production 
was due to enhanced transcription. Indeed, mRNA expression for tnfa and il1β was increased after 
BCG vaccination (Figure 2G). 
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Increased H3K4 trimethylation in monocytes after BCG vaccination.
As there is accumulating evidence that histone modifications (both acetylation and methylation) 
are crucial for long-term transcriptional regulation during inflammation (22-24), the involvement of 
epigenetic mechanisms was assessed. Increased trimethylation of histone H3 at lysine 4 (H3K4), which 
Figure 1: BCG vaccination increased the non-specific production of pro-inflammatory cytokines. (A) Diagram showing the 
course of the BCG vaccination trial. Blood was collected from twenty naïve (non-exposed) volunteers, before and after (2 weeks 
and 3 months) vaccination with BCG. (B‐D) PBMCs isolated from the twenty volunteers before and after (2 weeks and 3 months) 
vaccination were stimulated in vitro with sonicated M. tuberculosis, heat-killed S. aureus and C. albicans blastoconidia. Pro-inflammatory 
cytokine production (INFg (B), TNFa (C) and IL1β (D)) was assessed by ELISA in the supernatants.
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has been previously associated with an increased transcription of proinflammatory cytokine genes 
(23), could represent the mechanism responsible for the long-term modulation of monocyte-derived 
cytokines. In line with this hypothesis, H3K4 trimethylation was found significantly increased at the 
level of cytokine and TLR4 promoters in the circulating cells collected three months after vaccination 
with BCG, compared to the values before BCG vaccination (Figure 2H).
BCG‐induced protection is T and B cell‐independent.
To establish whether BCG-induced trained immunity is indeed mediated by innate immune cells (e.g. 
monocytes) and independent of T and B lymphocytes, we injected either BCG or saline in two groups 
of severe combined immunodeficiency (SCID) mice that lack both T and B cells. Two weeks later, 
both groups of mice were injected with a lethal inoculum of C. albicans. The BCG-vaccinated mice had 
a significantly better survival than the saline-injected animals (Figure 3A), and this was accompanied 
by a decreased fungal burden in the kidneys, the target organ of disseminated candidiasis in mice 
Figure 2: BCG alters the phenotype of circulating monocytes in healthy volunteers. (A) Flow cytometry analysis of CD45 
positive cells. (B) Histogram shows the expression level of CD14+ (% of total cells) in the cells isolated from 20 volunteers before 
and after BCG vaccination. (C) Flow cytometry analysis of TLR4 and CD14 in cells isolated from 1 volunteer before and 3 months 
after BCG vaccination. (D, F) Overlays of the surface expression level of TLR4 (D) and CD11b (F) within CD14+ cells isolated from 
1 volunteer before and 3 months after BCG vaccination. (E, G) Average surface expression level of TLR4 (E) and CD11b (G) within 
the CD14+ monocytes population isolated from 20 volunteers before and after BCG vaccination. *p<0.05, **p<0.01, ***p<0.005. (H) 
il-1β and tnfa mRNA expression after sonicated M. tuberculosis, heat-killed S. aureus and C. albicans hyphae in vitro stimulation of the 
PBMCs isolated from volunteers before and 3 months after BCG vaccination (n³3) (I) Chromatin immunoprecipitation analysis 
of the enrichment of H3K4me3 at the promoter of tnfa, il6 and tlr4 in human monocytes isolated from three subjects before and 3 
months after the BCG vaccination. *p<0.05, paired t-test.
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(Figure 3B). These data strongly support the notion that BCG can induce non-specific protection 
against non-mycobacterial infections through functional reprogramming of innate immune cells such 
as monocytes. In order to demonstrate that the “trained immunity” function of monocytes can also 
be found after BCG vaccination of SCID mice in vivo, we have performed an additional experiment 
in vaccinated mice. As previously, SCID mice lacking functional T and B cells and vaccinated with 
BCG (or with control PBS) were infected with C. albicans, and one week later spleen monocytes were 
re-stimulated in vitro with LPS, a classical inducer of innate immunity responses that is not related to 
mycobacteria. Innate proinflammatory cytokines production induced by LPS was significantly higher 
in the BCG-vaccinated mice (Figure 3C).
Training effects of BCG vaccination are NOD2 and Rip2 dependent.
The mechanisms responsible for the training by BCG was further explored in vitro using human cells. 
Freshly isolated human monocytes were pre-incubated with either culture medium or BCG for 24 
hours, followed by washing of the cells. After a washout period of 7 days, during which cells were 
incubated solely with culture medium, various secondary stimuli were added to the cell culture (Figure 
4A). During the first week monocytes had a viability > 95% either when trained with culture medium 
or BCG, but extension of the experiments beyond 10 days could not be done due to death of primary 
monocytes in longer-term cultures (based on morphology and trypan blue exclusion).  Pre-incubation 
of cells with BCG markedly increased the production of the proinflammatory cytokine TNFa after 
the secondary stimulus (Figure 4B), reproducing the effects observed during BCG vaccination. 
Remarkably, BCG increased production of cytokines induced by a secondary non-mycobacterial 
challenge, such as purified Toll-like receptor (TLR) ligands or whole heat-killed bacteria. 
In a following set of experiments we assessed the receptors and signaling pathways responsible for 
these effects. Blockade of TLR2 or TLR4 receptors by specific inhibitors, or the use of monocytes from 
a dectin-1 deficient individual, did not abolish the training ability induced by BCG (Figure 4C‐E). 
In contrast, monocytes isolated from patients with a complete NOD2 deficiency due to homozygous 
Figure 3: BCG vaccination protects mice against lethal Candida albicans infection through a T/B lymphocyte‐independent 
mechanism. (A) Survival rate of SCID mice to an infection with live C. albicans (2×106 CFU/mouse) injected intravenously. Mice 
were either vaccinated intravenously with PBS (Control) or BCG, 14 days prior to inoculation of lethal C. albicans dose (n≥15 per 
group, 2 independent experiments).  (B) Fungal burden of kidneys from control and BCG vaccinated SCID mice 3 and 14 days after 
the lethal C. albicans infection (n=5). (C) TNFa production of spleen monocytes after re-stimulation in vitro with LPS from control 
and BCG vaccinated SCID mice 7 days after the lethal C. albicans infection (n=5). *p<0.05, **p<0.01, ***p<0.005. vs control (PBS) 
animals.
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Figure 4: BCG primes the production of pro-inflammatory cytokines. (A) Diagram showing the course of the in vitro pre-
incubation experiment. Cells were pre-exposed to culture medium or BCG vaccine for 24 hours (1st stimulation - training). After 
the first stimulus was washed, the cells were incubated for 7 days in culture medium supplemented with serum. Afterwards, a 
second in vitro stimulation (2nd stimulation) of cytokine production with various PRR ligands was performed for an additional 
24 hours. (B) BCG training in vitro using freshly isolated adherent monocytes (C, D) Inhibition of TLR4 or TLR2 does not affect 
the training effects induced by BCG. (E, F) BCG training of monocytes is severely affected in cells obtained from NOD2-deficient 
volunteers (F) but not from Dectin1-deficient volunteer (E). (G) The training effects induced by BCG could be reproduced with 
MDP but not with Pam3Cys or LPS. (H, I) TNFa production in BCG-primed monocytes in the absence or presence of Rip2/p38 
inhibitor (I), the histone demethylase inhibitor pargyline, or of the histone methyltransferases inhibitor MTA (H). (C‐I) The ratios 
of cytokine production in BCG primed vs. non-primed monocytes are presented. Data presented in (E) are mean of two independent 
experiments (n=1+1). Data presented in (F) were each obtained from 12 healthy volunteers (control) and two different NOD2-
deficient individuals (NOD2-/-). (B‐D, G‐I) *p<0.05, **p<0.01, ***p<0.005. Data are presented as mean ± SD (n ³ 6). Wilcoxon signed 
rank test was used to detect significant differences.
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presence of the 1022insC frameshift mutation were not able to mount an increased cytokine response 
upon training with BCG (Figure 4F). This is a strong argument that NOD2, but not TLRs or the 
C-type lectin receptor dectin-1, is required for the training of monocytes by BCG. This conclusion is 
further supported by experiments showing that only the NOD2 specific ligand muramyl dipeptide 
(MDP), but not the TLR4 ligand LPS or the TLR2 ligand Pam3Cys, was able to mimic the effects of 
BCG pre-incubation on cytokines production by monocytes (Figure 4G). In line with this effect of 
MDP, an inhibitor of the Rip2 kinase also impaired the BCG induced training (Figure 4H). These 
data are further supported by a recent study demonstrating priming effects of NOD2 engagement for 
stimulation of human macrophages with mycobacteria (25).
Finally, as H3K4me3 was increased after BCG vaccination in vivo, we investigated whether blocking 
histone methylation may reverse monocyte training in vitro. Indeed, inhibition of histone methylation 
by the methyltransferase inhibitor MTA (5’-deoxy-5’-methylthio-adenosine) almost completely 
reversed the training induced by BCG (Figure 4I). In contrast, the histone demethylase inhibitor 
pargyline did not influence the training effects induced by BCG.
DISCUSSION
The non-specific adaptive features of innate immunity (26) that have been demonstrated in plants, 
invertebrates and mice and that we termed “trained immunity” (5) have not been demonstrated until 
now to be active in vivo in humans, and the molecular substrate of “trained immunity” has not yet been 
identified. In the present study, we demonstrate that monocytes can be functionally reprogrammed, 
or “trained”, to exhibit an enhanced and lasting phenotype after vaccination with BCG. These data 
point to the mononuclear phagocyte as the cell that mediates the non-specific protection against 
reinfection after BCG vaccination. Our data also imply that vaccination with BCG induces two types 
of immune response: on the one hand it induces classical specific immune response involving antigen-
specific T cells and memory leading to protection against TB; while on the other hand BCG induces 
adaptive trained immunity based on functional reprogramming of mononuclear phagocytes that induces 
protective effects not only against tuberculosis, but also against other infections. In a combination of 
in vivo and in vitro experiments, we demonstrate that a NOD2-mediated epigenetic change at the level 
of histone methylation (H3K4me3) is the mechanism through which BCG enhances innate immune 
responses.
The mechanisms activated by BCG vaccination are almost certainly multiple and complex: classical 
adaptive immune memory, epigenetic reprogramming (“training”) of innate immunity as described 
here, but possibly also secondary non-specific effect of adaptive immunity on innate immune responses 
(e.g. increased cytokines, as shown in the study of Strutt et al. (27)). Conceptually, it is important to 
discern between the classical adaptive immunity mediated by T and B lymphocytes and the trained 
immunity mediated by innate immune cells. In this respect, trained immunity reflects an increase 
in non-specific antimicrobial capacity through epigenetic reprogramming, close to the concept of 
adaptive characteristics of innate immunity, as described by Mantovani (26, 28). Moreover, whereas 
the adaptive immune cells mediated responses take some time to become robust, innate (trained) 
immunity becomes apparent much sooner. This was also recently demonstrated in epidemiological 
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studies in which the beneficial effects of BCG in newborn children are apparent already within days 
of the vaccination (29). The rapidity of the non-specific adaptive characteristics of innate immunity 
underlines that heterologous adaptive responses cannot fully explain trained immunity.  
The impact of the training effects on innate immune responses becomes apparent in our experiments 
in which SCID mice are vaccinated with BCG: these mice were protected from mortality, and the 
kidney burdens were reduced to 20-40% of the levels in the unvaccinated mice after a secondary 
lethal infection with C. albicans. Old studies with BCG in experimental schistosomiasis demonstrated 
similar protection that was at least partially T cell-independent (30). It is an obvious thing to link 
these experimental results to the non-specific protection against non-mycobacterial disease conferred 
by BCG (8,9,12-20). In the present study, we provide for the first time mechanistic insights into the 
processes mediating the adaptive features of innate immunity, or trained immunity, in humans. Both the 
modified methylation status of cytokine promotors after BCG vaccination in human monocytes, as 
well as the blockade of the in-vitro training effects with methyltransferase inhibitors, suggest that the 
innate immune response in humans can be reprogrammed epigenetically. Similar mechanisms have 
been demonstrated before in plants, during the so-called “systemic acquired resistance” (1), and in 
invertebrates (31), however, both classes of organisms are devoid of adaptive immune responses. The 
present study teaches us that also in the presence of adaptive immunity – as is the case in mammals - 
training of innate immunity is operational and serves to enhance resistance to infection.
One important point for discussion is also whether the training effects of BCG vaccination are 
exclusively due to epigenetic reprogramming of innate immune cells, or whether long-term BCG 
infection may also play a role. Little is known on how long BCG stays viable in the human body. 
Fortunately however, a very recent study by Minissian et al. has reported that four weeks after 
vaccination, only 50% of individuals still display viable BCG at the site of vaccination (32). Although 
we cannot fully exclude a low persistence of BCG in a minority of the volunteers, it is to be expected 
that in the majority of them, all the microorganisms have been cleared after three months. Moreover, 
in our in vitro experimental setting of trained immunity, monocytes were trained with live BCG as 
well as with inert muramyl dipeptide, highlighting that live BCG persistence is not mandatory for the 
training. 
It should be stressed that trained immunity in mammals is not solely induced by BCG. Indeed, murine 
CMV infection can induce protection to reinfection in a T/B cell-independent and NK cell-dependent 
fashion (4, 33); and systemic infection with C. albicans induced T/B cell independent non-specific 
protection in mice (34). The role of epigenetic reprogramming was not investigated in these studies. 
In conclusion, in this study we provide for the first time firm evidence that innate immunity in humans 
has adaptive features, and it has the capacity to display an enhanced response upon reinfection. This 
process of trained immunity is likely to represent a paradigm shift in immunity, as it demonstrates the 
existence of (non-specific) immunological memory in the absence of adaptive immune responses. Better 
insights into the relative role of adaptive immune memory and epigenetic reprogramming of innate 
immunity (trained immunity) may have important consequences for vaccine design, more specifically 
with regard to selection of antigens and the development of adjuvants. In this respect, answers remain 
to be provided regarding the strength and duration of epigenetically-induced trained immunity. In this 
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context, it is important to note that BCG and the NOD2-ligand MDP have long been known to induce 
non-specific protective effects against infections (7, 15) and neoplasms (35), providing the hope that 
trained immunity can indeed be harnessed for preventive and therapeutic purposes.
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SUPPLEMENTARY MATERIAL
Figure S1: Non-specific production of INFg after BCG vaccination. The production of INFg was assessed by ELISA 
in the supernatants collected after in vitro stimulation with heat-killed C. albicans pseudohyphae (A) or LPS (B). *p<0.05.
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Figure S2: BCG alters the phenotype of circulating monocytes. (A) Flow cytometry analysis of CD11b within CD14 in 
cells isolated from 1 volunteer before and after BCG vaccination. (B, C, D) Histograms show the expression level of the 
specific monocyte differentiation marker CD11b (B), CX
3
CR1 (C) and TLR4 (D) within the CD14+ monocytes population 
isolated from 20 volunteers before and after BCG vaccination. (E, F) Histograms show the average surface expression level 
of CD14+ (E), CX
3
CR1 (F) and dectin-1 (G) on the cells isolated from 20 volunteers before and after BCG vaccination. (H,I) 
Histograms show the expression level of the pattern recognition receptors TLR2 (H) and mannose receptor (I) within the 
CD14+ monocytes population isolated from 20 volunteers before and after BCG vaccination. (J,K) Histograms show the 
average surface expression level of TLR2 (J) and mannose receptor (K) on the cells isolated from 20 volunteers before and 
after BCG vaccination.*p<0.05, **p<0.01, ***p<0.005. 
Journal of Innate Immunity 
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ABSTRACT 
We have recently shown that BCG vaccination in healthy volunteers induces epigenetic reprogramming 
of monocytes, leading to increased cytokine production in response to non-related pathogens for up 
to three months after vaccination. This phenomenon was named ‘trained immunity’. In the present 
study we assessed whether BCG was able to induce long-lasting effects on both trained immunity 
and heterologous T-helper 1 (Th1) and Th17 immune responses one year after vaccination. The 
production of TNFa and IL1β to mycobacteria or unrelated pathogens was higher after two weeks 
and three months post-vaccination, but these effects were less pronounced one year after vaccination. 
However, monocytes recovered one year after vaccination had an increased expression of pattern 
recognition receptors such as CD14, TLR4, and mannose receptor, and this correlated with an increase 
in pro-inflammatory cytokine production after stimulation with the TLR4 ligand lipopolysaccharide. 
The heterologous production of Th1 (IFNgamma) and Th17 (interleukin (IL)17 and IL22) immune 
responses to non-mycobacterial stimulation remained strongly elevated even one year after BCG 
vaccination. In conclusion, BCG induces sustained changes in the immune system associated with 
non-specific response to infections both at the level of innate trained immunity, as well as at the level 
of heterologous Th1/Th17 responses.
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INTRODUCTION
Non-specific beneficial effects of BCG have been described for many decades. Soon after its 
introduction in the 1920s, epidemiological studies surprisingly demonstrated that BCG protects 
against infant mortality independent of its effect on tuberculosis (TB) (1-5). Recent studies supported 
these findings and suggested a reduction of the burden of infections other than TB (6-10). For example, 
BCG decreased by half the neonatal mortality of children in several recent trials in West-Africa (8, 9, 
11-14), while in a case-control study in Brazil, BCG reduced the risk of death from pneumonia by 50% 
in children less than one year of age (7). In light of these data, the question arises which mechanisms 
mediate these non-specific immune effects of BCG, and how long do they last. 
Two possible immunological mechanisms have been proposed to explain non-specific beneficial 
effects of vaccination. The first such mechanisms is heterologous immunity, in which cross-protection 
is mediated by heterologous T cell memory responses (15). However, heterologous immunity needs at 
least a couple of weeks to develop, and it is thus highly unlikely to be responsible for the very rapid 
effects observed on perinatal immunity (14). A second mechanism of protection has been recently 
proposed in the form of epigenetic reprogramming of immune cells, a phenomenon conferring non-
specific immune memory to innate immune responses and termed ‘trained immunity’ (16). Many 
species of organisms lacking adaptive immunity, such as plants (17) or insects (18, 19), manifest 
robust immune memory after previous exposure to infections or certain microbial components, 
and adaptive features of innate immunity have also been demonstrated in mice devoid of functional 
adaptive immune responses (20, 21). Prominent microbial components that are able to potentiate 
the effector function of innate immune cells and protect against infections are mycobacterial stimuli 
such as Bacillus Calmette-Guérin (BCG), complete Freund’s adjuvant and muramyl dipeptide (22-
25). Recently, we have shown that BCG vaccination in healthy volunteers led to NOD2-dependent 
epigenetic reprogramming of monocytes, which resulted in an increased expression of cellular 
receptors on the monocytes, accompanied by higher cytokine production in response to non-related 
pathogens (26). This newly described mechanism might represent the explanation for the rapid non-
specific protective effects induced by BCG vaccination. However, it is not known how long trained 
immunity and/or heterologous immunity persist after BCG vaccination.
Therefore, in the present study we investigated the long-term non-specific effects of BCG vaccination 
in healthy volunteers, by assessing the responses of both innate and adaptive immune cells to non-
mycobacterial stimulation in a period extending up till one year after the vaccination. 
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MATERIALS AND METHODS
Subjects
Individuals (age range 20-36 years) scheduled to receive a BCG vaccination at the public health service 
because of travel or work in TB-endemic countries were asked to participate in this trial. Twenty 
healthy individuals were included between August and November 2010. Blood was drawn before 
the vaccination, and two weeks, three months, and one year after the BCG vaccination. Two persons 
were lost to follow-up after three months. The study was approved by the Arnhem-Nijmegen Ethical 
Committee. 
PBMC stimulation assays
For the PBMC stimulation assays the mononuclear cell fraction was isolated by density centrifugation 
from blood diluted 1:1 in pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, PA, USA). Cells 
were washed twice in saline and resuspended in culture medium (RPMI, Invitrogen, CA, USA) 
supplemented with gentamicin 10 μg/ml, L-glutamine 10 mM, and pyruvate 10 mM. Cells were counted 
in a Coulter counter (Coulter Electronics) and the number was adjusted to 5x106 cells/ml. A total of 
5x105 mononuclear cells in a 100μl volume was added to round-bottom 96-wells plates (Greiner) with 
RPMI or with sonicated Mycobacterium tuberculosis (MTB) H37Rv (1μg/ml end protein concentration), 
heat-killed Candida albicans (1x106 microorganisms/ml, strain UC820), Staphylococcus aureus (1x106 
microorganisms/ml, clinical isolate), or E. coli lipopolysaccharide (LPS, Sigma-Aldrich, 1ng/ml). After 
24 hours, 48 hours, or 7 days supernatants were stored at -20°C. Cytokine concentrations were 
assessed in the supernatants using enzyme-linked immunosorbent assay (ELISA). 
Cytokine measurements
Circulating IFNg, IL17 and IL22 was measured in plasma with Sanquin Pelikine ELISA kits (IFNg) 
or R&D Quantikine ELISA kits (IL17 and IL22), respectively following the description of the 
manufacturer.
Cytokine measurements of TNFa, IL1β, IFNg, IL17, and IL22 after PBMC stimulation were performed 
in the supernatants using commercial ELISA kits from R&D Systems, MN, USA (TNFa, IL1β, IL17 
and IL22) or Sanquin, Amsterdam, The Netherlands (IFNg). In a small proportion of baseline samples 
in which cytokine concentrations were beyond the detection limit, these outliers were excluded from 
the analysis.
FACS analysis
Cells were phenotypically analyzed by ten-colour and five-colour flow cytometry using a Coulter 
Navios and Coulter Cytomics FC 500 respectively (Beckman Coulter, Fullerton, FL) and evaluated 
using Kaluza 1.1 software (Beckman Coulter). In order to guaranty reliable result the flow cytometry 
was calibrated with flow set pro beads (Beckman Coulter). Cells were washed with PBS with 1% 
bovine serum albumin before being labeled with fluorochrome-conjugated mAbs. After incubation 
for 30 min at 4°C in the dark, cells were washed twice to remove unbound antibodies and analyzed. 
For cell surface staining, the following mAbs were used: CD3-PECy7 (737657), CD4-PB (A82789), 
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CD8-APC-A700 (A66332), CD45-PO (A96416), CD11b-PE (IM25814), CD14-ECD (IM2707U), CD45-
PC7 (IM3548) (all from Beckman Coulter Corporation), CD284-PE (TLR 4) (312806) and CD206-PE 
(321106) (both form Biolegend), CD16-FITC (335035) and CD282-APC (TLR2) (558319) (both from 
BD biosciences) and dectin-1-APC ((FAB1859A) R&D Systems).  
Statistical analysis
Differences were analyzed using the Wilcoxon signed rank test or Friedman test for paired samples. 
P<0.05 was considered statistically significant. Unless otherwise stated, data are shown as cumulative 
results of data obtained in all volunteers (means + SEM).
RESULTS
The effect of BCG vaccination on heterologous Th1 and Th17 responses
FACS analyses of T-cell subpopulations did not show major shifts in CD4 and CD8 lymphocytes 
(Supplementary Figure 1). Circulating concentrations of the T cell derived cytokines IFNg, IL17 
and IL22 were below detection limit at all time points (data not shown). In contrast, two weeks and 
three months after BCG vaccination, IFNg production induced by MTB was seven-fold higher than 
the production before vaccination, as also reported previously (26). Interestingly, this effect remained 
present for at least one year (Figure 1A). A similar increase in cytokine production after two weeks and 
three months was observed when cells were stimulated with unrelated pathogens (Candida albicans; 
Figure 1B or Staphylococcus aureus; Figure 1C). The increased production persisted until one year 
after vaccination in case of S. aureus, while it largely retuned to pre-vaccination levels after C. albicans 
stimulation.
In addition to its effects on Th1 responses, we sought to investigate the effect of BCG vaccination on 
the production of Th17-derived cytokines, namely IL17 and IL22. MTB-stimulated IL17 production was 
significantly higher in cells retrieved after BCG vaccination (Figure 2A). Moreover, this effect was 
independent of the stimulating pathogen, as a persistently increased IL17 production was also observed 
upon stimulation with C. albicans (Figure 2B) and S. aureus (Figure 2C). The increased heterologous 
Th17 immunity was also reflected by the potentiated IL22 production after BCG vaccination. This was 
apparent after stimulation of cells with MTB, C. albicans or S. aureus (Figure 2D‐F).
The effect of BCG vaccination on trained immunity
Previously, we reported that BCG affected production of proinflammatory cytokines produced by 
monocytes, a prototypic innate immune cell population (26). While TNFa and IL1β production was 
higher two weeks and three months after vaccination, it largely returned to normal one year after 
BCG vaccination. This waning effect on TNFa and IL1β release was observed upon stimulation of the 
cells with MTB, as well as with the non-related pathogen C. albicans  (Figure 3A, B) or S. aureus (not 
shown).  Similar data were obtained on IL1β production (data not shown). However, LPS-induced 
TNFa (Figure 3C) and IL1β  (Figure 3D) production one year after vaccination remained significantly 
higher compared to pre-vaccination levels. 
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The effect of BCG vaccination on receptor expression on monocytes
The expression of several pattern recognition receptors and activation markers on monocytes showed 
a sustained rise in expression over time. Presented in Figure 4 are mean fluorescent indexes (MFI) of 
either markers of activity of monocytes (CD14; Figure 4A and CD11b; Figure 4B), Toll-like receptor 4 
(TLR4) and TLR2 (Figure 4C and 4D), and C-type lectins (CLRs) (Mannose receptor (MR); Figure 
4E, and dectin-1; Figure 4F). The increase in MFI was receptor specific, as not all TLRs or CLRs have 
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Figure 1. BCG vaccination increased the heterologous Th1 responses. (A‐C) PBMCs isolated from eighteen volunteers 
before and after (2 weeks, 3 months, and 1 year) vaccination were stimulated in vitro with sonicated M. tuberculosis (A), heat-
killed C. albicans yeast, (B), and S. aureus (C). IFNg production was assessed in the supernatants by ELISA. *p<0.05, **p<0.01.
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Figure 2. BCG induces long lasting heterologous Th17 responses. (A-F) PBMCs isolated from eighteen volunteers before 
and after (2 weeks, 3 months, and 1 year) vaccination were stimulated in vitro with sonicated M. tuberculosis (A,D), heat-
killed C. albicans yeast, (B,E), and S. aureus (C,F). IL17 (A-C) and IL22 (D-F) production was assessed by ELISA in the 
supernatants. *p<0.05, **p<0.01, ***p<0.005.
116
been influenced by the vaccination. The activity markers CD14 and CD11b showed persistent higher 
levels of expression on monocytes that lasted for at least one year. Also TLR4 and MR expression on 
monocytes were increased after BCG vaccination one year after vaccination. No effect was seen on 
the expression of TLR2 or dectin-1 (Figure 4D and F). Supplementary Figure 2 shows the gating 
strategy for monocytes used in Figure 4. In addition, supplementary Figure 3 presents representative 
histograms of all receptors shown in Figure 4.
DISCUSSION 
BCG has beneficial effects on infections other than tuberculosis, yet the immunological mechanisms 
responsible for these effects remain obscure. Recently, two immunological mechanisms have been 
suggested to mediate these effects: the short-time effects are most likely mediated by epigenetic 
reprogramming of innate immune cells, a process called ‘trained immunity’ (26), while long-term 
effects may be mediated by heterologous Th1/Th17 immunity (15), possibly in combination with 
residual trained immunity effects. In the present study we show that BCG vaccination induces non-
Figure 3. Effect of BCG on innate immune cytokines. (A-F) PBMCs isolated from eighteen volunteers before and after 
(2 weeks, 3 months, and 1 year) vaccination were stimulated in vitro with sonicated M. tuberculosis (A), heat-killed C. albicans 
yeast, (B), and LPS (C,D). TNFa (A-C) and IL1β (D) production was assessed by ELISA in the supernatants. *p<0.05, 
**p<0.01.
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specific potentiation effects of both innate trained immunity and heterologous T-helper responses that 
are clearly present for at least one year after vaccination.
The long-term effects after BCG vaccination are most prominent on heterologous Th1 and Th17 
responses. An explanation for this could be the process of ‘cross-protection’ described five decades 
ago (27), or termed later as ‘heterologous immunity’ (15, 28). The classical form of cross-protection 
is mediated by lymphocytes that release IFNg after stimulation with a first-encountered pathogen 
and subsequently activate bystander macrophages, generating a state of temporary heightened innate 
immunity against a secondary infection, which wanes rapidly once the primary pathogen is eliminated 
(29). The second form is long-lived and therefore maybe more comparable with our findings: Berg et 
Figure 4: BCG alters the phenotype of circulating monocytes in healthy volunteers. Average surface expression level 
of activation markers CD14+ (A) and CD11b (B), Toll like receptors TLR4 (C) and TLR2 (D), and C-type lectin receptors 
Mannose receptor (MR) (E) and Dectin-1 (F) within the CD14+ monocytes population isolated from 18 volunteers before 
and after BCG vaccination.  *p<0.05, **p<0.01, ***p<0.005
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al. described that both effector and memory CD8+ cells have the potential to secrete IFNg in response 
to IL12 and IL18 in the absence of a related antigen (30). The IL12 and IL18 are produced in the initial 
stages of a secondary infection. One additional possible explanation can be epitope sharing as described 
previously although this is unlikely to play a major role for explaining the increased responses to C. 
albicans or S. aureus  after BCG vaccination. 
One could speculate that the increased reactivity of Th17 cells occurs in a similar fashion. The general 
principle of the induction of Th17 responses is similar to that of Th1 immunity, with the difference that 
IL1β and IL23 (rather than IL12 and IL18) are the cytokines responsible for Th17 differentiation. The 
increased expression of pattern recognition receptors known to induce Th17 responses such as MR 
(31), and proinflammatory cytokines such as IL1β(32), may at least partly account for the induction 
of heterologous Th17 immunity. The increase in these typical innate immune responses during the 
induction of trained immunity could thus contribute to heterologous T-helper responses, but this 
direct relationship remains to be formally demonstrated by future studies. In addition, one may also 
speculate regarding potential deleterious effects of BCG-induced heterologous immunity during 
autoimmune processes. An important difference between BCG vaccination and autoimmune disorders 
is that while autoimmunity induces spontaneous IL17 production with autoimmune tissue damage, 
BCG vaccination only induces a primed status of the cells to respond stronger to secondary microbial 
stimulation. Without stimulation, no higher production of these cytokines was seen. In line with this, 
one study even reported a beneficial effect of BCG vaccination on type 1 diabetes mellitus (33), and 
beneficial effects on asthma and allergies have also been reported (34).
In addition to the effects on heterologous immunity, BCG vaccination also shows long-term effects on 
innate trained immunity. This is revealed by the persistent increase in LPS-mediated proinflammatory 
cytokine production, and expression of pattern recognition receptors (PRRs) and monocyte activation 
markers. One may hypothesize that these two effects are related, as it is mainly the expression of 
the LPS receptors TLR4 and CD14 (35) that remained high one year after BCG that are responsible 
for enhanced cytokine responses after LPS stimulation. In contrast, the expression of other PRRs 
such as dectin-1 and TLR2 was not affected by BCG vaccination. While alterations in S. aureus and C. 
albicans-mediated cytokine production were clearly present 2 weeks and 3 months after vaccination, 
these effects waned after one year. This suggests that at least for some innate immune pathways, the 
epigenetic reprogramming responsible for the trained immunity effects (26) are relatively short-lived 
and present for months, rather than years.
In conclusion, in the present study we characterize the long-term non-specific immunological effects 
of BCG vaccination. We have previously shown that innate immunity has adaptive features named as 
trained immunity (16). While a maximum duration of trained immunity effects of three months has 
been reported to date (26), in the present study we show that the non-specific training effects of BCG 
vaccination on receptor expression and LPS-induced proinflammatory cytokines is long-standing and 
present for at least one year. In addition, strongly increased heterologous Th1 and Th17 responses have 
been observed one year after the vaccination. These double effects of BCG vaccination on both trained 
immunity and heterologous T cell responses provide a likely explanation for both the short-term and 
long-term non-specific effects of BCG, which are already known for decades and may have important 
implications for vaccine development and healthcare policy.
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SUPPLEMENTARY MATERIAL
Figure S1. No differences in T cell population after BCG vaccination. Histograms show the expression level of CD4, 
CD8 or both receptors as percentage of totalcells (A, B, and C, respectively) and within the CD3+ population (D, E and F, 
respectively) isolated from 18 volunteers before and after BCG vaccination.
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Figure S2. Flow cytometry analysis of peripheral blood cells of one volunteer as example of the gating strategy forward 
scatter against side scatter and CD14 against CD16 positive cells.
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Figure S3. BCG alters the phenotype of circulating monocytes in healthy volunteers.Flow cytometry analysis of surface 
markets within CD14+ cells isolated from 1 volunteerbefore and 1 year after BCG vaccination, activation markers CD14+ 
(A) and CD11b (B), Toll like receptors TLR4 (C) and TLR2 (D), and C-type lectin receptors Mannose receptor (MR) (E) 
and Dectin-1 (F).
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ABSTRACT
Adaptive features of innate immunity, also termed ‘trained immunity’, have recently been shown to 
characterize monocytes of BCG vaccinated healthy volunteers. Trained immunity leads to increased 
cytokine production in response to non-related pathogens via epigenetic reprogramming of monocytes. 
Recently, memory-like properties were also observed in NK cells during viral infections, but it is 
unknown if memory properties of NK cells contribute to trained immunity due to BCG vaccination. 
BCG vaccination of healthy volunteers increased proinflammatory cytokine production following ex 
vivo stimulation of NK cells with mycobacteria and other unrelated pathogens up until at least three 
months after vaccination. In addition, in a murine model of disseminated candidiasis, BCG vaccination 
led to an increased survival in SCID mice, which was partially dependent on NK cells.
These findings suggests that NK cells may contribute to the non-specific (heterologous) beneficial 
effects of BCG vaccination.  
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INTRODUCTION
The traditional paradigm in immunology is that innate immunity - as opposed to adaptive immunity - 
is static, and does not adapt after encountering an external stimulus to an enhanced functional state. 
However, we have recently shown that Bacillus Calmette Guerin (BCG) (1) and Candida albicans (2) can 
induce enhanced non-specific protection to infections though epigenetic programming of monocytes, 
and we proposed the term ‘trained immunity’ for this effect (3). 
Natural killer (NK) cells are an important cellular component of innate immune system. Interestingly, 
recent studies have shown that mouse and human NK cells exhibit adaptive memory-like properties, 
as they can be primed for enhanced IFNg production upon restimulation (4-7). O’ Leary et al. 
were the first to report that mouse NK cells may have recall responses to haptens during a delayed 
hypersensitivity response, a phenomenon previously attributed to T cells (4). Later it was shown that 
initial stimulation of murine and human NK cells with interleukin 12 and 18 (IL12 and IL18) leads 
to increased IFNg production after restimulation with cytokines or activating receptor ligation up 
to three weeks afterwards (5, 6). In addition, Sun et al. described murine ‘memory’ NK cells with 
enhanced reaction upon restimulation, which are present after an initial infection with murine 
Cytomegalovirus (MCMV) (7).
These studies have shown adaptive characteristics of NK cells, with increased IFNg production 
upon re-exposure to cells with the same stimulus. In trained immunity, however, we observe that re-
exposure to both the same or unrelated stimuli induce an enhanced secondary response, due to the non-
specific nature of epigenetic priming of the cells (1, 2). Moreover, we have recently shown that trained 
immunity of monocytes induced by BCG vaccination lasts up to one year after the vaccination (8), and 
it is tempting to regard this effect as a mechanism for the non-specific (heterologous) protective effects 
of BCG vaccination (9). Considering the memory-like characteristics described for NK cells, in the 
present study we tested the hypothesis that NK cells also contribute to trained immunity after BCG 
vaccination in both human volunteers and in experimental murine disseminated candidiasis. 
MATERIAL AND METHODS
Subjects
Twenty-nine individuals (age range 20-36  years) scheduled to receive a BCG vaccination at the 
public health service because of travel or work in TB-endemic countries (starting after the study was 
finished) were included in the study. Blood was drawn before BCG vaccination, as well as two weeks 
and three months afterwards. In the first twenty volunteers the cytokine measurements were done 
on total PBMCs, therefore an extra nine volunteers were recruited to determine the role of NK cells. 
There are no demographic differences between the groups. The study was approved by the Arnhem-
Nijmegen Ethical Committee, and written informed consent was given by all the participants. 
Cellular stimulation assays
The mononuclear cell fraction was isolated from blood by density centrifugation of blood, diluted 1:1 in 
pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, PA, USA). Cells were washed twice in saline 
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and resuspended in culture medium (RPMI, Invitrogen, CA, USA) supplemented with gentamicin 10 
μg/ml, L-glutamine 10 mM, and pyruvate 10 mM. CD14+ (monocytes) and CD56+ (NK cells) subsets 
were purified from freshly isolated PBMCs using MACS microbeads, according to the instructions of 
the manufacturer (Miltenyi Biotec). Purity was checked with FACS and was >90%. Cells were counted 
in a Coulter counter (Coulter Electronics) and the number was adjusted to 5x105 cells/ml. A total of 1 
x 105 monocytes or NK cells in a 100μl volume was added to round-bottom 96-wells plates (Greiner) 
with RPMI (with a additions as previously mentioned) or with sonicated Mycobacterium tuberculosis 
H37Rv (1μg/ml final concentration), heat-killed C. albicans (1x106 microorganisms/ml, strain UC820), 
Staphylococcus aureus (1x106 microorganisms/ml), or Escherichia coli lipopolysaccharide 1ng/ml (LPS, 
Sigma-Aldrich, 1ng/ml). After 48 h supernatants were stored at -20°C. Cytokine concentrations were 
assessed in the supernatants using enzyme-linked immunosorbent assay (ELISA).
Cytokine measurements
Cytokine measurements of TNFa, IL1β, IL6, IFNβ and IFNg were performed in the supernatants using 
commercial ELISA kits from R&D Systems, MN, USA (TNFa and IL1β) PBL assay science, Piscataway, 
USA (IFNβ) or Sanquin, Amsterdam, The Netherlands (IL6 and IFNg). 
Flow cytometric analysis
Cells were phenotypically analyzed using a NaviosTM instrument with 10-color PMTs and three 
solid-state lasers (Beckman Coulter, Fullerton, FL). The list mode data files were further analyzed 
using KaluzaTM software (Beckman Coulter). In order to guarantee that the optics, laser, fluidics 
and fluorescence intensity were stable during all measurements calibration was performed using 
Flow Check Pro Fluorospheres (Beckman Coulter) and Cyto-Cal Multifluor + Violet Fluorescence 
Alignment Beads (Thermo Scientific, Fremont, CA). Cells were washed with PBS with 1% bovine 
serum albumin before being labelled with fluorochrome-conjugated mAbs. After incubation for 30 min 
at 4°C in the dark, cells were washed twice to remove unbound antibodies and analyzed. For cell 
surface staining, the following mAbs were used: CD3-ECD (A07748), CD16-FITC (IM0814U), CD45-
Krome Orange (A96416), CD56-APC-Alexa Fluor750 (custom made), CD158a-APC-Alexa Fluor700 
(custom made), CD158b-PC7 (A66901), CD158e1/e2-APC (A60795), CD159a-PC5.5 (custom made) 
(all from Beckman Coulter, Marseille, France) and CD159c-PE (FAB138P; R&D). 
Mouse experiments
Non-obese diabetic (abbreviated NOD) -Prkdcscid mice (abbreviated SCID) lacking functional B and T 
cells, and NOD-PrkdcscidIL2rgtm1Wjll (abbreviated NOD/SCID/IL2Rg, NSG) mice lacking B, T and NK cell, 
were obtained from Charles River Wiga (Sulzfeld, Germany). Female mice between 6 and 8 weeks of 
age were used. The mice were housed in a pathogen-free facility and were fed with sterilized laboratory 
chow (Hope Farms, Woerden, The Netherlands) and water ad libitum. The experiments were approved 
by the Ethics Committee for Animal Experiments of the Radboud University, Nijmegen. Mice were first 
injected with BCG vaccine SSI (750 μg/mouse) in a 100μL volume of sterile pyrogen-free phosphate-
buffered saline (PBS) or with PBS alone. Two weeks later, mice were infected intravenously with a 
lethal dose of C. albicans blastoconidia (2×106 CFU/mouse). Survival was monitored for 28 days after 
the C. albicans injection.
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Statistical analysis
Differences were analyzed using the Wilcoxon signed rank test or Friedman test for paired samples. 
P<0.05 was considered statistically significant. Otherwise stated, data are shown as cumulative results 
of level obtained in all volunteers (means + SEM).
RESULTS 
BCG does not change the proportion of NK cell subsets
In a first set of experiments, we examined possible changes in NK cell subsets following BCG 
vaccination. So far, no specific phenotypic marker has been described for memory or memory-like 
NK cells. For increased IFNg production there are some candidate markers that have an established 
correlation with human NK cell IFNg production, such as CD94, CD69, CD159a and CD159c (6). We 
decided to include some of these markers and in addition some novel activity and inhibitory markers 
of NK cells. NK cells can be divided into CD56dimCD16+ and CD56brightCD16- cell subsets, which differ in 
their homing properties. Because approximately 90% of peripheral blood NK cells are CD56dimCD16+, 
we decided to assess the differential expression of activation or inhibitory markers in this most 
prominent subset. The CD56brightCD16- NK cells dwell mainly in the lymph nodes and tonsils; hence 
their number in our samples is too low to observe changes in activity and inhibitory cell markers.
Significant changes were noted neither in the number and distribution of NK cell subsets following 
BCG vaccination (Table 1), nor in the mean fluorescence indexes of these markers (MFI; Table 2). 
Table 1. Percentage of total cells of 20 volunteers before and after BCG vaccination
Before BCG 2 weeks 3 months p
mean sd mean sd mean sd
CD56dimCD16+ 2.25 1.56 2.24 1.01 2.30 1.40 0.97
CD56brightCD16- 0.07 0.06 0.07 0.04 0.05 0.04 0.09
CD158a+    (KIR2DL1)A 25.8 6.91 24.9 5.86 25.0 6.92 0.76
CD158b+    (KIR2DL2)A 32.5 9.76 31.1 8.15 31.7 10.1 0.25
CD158e1+  (KIR3DL1)A 15.7 12.2 14.1 10.9 15.6 11.1 0.76
CD159a+     (NKG2a)A 46.1 14.1 46.9 13.9 45.2 13.3 0.07
CD159c+      (NKG2c)A 4.40 2.72 4.30 2.60 4.25 2.57 0.83
A percentage of CD56
dim
CD16+ for the activity markers (CD158a,b,e and CD159a,c) 
BCG vaccination does not increase interferon‐gamma production by NK cells 
Two weeks and three months after BCG vaccination, isolated monocytes displayed slightly increased 
IFNg production in response to unrelated stimuli including S. aureus and C. albicans (Supplementary 
Figure 1), in accordance with previous observations (1). In contrast, isolated NK cells did not display an 
increase in IFNg production following BCG vaccination (Figure 1). IFNβ concentrations were below 
detection limits in stimulated NK cells and in monocytes in these experiments (data not shown).
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Table 2. Mean fluorescence indexes of 20 volunteers before and after BCG
Before BCG 2 weeks 3 months p
mean sd mean sd mean sd
CD56dimCD16+B 51.1 8.30 50.0 9.70 49.3 10.3 0.35
CD56brightCD16-C 30.0 5.55 30.6   5.37 28.5 5.43 0.25
CD158a+    (KIR2DL1)D 13.5 3.28 13.4 3.59 12.9 4.08 0.31
CD158b+    (KIR2DL2)D 8.66 1.89 8.52 2.06 7.95 2.58 0.45
CD158e1+  (KIR3DL1)D 8.56 5.85 10.0 7.51 9.81 6.96 0.35
CD159a+     (NKG2a)  D 10.3 2.58 10.3 2.46 9.73 2.23 0.21
CD159c+     (NKG2c)  D 6.56 3.31 5.99 1.22 5.89 1.26 0.12
B MFI of CD16
C MFI of CD56
D MFI on CD56
dim
CD16+ for the activity markers (CD158a,b,e and CD159a,c) 
BCG enhances NK cell production of proinflammatory cytokines 
BCG induces trained immunity in monocytes resulting in an increased production of proinflammatory 
cytokines (1).  We examined whether BCG induces similar changes in NK cells. Indeed, NK cells 
isolated 2 weeks and 3 months after BCG vaccination produced more pro-inflammatory cytokines 
upon stimulation (Figure 2). This was especially true for IL1β, which showed after BCG vaccination 
a marked increase after stimulation with either MTB, C. albicans or S. aureus (Figure 2A, D, and G, 
respectively). Similar changes were noted, although not significantly in all cases, for IL6 and TNFa 
(Figure 2 B, E, and H and Figure 2 C, F, and I, respectively). 
Figure 1. BCG vaccination does not increase interferon-gamma production by NK cells. NK cells isolated from naïve 
(non-exposed) volunteers, before and after (2 weeks and 3 months) vaccination with BCG were stimulated in vitro with 
sonicated M. tuberculosis, heat-killed S. aureus and C. albicans blastoconidia. INFg production was assessed by ELISA in the 
supernatants. Data are presented as mean ± SEM (n = 9).
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BCG‐induced protection against disseminated C. albicans infection is partially NK cell 
dependent
We have previously demonstrated that BCG vaccination protects SCID mice, which lack functional 
T and B cells, against systemic lethal candidiasis (1). We examined the role of NK cells for this BCG-
induced protective effect, by comparing SCID mice with NOD/SCID /IL2Rg (NSG) mice that both lack 
functional T and B cells, the latter lacking functional NK cells as well. In two separate experiments, we 
injected i.v. NSG and SCID mice with either BCG or saline. Two weeks later, all groups of mice were 
challenged with a lethal intravenous inoculum of C. albicans. Saline-injected SCID and NSG animals 
were similarly susceptible to the lethal infection, succumbing at the same rate to the candidiasis 
(Figure 3). As previously demonstrated, all BCG vaccinated SCID mice survived. This protective effect 
was partially lost in NSG mice, suggesting a role for NK cells in the protection conferred by BCG 
(Figure 3).
Figure 2. BCG vaccination increased the non-specific production of proinflammatory cytokines  NK cells isolated 
from naïve (non-exposed) volunteers before and after (2 weeks and 3 months) vaccination were stimulated in vitro with 
sonicated M. tuberculosis (A‐C), C. albicans blastoconidia (D-F) and heat-killed S. aureus (G‐I). Pro-inflammatory cytokine 
production ((IL1β (A,D,G), IL6 (B,E,H) and TNFa (C,F,I)) was assessed by ELISA in the supernatants. *p<0.05, **p<0.01, 
***p<0.005. Data are presented as mean ± SEM (n = 9). Friedman test was used to detect significant differences.
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DISCUSSION 
In the present study we show that BCG vaccination in healthy volunteers leads to an  increased 
proinflammatory cytokine production by NK cells in response to mycobacteria, as well as to unrelated 
bacterial and fungal pathogens. This effect, most profoundly seen with IL1β, lasts for at least three 
months, in contrast to classical non-specific activation of innate immunity, but is not accompanied 
by changes in NK cell subset distribution or expression of cell surface markers. These effects of BCG 
on NK cells are biologically relevant, as we demonstrate a functional role for the trained NK cells in 
a murine model of lethal systemic candidiasis, in which the protection induced by BCG vaccination 
in SCID mice seems partially dependent on NK cells. Surprisingly, this improved response does not 
involve an increase of IFNg production, which is described in literature as an important memory-like 
property of NK cells (4-7). 
Several recent studies have provided arguments for the existence of adaptive characteristics of NK 
cells, implying a paradigm shift in our understanding of the function of this innate cell population (4-
7, 10). Several pathways have been described that may lead to functional reprogramming of NK cells. 
Firstly, infection with specific pathogens such as the virus MCMV results in an antigen-specific recall 
response of memory NK cells after reinfection. This process results in increased IFNg production and 
enhanced cytotoxicity (7). Secondly, proinflammatory cytokines such as IL12, IL15 and/or IL18 can 
induce memory characteristics in NK cells. These NK cells do not possess a distinct surface phenotype, 
nor does restimulation result in enhanced cytotoxicity (5, 6). Thirdly, hapten or viral antigens can 
induce liver-restricted memory NK cells with increased cytotoxicity, an effect that is dependent on 
CXCR6 (4, 11). In the present study we uncover an additional dimension to the adaptive capabilities 
of NK cells in contrast with memory in the classical sense what is antigen specific: we demonstrate 
that a vaccination such as BCG induces non-specific priming of NK cells, resulting in an increased 
inflammatory cytokine response to unrelated stimuli, as well as enhanced resistance against an 
Figure 3. BCG‐induced protection against disseminated Candida albicans infection is partially NK cell dependent (A) 
Survival rate of SCID and NSG mice to an infection with live C. albicans (2×106 CFU/mouse) injected intravenously. Mice 
were either vaccinated intravenously with either PBS (Control) or BCG, 14 days prior to inoculation of lethal C. albicans 
dose (n≥15 per group, 2 independent experiments). ***p<0.005 vs control (PBS) animals.
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unrelated fungal infection. 
The mechanisms that mediate the protective effects induced by NK cells during reinfection vary 
between the different models. Murine CMV infection induces NK cell expansion and contraction, 
reminiscent of T cell activation, and the protection depends on increased expression of the Ly49H 
NK cell receptor, on enhanced degranulation, and on increased production of IFNg (7). Interestingly, 
as we show here, BCG-induced activation results in an improved production of proinflammatory 
cytokines such as IL1β and TNFa, rather than IFNg.  Altogether, these studies suggest that NK cells 
have the capacity to react differently to various stimuli, and to adapt their memory function depending 
on the infectious agent they encounter. Whether epigenetic changes are at the basis of the increased 
expression of Ly49H after MCMV or the increased cytokine production after BCG, similarly to the 
trained immunity in monocytes, remains to be investigated. 
The low IFNg-production capacity reported in our experiments after stimulation with microbial 
stimuli is in line with earlier data in literature (12), which showed that NK cell production of IFNg 
only occurs after co-stimulation of a viral or mycobacterial stimulus and a stimulatory cytokine (IL2, 
IL12 or IL15 and IL18) (13-15). Another explanation for the lack of IFNg production in our experiments 
could be the fact that IFNg is mainly produced by CD56brightCD16- NK cells, which dwell in the lymph 
nodes however, have a low frequency in peripheral blood. Different from IFNg, we did see increased 
ex-vivo production of IL1β, TNFa, and IL6, both after stimulation with mycobacteria and unrelated 
pathogens, up until at least three months after BCG vaccination. Despite the relatively small number 
of individuals who participated in the study, and the known biological variability in cytokine 
production, a large number of the parameters describing the proinflammatory cytokine production 
capacity differed significantly before and after BCG vaccination. 
Considering the memory-like features of NK cells described in the literature and in this study, one could 
reasonably hypothesize that the differences in protection induced by BCG between SCID and NSG 
mice are due to the NK cells. However, defects of differentiation and function of antigen presenting 
cells (APCs) have been also reported in NSG mice (16), and therefore we cannot exclude that the BCG 
effects observed here are due to combined effects of NK cells and APCs such as macrophages and/or 
dendritic cells.
 
An important observation of the present study is the long-term effect on NK cell function exerted 
by BCG vaccination. Long-lasting effects have been previously reported in studies showing that pre-
activated NK cells that underwent cell divisions had similar degrees of enhanced IFNg production, 
indicating heritable memory-like properties (5, 6). Others have also shown that in mice memory-
like NK cell responses persist for at least one month in vivo after adoptive transfer (4, 5). Similarly, 
epigenetic reprogramming leads to enhanced inflammatory properties in monocytes for up to 3 months 
(1) or even one year (8) after BCG vaccination. One could speculate on the mechanisms inducing 
these effects. The process of trained immunity in monocytes is mediated by epigenetic regulation (1, 
2), and similar processes have been reported to mediate at least some aspects of NK cell maturation 
and adaptive change (17). Although with the currently available technology it is not yet possible to 
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investigate epigenetic profiles of circulating NK cells, given the low numbers of circulating NK cells in 
normal individuals, studies using an improved methodology in the near future are warranted. 
In conclusion, we demonstrate that BCG vaccination enhances the cytokine production by human 
NK cells after re-challenge with an unrelated microbial stimulus, a process earlier termed ‘trained 
immunity’. This effect is long lasting, and demonstrates important adaptive characteristics of NK cells, 
a prototype innate immune population. These findings have important consequences on the one hand 
for our better understanding of innate immunity, and on the other hand, to explain and better exploit 
the effects of vaccines. Non-specific effects of BCG vaccination are widely known in literature (18) 
and our results with NK cells may explain some of these non-specific protective effects of BCG. Better 
insights into the role of trained immunity may thus have important consequences for vaccine design, 
more specifically with regard to selection of antigens and the development of new adjuvants that boost 
both specific immunity and the adaptive properties of innate immune cells. 
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SUPPLEMENTARY MATERIAL
Supplementary figure 1: BCG vaccination increases interferon-gamma production by monocytes Monocytes isolated 
from naïve (non-exposed) volunteers, before and after (2 weeks and 3 months) vaccination with BCG were stimulated in 
vitro with sonicated M. tuberculosis, heat-killed S. aureus and C. albicans blastoconidia. INF production was assessed by ELISA 
in the supernatants. Data are presented as mean ± SEM (n = 9).
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ABSTRACT
A growing body of evidence from epidemiologic and immunologic studies have shown that in addition 
to target disease-specific effects, vaccines have heterologous effects towards unrelated pathogens. 
Like some other vaccines, BCG has shown in observational studies and randomised clinical trials to 
increase survival beyond the disease burden of the target disease. The immunologic substrate for these 
non-specific protective effects have been ascertained to heterologous T cell effects on the one hand, 
and to priming of innate immunity on the other hand. The term ‘trained immunity’ has been proposed 
to describe these potentiating effects of vaccines on innate immune responses.  This latter process 
can explain the rapid effects of BCG vaccination and has been suggested to be mediated by epigenetic 
programming of monocytes or macrophages. This novel concept has important implications for the 
possible use of vaccines, for vaccination policy, and even for the design of novel immunotherapeutic 
approaches. 
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INTRODUCTION
Bacille Calmette-Guerin (BCG), the vaccine that is used for the prevention of tuberculosis (TB) has 
continuously been in use for more than 90 years. Beside the protection against TB, BCG has non-
specific immunological effects that might be valuable for prevention or treatment of other diseases, the 
best example being the use of intravesical BCG in the treatment of bladder cancer (1). However, many 
more reports of non-specific effects of BCG have been published; such as treatment of other forms of 
cancer (2-6),  protection against asthma (7), effects on severity of auto-immune diseases like type 1 
diabetes (8), or multiple sclerosis (9) and use as treatment for infectious diseases like warts (10, 11). 
There is an increasing amount of evidence from old and recent studies on these heterologous effects 
of BCG. 
Historical observations
Shortly after the introduction of BCG in the 1920s, reports were published on the ‘non-specific’ effect of 
this vaccine (12). In a report from Sweden in 1931, BCG improved survival of infants, (12) and this effect 
exceeded the disease burden of tuberculosis in that age group.  It was therefore concluded that the 
nearly three-fold lower mortality of the BCG-vaccinated children was due to protection against other 
diseases. Similar observations were made around the world in the following decades (13-16). Although 
these observations cannot definitively prove a causal relationship between BCG vaccination and the 
decreased mortality, due to the lack of  information needed to exclude biases, they are suggestive for an 
important unexplored beneficial effect of BCG vaccination.  
Besides the beneficial effects on survival in general, BCG was successfully used as treatment against 
different forms of cancer since the sixties and seventies of the previous century (2-6).  These treatments 
could be either locally (intralesionally in prostate cancer (2) and melanomas (3)  intrapleurally in the 
case of lung cancer (4) or intravesically in bladder cancer (5)) , or  intradermally, as in patients with 
Hodgkin disease (6) . 
BCG is not the only vaccine with potential beneficial non-specific effects. The positive side effects 
of the widely distributed vaccinia virus vaccine were already noticed by doctors in the nineteenth 
century (17). There were claims that vaccinated persons were less susceptible to measles, scarlet fever, 
whooping cough and syphilis. Furthermore, observations of cure of leprosy or whooping cough by 
smallpox vaccination were reported (18, 19). 
After much attention and debate on non-specific effects of BCG and other vaccines following their 
introduction, this topic became somewhat forgotten. However, a second wave of interest on this 
phenomenon emerged in the last two decades, when a series of studies analyzed and reported the effects 
of vaccines in countries with high infectious disease pressure. Again, starting from large observational 
studies,  measles vaccine (another live preparation) was suspected to have capabilities beyond its 
target disease. Shortly after its introduction in Guinea-Bissau, the group of Aaby et al reported a 
massive reduction in childhood mortality, also beyond measles mortality (20). This first observation 
let to a large-scale analysis of non-specific effects of measles vaccine in developing countries, (21) 
and  in addition, to analysis of possible non-specific protective effects of other vaccines such as BCG 
(22) and vaccinia (23). Several large epidemiological studies have suggested that BCG reduces the 
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incidence of asthma; a recent meta-analysis of these studies indeed showed an protective effect of BCG 
on developing childhood asthma (odds ratio 0.86, 95% CI 0.79-0.93) (7). Similarly, recent data suggest 
that vaccinia and/or BCG may reduce the incidence of melanoma (24), and improve its prognosis (25). 
Interestingly, not all the heterologous effects of vaccines appear to be beneficial, deleterious effects 
for diphtheria-tetanus-pertussis (DTP) vaccine have been  reported (26).  It seemed that mainly the 
sequence of the vaccines (DTP being the latter) explained this effect. Some of the factors influencing 
heterologous effects of vaccines are summarized in Box 1. 
Box 1. Factors that may influence the heterologous effects of vaccines
• Timing of the vaccine (newborn, infants, adults, elderly)
• Gender
• Geographic location 
• Sequence of vaccinations
• Other immune modulators (high dose vitamin A, iron and zinc)
EVIDENCE FROM RANDOMISED CLINICAL TRIALS
Observational studies are prone to selection bias: healthier children may be vaccinated more often; or 
children from parents who provide better care are probably also more likely to be vaccinated (‘good 
parenting’). Therefore, doubts remained about the non-specific/heterologous effects of vaccines (27). 
Strong arguments for heterologous effects of vaccines were however provided thereafter by randomised 
clinical trials (RTCs) performed with BCG (28) and measles (29)  vaccines. Because these vaccines 
have established effects on its target disease, denying infants this vaccine would be unethical. In low 
birth-weight children however, BCG vaccination is mostly postponed, providing an opportunity to 
perform a randomised trial in these children. The observed survival benefit of BCG was significant 
at 1 month of age before the control group was vaccinated, with less neonatal sepsis and respiratory 
infections (28) . Similarly, advancing measles vaccination in children from 9 months to 4,5 months 
resulted in less non-measles hospitalization, again decreasing  respiratory infections (29). With regard 
to the possible beneficial effects of BCG on allergies, one RCT failed to show a significant effect at 
18 months, however a trend was observed for lower rates and treatment needs of eczema (30). In 
addition, the efficacy of BCG installation on bladder cancer was proven by multiple RCTs (31, 32) and 
a pooled analysis of controlled trials from 1966-1992 suggested a limited benefit of intralesional BCG in 
melanoma (33).  Additional RCTs are currently under way in high-income countries such as Denmark 
(ClinicalTrials.gov Identifier: NCT01694108) and Australia (NCT01906853) to examine the benefit of 
BCG in settings with a lower infectious disease burden, and to address additional questions like those 
related to possible reduction of allergies. However, in the absence of a biological explanation, many 
investigators remained sceptical regarding to heterologous effects of vaccines.
HETEROLOGOUS EFFECTS OF VACCINES  ‐ ADAPTIVE OR INNATE IMMUNITY? 
Shortly after the first observations were made on heterologous effects of vaccines, researchers started 
exploring biologically plausible mechanisms. In 1928 Louise Pearce was the first to publish the 
beneficial effects of vaccinia vaccine on syphilis in an experimental setting with rabbits. She speculated 
that ‘it appears that the influence of a preexisting vaccinal immunity is mainly concerned with the properties of host 
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reaction and resistance’ (34). No comments were made about the distinction of either innate or adaptive 
immunity as the dichotomy was not established by then. Nowadays, we consider both to play a role in 
heterologous effects of vaccines.
An adaptive immune mechanism of non-specific effects could be heterologous immunity (35); vaccines 
can give rise to T cell cross-reactivity and antibody production that may confer some protection against 
unrelated pathogens (35). This concept is reminiscent of the phenomenon of ‘original antigenic sin’ 
first described with influenza. Different strains and variants of influenza virus are commonly cross-
reactive as was already recognized decades ago (36). Vaccination with a specific subtype of influenza 
leads to an antibody response to a previous encountered subtype and this effect can be transferred to 
naïve animals. Besides cross-protection between somewhat related viral species the same phenomenon 
was also observed with BCG, a mycobacterial vaccine, and vaccinia virus (37). This protection was 
CD4 T cell dependent, as was confirmed in adoptive transfer, and these cells were the main IFNɣ-
producing cells after challenge with vaccinia virus.  The effects of heterologous adaptive immunity 
have been reviewed extensively (35) and  its influence on non-specific effects of vaccines is subject of 
a recent review (38).
Still, adaptive immunity cannot fully explain the heterologous effects of BCG. In fact, experiments 
performed simultaneously with the original antigenic sin experiments showed that some effects are 
independent of T and B cells. BCG-vaccinated mice could be protected against a later challenge with 
Candida albicans and Staphylococcus aureus, even after a strong suppression of T and B cell activity by 
cyclophosphamide prior to BCG vaccination (39). Similarly, BCG conferred non-specific protection 
against Schistosoma mansoni in nude mice, which have no mature T cells (40). Finally, in a recent study 
it was shown that BCG vaccination protects SCID mice, which lack both T and B cells, from a lethal 
challenge with C. albicans (41). These experiments clearly show that these non-specific effects of 
vaccines may be independent of adaptive immunity, and that innate immunity plays an important role.
In addition to T and B cells, monocytes or macrophages also seem essential for heterologous effects 
of BCG. In an experimental model, BCG vaccination protected mice against a subsequent ectromelia 
virus infection, but this effect was abolished by use of anti-macrophage serum (serum from rabbits 
injected with murine macrophages) (42). A key role of macrophages was also supported by an older 
study that examined the effect of BCG vaccination on in vitro challenge with Brucella melitensis. In these 
experiments, bacterial clearance and cell survival were much higher in vaccinated animals (43).  Also in 
bladder cancer, monocytes play an important role. Depleting these cells, in an in vitro setup, abolished 
the cytotoxicity of the T cells, while addition of only 1% of monocytes was enough to restore this effect 
(44).
BCG vaccine‐induced alterations of innate immune cell function
Different studies examined how BCG vaccination could alter function of monocytes or macrophages, 
showing effects on phagocytosis, as well as on reactive oxygen species (ROS) production and 
intracellular killing.  Already in 1959 a correlation was found between resistance against Salmonella 
enteritidis infection and improved phagocytic functions in BCG vaccinated mice (45).  A causal 
relationship, however likely, was not shown.  A few years later it was observed that macrophages 
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from BCG-vaccinated animals were in a more active state, with rapid movements and packed with 
lysosomal structures (46). Confirmation of this effect of BCG on macrophages came almost 25 years 
later, when macrophage activity was assessed by increased production of ROS to an unrelated 
stimulus, leading to increased intracellular killing of intracellular fungi compared to macrophages of 
non-vaccinated mice (47). In addition, more recently it was shown that BCG increases expression of 
pattern recognition receptors and other activation markers on human monocytes (41). In the same 
study the BCG vaccination induced higher production of proinflammatory cytokines when stimulated 
with non-related pathogens. 
BCG may also have an effect on other innate cells. There is clear support for memory-like characteristics 
of natural killer (NK) cells, and it is tempting to speculate about their role in heterologous effects of 
vaccines. Indeed, BCG vaccination appears to have an effect on NK cells in healthy human volunteers. 
Purified NK cells from these individuals produced higher amounts of pro-inflammatory cytokines to 
unrelated bacterial and fungal pathogens after vaccination. In addition, an animal model using NSG 
mice (severely immune compromised mice lacking T-, B-cells, and NK cells) demonstrated a clear role 
that NK cells play in the BCG-induced protection against C. albicans (48). This may be a direct effect, 
as it is known that NK cells can directly recognize BCG without involvement of antigen-presenting 
cells  (49). Importantly, the well-known effect of BCG on bladder cancer is at least partly dependent 
on NK cells as NK-deficient mice could not be protected with BCG immunotherapy in contrast to 
control mice (50). Collectively, these data clearly support a role for NK cells in heterologous immunity 
of BCG vaccination. 
Epigenetic reprogramming explaining ‘trained immunity’ 
Considering these data on the role of innate immune cells in the heterologous effects of vaccines, 
an important question remains concerning the molecular mechanism mediating these adaptive 
characteristics of innate immune cells. Recently, we proposed the term ‘trained immunity’ for a state 
of improved reaction of innate immune cells to reinfection with the same or a different pathogen (51), 
and some characteristics of this phenomenon are shown in Box 2.  The fact that innate immune cells 
have capabilities of improving their responses is generally accepted in plant immunology for decades, 
under the term ‘systemic acquired resistance’   (52, 53) and is much studied in invertebrates (54), 
both of which lack adaptive immune cells.  A process of epigenetic reprogramming through histone 
modification
Box 2. Characteristics of trained immunity
• Induced after a primary infection or vaccination, and confers protection against a secondary infection 
through mechanisms independent of T and B cell adaptive responses.
• Increased non-specific resistance of the host to reinfection, and thus provides cross-protection to other 
infections
• The cellular mechanisms that mediate trained immunity involve innate immune cells such as macrophages 
and natural killer (NK) cells, and lead to improved pathogen recognition by pattern recognition receptors 
(PRRs) and an enhanced protective inflammatory response.
• Molecular mechanisms that induce trained immunity involve epigenetic reprogramming (e.g. histone 
modifications, miRNA), rather than gene recombination that characterizes adaptive immune memory.
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underlies trained immunity, with increased transcription  of innate immune genes due to methylation 
of histones in regions increasing chromatin availability. We have recently shown that epigenetic 
reprogramming of monocytes is responsible for the heterologous effects of BCG vaccination, as 
displayed in Figure 1 (41). A known mark of transcriptionally active genes, trimethylation of histone 
3 lysine at position 4 (H3K4me3) (55), was increased at the promoter regions of the genes encoding 
immune receptors and cytokines. NOD2 is essential for this effect, with NOD2-deficient cells lacking 
the capacity of being ‘trained’ by BCG. Epigenetic reprogramming has also been demonstrated to be 
the mechanism of the systemic acquired resistance in plants (56). In plants these epigenetic changes 
can be transferred to their progeny through seeds, with a central role of acetylation of H3K9 in this 
process (56). 
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Figure 1. Schematic presentation of ‘trained immunity’ in heterologous effects of Bacille Calmette Guerin.
a) Naïve monocytes with its pattern recognition receptors (PRRs) and  detailed presentation of histones (insert). b) 
Trained monocyte: BCG vaccination (1) signals through NOD 2 and RIP 2 (2) resulting in increased trimethylation 
of H3K4 (H3K4me3); (insert;3) and, increased expression of PRRs on the cell surface (4). c) Trained monocyte; 
restimulated with pathogen X: Recognition of X through PRRs (5) leads to increased cytokine production (6) by 
increased accessibility of transcription of certain genes (insert;7).
The effect of BCG on human monocytes last at least 3 months and some protective effects even up to 1 
year after vaccination (57). This is puzzling given the short half-live of these cells in the circulation. 
One explanation might be, in-line with the observations in ‘memory’-NK cells, that a pool of 
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epigenetically-changed monocytes remain elsewhere in the body with the possibility of being attracted 
whenever needed: the spleen has been proposed as such a site. Another possibility could be that 
monocyte precursors (stem cells) could become ‘trained’ while still in the bone marrow, through yet 
undetermined factors, and would give rise to the longevity of this process. An argument for this process 
is represented by a recent study demonstrating functional reprogramming of bone marrow myeloid 
cell precursors by TLR2 ligands (58). In addition, a recent publication showed that monocytes have 
the most conserved chromatin state during differentiation (59).
CLINICAL AND PUBLIC HEALTH IMPLICATIONS
With a wealth of evidence on heterologous effects of vaccines, it is important to consider possible 
implications of this phenomenon for public health or clinical practice (summarised in Box 3).
Box 3. Clinical and public health implications of heterologous effects of vaccines
• Changing vaccine police (sequence, timing etc.) 
• Including heterologous effects in discussions on new (tuberculosis) vaccines  
• Discussion about unintended effects of abrogation of vaccines after eradication of its target disease
• Potential to booster low-efficiency vaccines 
Firstly, these findings may have  implications for vaccination policy; as it is clear that the outcome 
of non-specific effects are influenced by many factors (see Box 1), these factors should be involved in 
planning the vaccination strategy. Sequence of vaccines, its importance mainly shown in the studies 
on DTP (26), and timing of vaccination (28, 29) , could have enormous impact on childhood mortality 
without changing the vaccines in use.  The importance of this subject in potentially changing vaccine 
policy is supported by the WHO in the strategic advisory group of experts (SAGE) (http://www.who.
int/immunization/policy/sage/en/).
Second,  data on the heterologous effects of vaccines should be incorporated in evaluating potential 
vaccine replacements. Soon after introduction of BCG debates were raised not only about the non-
specific effects of BCG, but also about the protective effect against TB (12, 60). Many questioned the 
degree and length of specific immunity against TB and calls for an improved vaccine were made (13). 
Significant efforts have been made in this field (61, 62) however a valuable addition would be to include 
the non-specific effects of BCG while evaluating its potential successor.
Another point of consideration regarding the optimal use of the heterologous effects of vaccines is 
the abrogation of some vaccines when the target disease is eradicated, like in the case of smallpox. 
Depriving people from this vaccine might have more repercussions than previously considered.
Similarly, heterologous effects of vaccines might help booster the response to other vaccines with a 
low efficiency like Salmonella  typhi vaccine or influenza vaccine (a trial concerning the latter has begun; 
NCT02114255) as several reports suggest a valuable role for BCG (63-66). BCG may also act as booster 
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in groups who have a low vaccination response, like HIV–infected individuals, however the fact that 
these are live vaccines limits its use in this group. 
Moreover, the heterologous effects of vaccines through trained immunity might also have implications 
beyond vaccination. For example, vaccines might help ‘training’ a person’s innate immune system in 
waning immunity in old age or other immunocompromising states. More research needs to be done to 
demonstrate whether this may be a valid approach. 
Concluding remarks and research challenges 
Heterologous effects of vaccines are a long-described phenomenon with recent progress in describing 
its biological mechanisms. Both heterologous adaptive immunity and trained immunity are likely to be 
involved as  biologically-plausible mechanisms.  More research is warranted to assess these mechanisms 
in vivo and their possible implications. Questions regarding the longevity of this phenomenon were 
already raised and are of vital importance in determining its clinical implications. Another question 
waiting to be answered is whether trained immunity can be generalised to all innate immune cell 
types, with a focus on monocytes/macrophages and NK cells, but also dendritic cells and neutrophils. 
The major impact of vaccines is illustrated by their worldwide coverage. To improve vaccine usefulness, 
both their specific and heterologous effects should be considered.
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Studying host response to mycobacteria can help us to understand this complex disease tuberculosis 
in all its presentations, and inform our method of treatment. The vital role of an intact immune system 
is proven in increased susceptibility of different immunocompromised patients to TB. The immune 
response consists of numerous different components, each playing a role in a combined defence against 
mycobacteria.
The present thesis has two objectives: firstly, to elucidate the host response to MTB with a focus on the 
innate immune system, in order to provide insight in TB pathogenesis and crucial immune processes 
which may eventually translate to an improvement in TB treatment; secondly, to explore the role of 
BCG on the recently described phenomenon of innate memory or ‘trained immunity’. This paradigm 
shift in immunology will have numerous implications beyond this thesis subject. When considering 
its role in this thesis we hope to contribute to the development of immunomodulatory strategies in the 
management of infectious diseases as well as to provide grounds for improving vaccination strategies. 
This chapter addresses the main findings in this thesis, puts them in context with other literature, 
describes the possible implications of these findings, and finally addresses the future research 
challenges.
Innate immunity and tuberculosis
In the last few decades huge endeavours have led to revolutionary breakthroughs in innate immunity in 
general and in TB research specifically. The field has changed enormously with the establishment of the 
role of TLRs in humans, which led to better understanding of recognition of pathogens and underlined 
the important role of innate immune cells in host response. The interaction of the innate and adaptive 
immune system has also been an area of increasing knowledge. That both are indispensable and 
influence each other has been the subject of many papers. Finally, another ground-breaking discovery 
has redefined basic principles of immunology: innate memory has become an established phenomenon 
in the last few years.
In host defence against TB the main focus in the previous decades was the adaptive immune response.
However, the role of innate immune system is proven in experiments were T cell memory could protect 
mice against disseminated TB but not against the preceding pulmonary infection (1, 2). In humans we 
know that vaccination induced memory does prevent disseminated TB but not pulmonary TB, (3) 
and the same holds true for naturally acquired memory (4). T cell-independent mechanisms therefore 
have important implications, also in early clearance wherein MTB is eliminated without development 
of T cell memory (5). Knowledge of innate host response against MTB has developed apace in the 
recent years. The indispensable role of cytokines has become clearer in absence of these cytokines. 
Patients lacking IFNg, IL12, or its receptors appeared to be very susceptible to mycobacteria, implying 
a crucial role for these cytokines (6). However, only anecdotal case reports show treatment with IFNg 
in patients with dissimilated mycobacterial infections unresponsive to other treatments with variable 
success (7-9). Similar observations were made with the introduction of TNFa blocking agents in 
the treatment of rheumatoid arthritis. Progression to active TB in these patients was exceeding the 
background incidence starting as soon as two weeks after treatment, strongly suggesting a role of 
TNFa in protection against active TB (10).
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Autophagy is another main player in the host response whose role has been recently established recently. 
It is a process for the degradation of cellular components, recently shown to be able to degrade micro-
organisms as well. Mycobacteria escape the immune system, hiding away in macrophage phagosomes, 
and can influence the phagolysosomal process in inhibiting their fusion with lysosomes. Activation 
of autophagy (with for example IFNg) can overcome this blockage, (11) leading to degradation and 
subsequently antigen processing for antigen presentation.
These important parts of the innate immune response to mycobacteria were the subject of the first part 
of this thesis, and the results will be summarized in the following paragraph.
Summary of research findings
In chapter 2 we described the production of IL1β in infection with MTB from beginning till end. We 
showed in murine knock-out models that TLR2/6 and NOD2 are indispensible in recognition of MTB, 
leading to transcription of pro-IL1β, this in contrast to other receptors known to be involved in the 
recognition of mycobacteria (TLR1, TLR4, and TLR9). Intracellularly MyD88, ERK, RIP2, and p38 
make-up the signalling pathway leading to IL1β transcription with no role for TRIF and JNK. The last 
step in producing active IL1β is cleavage of pro-IL1β through caspase-1. We showed in this chapter that 
in contrast to what was previously believed, there is no need for a second signal in order to activate 
caspase-1 or the inflammasome as monocytes already possess activated caspase-1. Stimulation of these 
cells with bacterial pathogens hardly increased the amount of active caspase-1. Finally, we confirmed 
that release of IL1β is dependent on P2X7 and endogenous ATP as the release could be significantly 
reduced by blocking P2X7, as was shown before (12).
Autophagy and cytokines are closely linked; IFNg can activate this process, and autophagy in turn can 
influence cytokine production as well (13). We explored this interaction in Chapter 3. We showed 
that autophagy has important immunomodulatory effects on the MTB-induced cytokine production.
Blocking autophagy inhibited TNFa mRNA production while enhancing IL1β transcription. Induction 
of autophagy with either starvation medium or IFNg logically showed the opposite effect. The effect of 
IFNg on cytokine production could be eliminated through inhibition of autophagy, showing that the 
known IFNg-induced effect is at least partly dependent on autophagy. In addition, we examined the 
effect of functional polymorphisms in autophagy genes ATG16L1 and IRGM, involved in susceptibility 
to Crohn’s disease (14), on cytokine production. Due to the fact that there were only a limited number 
of individuals carrying the functional SNPs, conclusions were difficult to draw. However, a trend 
in lower production of IFNg was seen in individuals homozygous for the 300A allele of ATG16L1, 
suggesting a role in host defence against MTB.
To investigate the possible clinical implications of autophagy on TB susceptibility, we searched for 
differences in autophagy gene-related SNPs in a cohort of 1000 Indonesian TB-patients and a matched 
control group. In Chapter 4 we showed that these fourteen genes do not influence the susceptibility 
to TB in this large population. Furthermore, we studied the effect of these SNPs on MTB-induced 
cytokine production, which showed no differences in the studied Caucasian cohort. This set of SNPs 
included two genes previously associated with susceptibility to TB. IRGM, a downstream effector 
protein of IFNg, induces autophagy and was shown to influence susceptibility to TB caused by MTB 
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Euro-American lineage but not for East-African-Indian, Beijing, Delhi, M. africanum and M. bovis lineages 
in an African cohort (15). The most common MTB lineage in our Indonesian cohort is the evolutionary 
successful M. tuberculosis Beijing genotype; however, no influence of any of the investigated SNPs on 
infecting lineage could be found. The other gene that has previously been linked to susceptibility to 
TB in an African cohort is P2RX7, which codes for the P2X7-receptor that mediates ATP-induced 
autophagy. No effect was observed in our Indonesian population. This underlines the importance of 
validating a correlation of SNPs and disease in cohorts of different ethnic background.
In Chapter 5 we gave an overview of the recognition of MTB by the innate immune system. In this 
review, we describe the importance of the different classes of pattern recognition receptors in the 
recognition of MTB. Their importance is underlined in the fact that in human epidemiological studies, 
genetic variation in genes encoding for these receptors influence susceptibility, severity, and outcome 
of the disease. Pattern recognition of MTB is a complex process in which a multitude of receptors 
recognize specific PAMPs of the microorganism. Recognition by specific receptors is followed by 
different intracellular signalling pathways, in order to integrate and induce an efficient activation of 
the innate host defence mechanisms. While activation through TLRs, NLRs and dectin-1 initiates 
essentially a proinflammatory response, signalling through the C-type lectins DC-SIGN or MR have a 
mainly modulatory function. The interplay between these pathways leads to a finely tuned response of 
the immune system during the encounter with MTB.
BCG‐induced trained immunity
As mentioned before, old studies described non-specific beneficial effects of BCG, the well-known 
vaccine against tuberculosis, in both animal models and epidemiological studies (16-19). Mice could be 
protected against a subsequent infection with another pathogen, and in these studies innate immune 
cells played a prominent role (16, 17). In large cohort studies of BCG vaccinated children, a survival 
benefit, larger than the disease burden of TB, suggested non-specific effects as well (18, 19).
While heterologous immunity was considered as a possible explanation, it could not explain the 
animal studies lacking adaptive immune cells and the suggestive protective effect shortly after 
vaccination (20). We show in this second section of this thesis an additional biological explanation 
for these effects: trained immunity (21). Besides this possible explanation of BCG survival benefit, we 
prove another more fundamental scientific point: the existence of innate memory in humans.
Summary of research findings
In Chapter 6 we demonstrate the validity of this concept of trained immunity for the first time in 
mammalian hosts. In human volunteers vaccinated with BCG we showed enhanced responses to 
nonmycobacterial stimuli, accompanied by phenotypic changes of circulating monocytes, even three 
months after vaccination. We developed an in vitro model for this concept, training monocytes with BCG 
in order to decipher the molecular mechanisms of this process. With this model we discovered that a 
process of epigenetic reprogramming through histone modification underlies these changes, resulting 
in increased chromatin availability. A known mark of transcriptionally active genes, trimethylation 
of lysine at position 4 of histone 3 (H3K4me3) (22), was increased at the promoter regions of the 
genes encoding immune receptors and cytokines. In addition, we showed that NOD2 is essential for 
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this effect as cells of NOD2-deficient patients lack these improved actions. Furthermore, the clinical 
relevance was shown in an in vivo murine model of BCG-vaccinated SCID mice. After vaccination, these 
mice, which are devoid of T and B lymphocytes, showed a strong protection against disseminated 
candidiasis, proving the role of innate immune cells.
As a novel and potentially vital concept, the duration of trained immunity would be of major 
importance. We therefore assessed this in Chapter 7 using the same model, BCG vaccinated healthy 
volunteers. The phenotypical changes of monocytes described in Chapter 6 were present until one year 
after vaccination. However, some other effects of trained immunity wane over time; proinflammatory 
cytokines produced by monocytes returned to prevaccinated levels, with the exception of TLR4 
induced responses. In contrast, the skewed Th1 and Th17 responses were still present after one year 
even in response to unrelated pathogens.
Another important question regarding trained immunity is whether this concept can be extended to 
other cell types of the innate immune system. Therefore, the role of trained immunity in NK cells was 
the subject of Chapter 8. Circulating NK cells from BCG vaccinated healthy volunteers displayed 
increased production of pro-inflammatory cytokines in response to both mycobacterial and other 
bacterial and fungal pathogens, similar to what we saw with monocytes. No changes were observed in 
the surface markers of these NK cells. In addition, we demonstrated a functional role for BCG-trained 
NK cells as NSG mice, lacking in addition to T and B cells also NK cells, could not be protected against 
lethal systemic candidiasis as well as SCID mice.
In Chapter 9 we gave a historical perspective on heterologous effects of vaccines and discussed the 
recent progress in describing their biological mechanisms. The review mainly focussed on BCG, as 
most literature is on this vaccine, and because it is the world’s most-used vaccine.
General discussion
This thesis clearly shows the complexity of the immune response to TB; while certain processes are 
known to play a role in host defence against MTB, not all can be clinically confirmed. This redundancy 
in immune processes is a challenge in implications of research findings.
We described the crucial steps in producing IL1β upon stimulation with MTB, which is an important 
cytokine in murine TB. However, its role in disease susceptibility or severity in humans is not that 
clearly shown. For example, patients receiving anakinra, an IL1 receptor antagonist, do not show an 
increased incidence of TB; this is in contrast to patients on TNFa blockers. In addition, the clinical 
implications of autophagy, a vital part in many immune processes from cytokine production to 
degradation of the bacteria facilitating antigen presentation, are difficult to confirm. While results 
described in this thesis underline these biological mechanisms of autophagy in host defence against 
TB, SNPs in autophagy genes lack an association with TB susceptibility.
The main models used in these papers are in vitro models, animal models (mainly mice), and association 
studies combining certain genetic profiles and susceptibility to TB. One has to acknowledge that 
both in vitro and in vivo studies suffer from specific limitations, which may at least partly explain some 
discrepancies between experimental and immunogenetic studies in TB patients.
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In vitro studies use various cell types, murine macrophages (bone-marrow derived or alveolar), DCs, 
or PBMCs. This can influence the outcome due to the preferential expression of specific receptors 
on different cell types. A second limitation is that in most in vitro studies only a single receptor is 
examined, isolated from its physiological environment. In both situations the interplay between 
different pathways is probably one of the most relevant aspects of the immune response.
Animal models have different limitations concerning disease entities of TB. Murine models cannot 
present all the aspects present in human TB. Mice are relatively resistant to TB, and are therefore 
infected with sublethal amounts of bacilli. They can control the infection with a high but stable 
burden of bacilli until senescence or immunosuppression and subsequently progressive respiratory 
disease occurs (23). Therefore, one of the characteristics of TB, the formation of granulomas, is not 
present in murine models. There are animal models that better present the human pathology of TB, 
namely the guinea pig and rabbit. Latency is not investigated in the guinea pig model, but besides 
that, the similarities with human TB in route of infection, course of disease, granuloma formation, 
and vaccination response to BCG is remarkable (24). Another animal model used frequently since the 
1930s is the rabbit. Lurie determined the different stages of pulmonary infection in this model, stages 
also present in humans. (25). Although these animals better represent the human disease activity of 
TB a disadvantage is the higher costs in comparison with rodents. In addition, as most research is 
performed in murine models, knowledge of that immune system is greater and commercially accessible 
tools for this research are widely available.
Association studies in TB are influenced by differences in infecting genotypes as they differ 
geographically, which could be a result of evolutionary selection in specific ethnic groups. Humans and 
MTB have co-evolved for millennia, and it is likely that a close relationship exists at the genomic level. 
Indeed, two studies have shown a direct association between the genetic characteristics of patients 
with tuberculosis and their infecting mycobacterial strains (26, 27). Both polymorphisms studied in 
these papers, TLR2 and SLC11A1 (NRAMP1), were associated with a higher chance of being infected 
with the MTB Beijing strain. Globally, MTB shows strong geographical differences (28, 29), and this 
might be triggered by evolutionary pressure from the innate immune system (‘co-evolution’) as besides 
the pathogen, host immune gene polymorphisms also show strong geographical differences.
These observations further complicate research on TB, as there is not one ‘MTB strain’ nor one 
representative host. Usually these differences are not taken into account when SNPs are studied in 
host defence against TB. Another limitation of human genetic studies is that the already mentioned 
focus on one SNP ignores the redundancy in the system composed of a complicated interplay of innate 
and adaptive immune response. The value of one SNP in host response to TB would be more adequately 
shown in combination with functional assays on a protein level. Showing these SNPs to be functionally 
relevant could improve the scientific value of these studies.
Innate memory
Trained immunity is a novel description of the immune system; the traditional dichotomy--where the 
innate immune cells are, as first line defenders, thought to be incapable of tailoring their response in 
contrast to the slower, specific, and, more importantly, educational adaptive immune cells--is in need 
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of revision. Trained immunity is a process of improved reaction of innate immune cells after an initial 
stimulus (for example BCG) to reinfection with the same or a different pathogen.
Adaptive immune responses also have non-specific effects, termed heterologous immunity. Vaccines 
can give rise to T cell cross-reactivity and antibody production that may confer some protection against 
unrelated pathogens (30). A suggested mechanism is that CD8+ cells have the potential to secrete IFNg 
in response to IL12 and IL18 in the absence of a related antigen (31). The IL12 and IL18 are produced 
in the initial stages of a secondary infection. Heterologous immunity was previously observed with 
BCG and vaccinia virus (32). This protection was CD4 T cell dependent, as was confirmed in adoptive 
transfer, and these cells were the main INFg-producing cells after challenge with vaccinia virus. In 
our experiments we did not see differences in number or subtypes of T cells, but the function was 
not assessed in adoptive transfer. No observations have been published on heterologous immunity in 
Th17 cells; however, one could speculate about a similar mechanism for these responses including IL1β 
and IL23 (instead of IL12 and IL18) necessary for the Th17 differentiation. This thesis shows that BCG 
potentiates both immune processes, which can explain non-specific effects of this vaccine. How these 
two distinct processes work together is not yet clear.
Non-specific effects of vaccines are a long-described phenomenon dating from the introduction 
of these vaccines. Implications of these effects are potentially enormous because of the worldwide 
distribution of vaccines and because of the mortality of infectious diseases, particularly in tropical 
areas. To underline this importance, the WHO formatted a strategic advisory group of experts (SAGE) 
to advise them in policy making on vaccine strategies.
Trained immunity distinguishes itself from other innate immune memory descriptions like NK cell 
memory by its non-specific nature. Recently, NK cell memory was described in a landmark study of 
Sun et. al (33) which describes innate memory of NK cells in mice with MCMV infection. The NK 
memory Ly49H+ cells could adoptively transfer memory and subsequently protection to MCMV 
in naïve animals. Later publications showed different forms of NK cell induced memory: cytokine-
induced (34) and hapten-antigens-induced NK cell memory (35). However, NK memory results in 
improved response to the same stimulus, while BCG trained immunity generates a generally improved 
response to any secondary stimulus.
The strength of this research lies in combining well-known data from epidemiological studies with 
prospective observations in humans, and in describing an in vitro model in which the mechanistic details 
could be investigated. Combining all these different strategies and coming to one fitting explanation 
makes the outcome more robust and trustworthy. However, the separate components still have their 
potential confounding properties.
Regarding the epidemiological studies, investigating the effects of vaccines could be confounded by 
‘good parenting’: parents who vaccinated their children might take better care of them as well. In 
addition, healthier children are vaccinated more often, which might result in selection bias.
Randomised clinical trials with vaccines might be considered unethical because of the established 
value on the target disease. However, some small randomised clinical trials were performed in children 
who normally were not vaccinated (low birth weight children), showing similar results (20, 36).
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Shortcomings of in vitro systems were previously discussed but necessary in this research to explore the 
role of different cell subtypes in trained immunity. Even our human in vivo model that might seem to be 
the ‘gold standard’ in immunology has some disadvantages. The immune cells we want to study are not 
necessarily restricted to the easily accessible peripheral blood. Highlighting the vital role of immune 
cell source is reflected in the liver-restricted CXCR6+ NK cells in hapten-induced memory.
Host response to mycobacteria starts with recognition of these pathogens. Many receptors are 
involved herein, such as TLRs, NLRs, and C-type lectins; however, signalling through these receptors 
leads to different actions. While TLR1, 4, and 9 are known to be involved in host response to MTB, 
they do not have a role in initiating IL1β production upon stimulation with this pathogen. In contrast, 
the role of TRL2 herein is indispensible. More importantly, TRL2 is involved in susceptibility to TB 
meningitis by the successful Beijing strain, in contrast to Euro-American and Indo-Oceanic strains 
in Vietnamese patients. Another receptor involved in IL1β production upon stimulation with MTB 
is NOD2. This receptor also has another important function: it initiates trained immunity by BCG. 
These different and dual functions make recognition a crucial but complicated aspect of host response 
to mycobacteria. In the next section I will address some of the most pressing and potential clinically 
relevant issues regarding immune responses to mycobacteria.
Future perspectives
Host response against MTB is complicated. Many complementary systems coexist and influence each 
other, intertwined in unknown ways. In addition, some parts of the system are redundant, as we see 
in studies where SNPs, despite their recognized role in host defence, do not influence susceptibility.
Research starts with questions on clinical dilemmas. Who will get primary tuberculosis in a population 
with similar exposure? Who develops latent tuberculosis? Who from those latently infected people 
will eventually develop post-primary tuberculosis?
Genome-wide screenings of people in one of these groups are done in order to identify important 
players in the immune response that might lead to explanations of why these people belong to one of 
these groups (37). Basic research in model systems of the human immune system like in vitro systems 
or animal models investigate these separate components of apparent important players in determining 
outcome during MTB infection. Huge breakthroughs have been detected this way: a transcriptional 
signature, the importance of autophagy, IFNg, and macrophages. However, this knowledge did not lead 
to improvement of clinical TB. Autophagy seems vital, and therefore a stimulating agent might have 
effects in treating TB. However, its actions on cytokines are dual: while it stimulates TNFa it blocks 
IL1β. As in humans the role of TNFa is established quite firmly and the role of IL1β is less clear, future 
research should lean more towards a potential role of inducing autophagy. One way of stimulating it, 
through IFNg, is a sporadically used regime in patients with severe mycobacterial infections, although 
this has variable results (7-9). Thus, it is not all that clear whether stimulating autophagy through 
other mechanisms might be beneficial.
A pivotal approach will be to combine genetic studies with functional studies; what does a SNP 
associated with susceptibility to TB mean in terms of the function of the immune response? This is 
especially relevant considering the importance of host and mycobacterial genetic background and 
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their co-evolution. SNPs differently influence susceptibility to TB caused by different mycobacterial 
strains. Genetic association studies should therefore focus on both the genetic profile of the host and 
the pathogen. Studies wherein this association is already proven could serve as a starting point for more 
thorough investigation on the mycobacterial side. What makes this strain so vulnerable to recognition 
through TRL2, for example? As a result, host-specific (or pathogen-specific) therapy might become an 
option within reach.
As we better understand the immune response to mycobacteria, we might be able to improve our 
vaccine as well. Big efforts are invested in finding an improved vaccine. However, trained immunity 
might have important implications in protection against TB in addition to its recognised effects 
on other infections. BCG might improve long-lasting innate immune responses to mycobacteria in 
addition to the adaptive response. Maybe this explains some of the disappointing protective effects of 
the initially promising MVA85A vaccine (38). It is quite possible that innate immune cells play a vital 
role in vaccination initiated host defence to TB in addition to the more-studied adaptive response.
Consequently, the focus should be broadened while evaluating new TB vaccine candidates on both 
the adaptive response and on the effect of trained immunity. In addition, the non-specific beneficial 
responses should be included in evaluating a vaccine that might replace BCG. Endpoints of these trials 
should be reduction of all-cause mortality or infection not restricted to solely TB.
Innate memory is an entirely new research area where many questions remain to be answered, from the 
underlining molecular foundations to the clinical implications in protection against infectious diseases 
and vaccine strategies. There are two further possible further clinical implications worth investigating. 
People who are scheduled to become immunocompromised (e.g. from stem cell transplantation or 
chemotherapy) might benefit from vaccination with BCG in training their innate immune system, 
something that could be investigated in a small pilot study. Another known effect of BCG is as booster 
for other vaccinations. This might be an effect of trained immunity as well, as improved innate immune 
effects might help in initiating the adaptive vaccination response. This is especially important for 
vaccines with low efficacy, like influenza and typhoid fever.
Future challenges lie in combining all these key findings done in previous decades ‘on the benches’ 
and transforming them to possible implications ‘at the bedside’, thereby addressing the initial clinical 
dilemmas. The ‘from bedside to bench’ approach for generating research questions is being used 
constantly; however, the attention should focus on the more challenging ‘from bench to bedside’ 
approach in applying this scientific knowledge in clinical implications about susceptibility to 
tuberculosis, its treatments, and vaccination, to improve health all over the world.
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NEDERLANDSE SAMENVATTING
Tuberculose (TB) is een complexe ziekte met vele verschillende uitingsvormen veroorzaakt door 
Mycobacterium tuberculosis, (MTB). Het bestuderen van de reactie van het immuunsysteem tegen deze 
bacterie kan ons helpen de ziekte en de mogelijke behandeling beter te gaan begrijpen. We weten 
dat het immuunsysteem erg belangrijk is als bescherming tegen MTB omdat mensen bij wie het 
immuunsysteem minder goed werkt meer kans hebben om TB te ontwikkelen. Ook de immuunrespons 
tegen MTB is erg complex, bestaat uit meerdere componenten met elk een eigen rol die samen de hele 
reactie van het immuunsysteem tegen MTB bepalen. 
Dit proefschrift bestaat uit 2 onderzoeksdelen: in het eerste deel beschrijven we in een aantal 
hoofdstukken welke componenten van het aangeboren immuunsysteem belangrijk zijn in de respons 
op MTB. In het tweede deel focussen we op een nieuw ontdekt onderdeel van het aangeboren 
immuunsysteem wat we ‘trained immunity’ hebben genoemd. Deze nieuwe ontdekking werpt 
een nieuw licht op een van de belangrijkste fundamenten van het immuunsysteem, het vermogen 
tot aanpassing van de immuunrespons. Ons inzicht van de mogelijkheden van het aangeboren 
immuunsysteem zijn hierdoor totaal veranderd. Dit heeft implicaties ver buiten dit proefschrift, maar 
in dit proefschrift bekijken we de rol van trained immunity in het sturen van de immuunrespons in 
infectieziekten en in de mogelijkheid om vaccinatie strategieën te kunnen verbeteren. 
Deel 1: aangeboren immuunsysteem en tuberculose
De rol van het verworven immuunsysteem in de bescherming tegen MTB is beter bekend, die rol 
verbeteren is ook het doel van vaccineren. Dat het aangeboren immuunsysteem hierin ook een 
belangrijke rol speelt wordt de afgelopen jaren steeds duidelijker. Zowel uit dierstudies als uit humane 
epidemiologie waaruit blijkt dat het hebben van een goede verworven immuunrepons (door vaccinatie 
of door het hebben doorgemaakt van TB) niet beschermt tegen alle vormen van TB.  
Zoals gezegd bestaat de aangeboren immuunrespons uit meerdere componenten (zie ook figuur 
1 van de introductie blz 11). De immuunrespons begint zodra de (in dit geval) mycobacterie wordt 
herkent door de cellen van het immuunsysteem. Dit gebeurd door  pathogeen  herkeningsreceptoren 
op en in deze cellen. Deze receptoren herkennen bepaalde onderdelen van een bacterie, virus of andere 
pathogenen. Door deze herkenning wordt een cascade van activiteiten in gang gezet. De cel gaat onder 
andere cytokines (afweerstofjes) maken, de bacterie wordt gefagocyteerd (opnemen in de cel om deze 
te vernietigen) waardoor er andere cellen betrokken raken in de immuunrespons. 
Een van die belangrijke cytokines die er gemaakt worden is interleukine (IL)1β. In hoofdstuk 2 
beschreven we het hele proces van het maken van IL1β: welke van deze pathogeen herkenningsreceptoren 
(PRRs) zijn nodig om de cel aan te zetten tot het maken van IL1β, welke signaleringspaden zijn hiervoor 
nodig en hoe gaat de verwerking van IL1β. Het blijkt dat, hoewel we weten dat meerdere PRRs MTB 
kunnen herkennen er maar een paar nodig zijn als het gaat om het maken van IL1β, namelijk TLR2, 
TLR6 en NOD2. In de cel zijn er signaleringpaden die de signalen van de PRRs doorgeven aan de 
celkern. We vonden dat er van deze signaleringspaden MyD88, ERK, RIP2 en p38 belangrijk waren 
om IL1β te maken in tegenstelling tot TRIF en JNK. De productie van IL1β is anders dan van andere 
cytokines omdat er een extra stap is ingebouwd, er wordt eerst niet actief pro-IL1β gemaakt en voor 
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die laatste stap is er een actief complex van eiwitten (inflammasome) nodig. In tegenstelling met wat 
er tot dan toe was beschreven in de literatuur vonden we dat in monocyten het inflammasome al actief 
is waardoor het produceren van IL1β niet afhankelijk is van het activeren van dit inflammasome. 
Een ander belangrijk onderdeel van de aangeboren immuunrespons tegen MTB is autophagy. 
Autophagy is een mechanisme van de cel om oude celonderdelen af te breken en de bouwstoffen te 
recyclen. Dat afbreken gaat met bepaalde enzymen en datzelfde proces kan ook gebruikt worden om 
bacteriën of andere pathogeen af te breken. In hoofdstuk 3 bekeken we de interactie van autophagy 
en cytokines tijdens de immuunrespons tegen MTB. Als we autophagy blokkeerden werd er minder 
TNFa geproduceerd en meer IL1β, als we autophagy stimuleerden zagen we het omgekeerde. Een 
manier om autophagy te stimuleren is met IFNg een voor MTB erg belangrijk cytokine. Uit de literatuur 
was al bekend dat IFNg kan zorgen voor een verhoogde cytokine productie en we denken nu dat dat 
in ieder geval voor een deel komt door het effect op autophagy. Er zijn genafwijkingen (SNPs) bekend 
waardoor autophagy minder goed werkt. Als laatste keken we in dit hoofdstuk of sommige van deze 
SNPs een effect hebben op de hoeveelheid cytokines die er werd geproduceerd. Dit bleek niet zo te 
zijn, alhoewel dit moeilijk te zeggen was aangezien er in de groep mensen maar weinig waren die die 
bepaalde genafwijking hadden. 
In hoofdstuk 4 kijken we verder naar bepaalde SNPs in autophagy maar nu in patiënten met TB. We 
zochten in een Indonesische populatie van 1000 TB patiënten en een vergelijkbare controlegroep naar 
het vóórkomen van deze 14 SNPs om zo vast te stellen of het hebben van één van deze SNPs zorgt dat 
iemand sneller TB krijgt. Dat bleek niet het geval, ook niet als we keken naar een bepaalde soort MTB 
stam die in Indonesië veel voorkomt. In de literatuur was eerder wel een effect van bepaalde SNPs op 
het krijgen van TB beschreven in populaties met een ander etniciteit. Dit geeft aan hoe complex TB 
en de immuunrespons tegen MTB is. Er zijn verschillende MTB stammen die zich anders gedragen 
en waarop de immuunrespons ook kan verschillen. Verder is het immuunsysteem van alle mensen 
een klein beetje anders geworden gedurende de evolutie en kunnen er daarom tussen mensen met 
verschillende etniciteit grote verschillen ontstaan in immuunresponsen.
In hoofdstuk 5 gaven we een overzicht over alle PRRs en signaleringspaden die betrokken zijn 
bij de herkenning van MTB. Dat deze onderdelen in de immuunrespons belangrijk zijn blijkt uit 
de talloze associaties studie naar mensen met gendefecten in deze onderdelen en hun kans op het 
ontwikkelen van TB. Overigens worden deze associaties niet in alle studies bevestigd zoals hierboven 
ook reeds beschreven. Ook hebben verschillende PRRs verschillende effecten sommige (TLRs, 
NLRs en dectin-1) hebben met name een actieve inflammatoire respons terwijl andere (DC-SIGN 
en MR) de immuunrespons reguleren en in te dammen. Aangezien er meerdere receptoren tegelijk 
worden geactiveerd als een cel in contact komt met MTB leidt dit tot een complex geïntegreerde 
immuunrespons.   
Deel 2: BCG geïnduceerde trained immunity
BCG is het vaccin tegen TB, het werd al in de jaren 20 ontdekt en in gebruik genomen en is een van 
de meest gebruikte vaccins wereldwijd. Kort na de introductie viel op dat er niet alleen minder TB 
voorkwam maar dat kinderen ook minder stierven door andere oorzaken. In dit deel van het proefschrift 
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beschreven we een mogelijke biologische verklaring voor deze niet-specifieke effecten van BCG.
De immuunrespons bestaat uit 2 onderdelen: het aangeboren en het verworven deel, ze beïnvloeden 
elkaar maar het blijven aparte onderdelen. Het aangeboren immuunsysteem geeft de eerste respons, 
reageert snel en er werd gedacht dat de respons ook altijd hetzelfde was. De verworven immuunrespons 
duurt langer om te vormen maar is specifiek gericht op de microbiële dreiging en deze respons vormt 
een geheugen om bij dezelfde dreiging de volgende keer sneller te kunnen reageren. Meer en meer 
artikelen worden gepubliceerd over geheugenfuncties in cellen van het aangeboren immuunsysteem. 
Het lijkt dus dat de oude fundamenten van de immunologie aan herziening toe zijn. Recent is er vanuit 
onze researchgroep de term ‘trained immunity’ geopperd om dit fenomeen te beschrijven. Trained 
immunity beschrijft een reactieverandering in cellen van het aangeboren immuunsysteem wanneer 
ze na een eerste contact met (bv) BCG  anders reageren in een volgend contact met een pathogeen. 
De zogenaamde training of leerbaarheid van deze cellen. Ze reageren dus niet continue hetzelfde 
maar kunnen hun respons aanpassen op basis van eerdere gebeurtenissen. In het geval met een eerder 
contact met BCG leidt dit tot een verbeterende respons tegen de volgende microbiële dreiging. 
In hoofdstuk 6 beschreven we het concept van trained immunity voor de eerste keer in mensen. In 
vrijwilligers die een BCG vaccinatie kregen zagen we een verbetering van hun cytokine productie 
en veranderingen van receptoren (oa PRRs) op hun cellen ten opzichte van voor de vaccinatie. Dit 
effect hield aan tot wel 3 maanden na de vaccinatie. Om de onderliggende moleculaire mechanismes te 
ontrafelen ontwikkelden we een in vitro model waarbij we immuuncellen buiten het lichaam ‘trainden’. 
Dankzij dit model vonden we dat betere respons kwam doordat sommige immuungerelateerde genen 
beter bereikbaar werden en daardoor hun informatie makkelijker konden ter beschikking konden 
stellen. Verder lieten we zien dat NOD2 (een PRR) noodzakelijk is voor BCG geïnduceerde trained 
immunity. Als laatste bewezen we de klinische relevantie in een diermodel. Muizen zonder cellen 
van het verworven immuunsysteem (SCID) kregen een letale hoeveelheid Candida albicans toegediend, 
één groep kreeg 2 weken ervoor een BCG vaccinatie de andere groep een nep vaccinatie. De BCG 
gevaccineerde dieren overleefden dit allemaal terwijl van de nep gevaccineerde dieren meer dan de 
helft stierf. Aangezien deze dieren geen functioneel verworven immuunsysteem had bewijst dit dat 
de effecten van BCG zoals hierboven beschreven toegeschreven kunnen worden aan het aangeboren 
immuunsysteem. 
Aangezien trained immunity een nieuw beschreven fenomeen is, is het belangrijk te weten hoelang 
dit aan zou kunnen houden. Daarom was dit onderwerp van hoofdstuk 7. Opnieuw keken we in 
BCG gevaccineerde vrijwilligers naar hun respons op andere pathogenen voor en na de vaccinatie. 
De veranderingen in de celreceptoren waren nog aanwezig een jaar na vaccinatie echter sommige 
cytokines werden in dezelfde hoeveelheden geproduceerd als voor de vaccinatie. Dit gold niet voor 
alle cytokines, de cytokines geproduceerd door T cellen (IFNg, IL17 en IL22) bleven hoger dan voor de 
vaccinatie en deze blijvende verhoging bleef ook te zien als TLR4 (een PRR) geactiveerd werd. 
Een ander belangrijk aspect van trained immunity is of het geldt voor alle cellen van het aangeboren 
immuunsysteem. In de vorige hoofdstukken bekeken we de rol van monocyten; in hoofdstuk 8 werd 
een ander celtype van het aangeboren immuunsysteem onder de loep genomen, de natural killer cel 
(NK cel). Zoals bij de monocyten zagen we dat de NK cellen van mensen na de BCG vaccinatie meer 
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cytokines gingen produceren. Verschillen in de celreceptoren konden we niet waarnemen. Verder 
herhaalden we het experiment met de muizen zonder actief verworven immuunsysteem waarbij de 
voor dit hoofdstuk ook een groep muizen toevoegden die geen NK cellen hadden (NSK). Het effect 
van BCG op deze NSK muizen was minder dan het effect op de SCID muizen, wat laat zien dat NK 
cellen een rol spelen in deze bescherming door BCG. In hoofdstuk 9 gaven we een historisch overzicht 
over niet-specifieke effecten van vaccins en bespraken de recente ontdekkingen in de onderliggende 
biologisch mechanismes. 
Conclusies en toekomstperspectieven
Immuunrespons tegen MTB is complex en bestaat uit vele complementaire onderdelen die ook elkaar 
onderling beïnvloeden. En bij sommige van deze onderdelen is de klinische implicatie niet altijd 
duidelijk;  met andere woorden, ook al functioneert een onderdeel niet leidt dat niet altijd tot TB. 
Gendefecten lijken ook relevanter bij sommige MTB stammen, ook dat zou een startpunt kunnen zijn 
van onderzoek, wat maakt een bepaalde stam zo gevoelig voor een bepaalde PRR? MTB bestaat al 
40.000 jaar en heeft zich in die tijd kunnen aanpassen aan de zwakke plekken in ons immuunsysteem. 
Ook het humane immuunsysteem aan evolutie onderhevig en samen leidt dit tot co-evolutie. De mens 
en de bacterie passen zich aan elkaar aan en proberen steeds aan elkaar te ontsnappen. Door meer 
kennis hierover zouden we uiteindelijk misschien wel personalised medicine kunnen toepassen bij TB 
voor zowel de gastheer als het pathogeen. 
Als we de immuunrespons beter begrijpen zouden we misschien ook in staat zijn ons vaccin te 
verbeteren. Daar wordt al volop onderzoek naar gedaan maar de kandidaatvaccins die getest zijn 
leveren helaas geen duidelijke verbetering op. Ondanks dat BCG niet heel goed beschermt tegen TB 
weten we nu dat het duidelijke niet-specifieke effecten heeft wat zal bijdragen aan de immuunrespons. 
Deze voordelen van BCG zouden meegenomen moeten worden indien er een vervanging van dit vaccin 
voor handen is. Het feit dat cellen van het aangeboren immuunsysteem trainbaar zijn in hun respons 
is een totaal nieuw veld van onderzoek met vele mogelijke implicaties. Bijvoorbeeld het optimaliseren 
van het aangeboren immuunsysteem voor de start van medicatie die het immuunsysteem beïnvloed 
(zoals chemotherapie). Ook wordt BCG wel als booster voor andere vaccins gebruikt mogelijk 
werkt dit op dezelfde manier; het optimaliseren van het aangeboren immuunsysteem leidt tot beter 
totstandkoming van de verworven respons. 
Kortom, dit proefschrift heeft bijgedragen aan onze kennis over de immuunrespons tegen 
mycobacteriën en aan de belangrijke ontdekking; trainbaarheid van cellen van het aangeboren 
immuunsysteem. Door deze nieuwe informatie ontstaan er nieuwe onderzoeksuitdagingen met 
belangrijke gezondheidsimplicaties wereldwijd. 
169
DANKWOORD
Het boekje is af! Mijn naam staat er boven maar zonder een aantal mensen was het me niet gelukt 
(of was het in ieder geval een stuk minder leuk geweest) en daarom wil ik een paar mensen specifiek 
bedanken.
Als allereerste natuurlijk mijn promotor en copromotor.
Professor doctor M.G. Netea, Mihai, zonder jou was het hele idee er niet geweest. Ik wilde graag een 
PhD. bij jou doen en ik mocht zelf mijn micro-organisme kiezen; het werd M. tuberculosis en het project 
was geboren. Dat je me daarnaast ook aan ‘jouw trained immunity’ hebt laten werken, vind ik een eer. 
Hoe jouw brein werkt; de snelheid van inzicht en verbindingen leggen is onnavolgbaar maar je heldere 
uitleg en je aanstekelijke enthousiasme maakten dat ik altijd vol energie én plannen je kamer uitliep. 
Doctor R. van Crevel, Reinout, zonder jou had het boekje er een stuk minder leesbaar uitgezien. Het 
is indrukwekkend hoe jij met weinig woorden de essentie weet over te brengen. Van jou heb ik (een 
beetje) leren schrijven. Het was af en toe of we een verschillende taal spraken maar toen ik je ben gaan 
verstaan, ben ik je enorm gaan waarderen niet alleen als onderzoeker maar ook als arts. Je bent een 
voorbeeld in hoe deze twee rollen te combineren. 
Naast PhD-student was ik ook internist-in opleiding; het afwisselen van bench en bedside was soms 
zwaar maar ook erg waardevol. Ik wil daarom mijn opleiders, Jos van der Meer, Jacqueline de Graaf, 
Jan Smit, Bart-Jan Kullberg en Aart Mudde bedanken voor de mogelijkheid deze combinatie uit te 
voeren en jullie vertrouwen in mij. 
Al had ik een (beperkte) lab-achtergrond voor het onderzoek heb ik veel bij moeten leren en de 
analisten van lab EIG stonden altijd voor me klaar. Bedankt Anneke, Cor, Heidi, Helga, Ineke, Johanna, 
Liesbeth, Magda en Trees. En natuurlijk al mijn collega’s op het lab. In die 5 jaar dat ik er afwisselend 
was zijn er teveel geweest om op te noemen, maar iedereen bedankt voor jullie hulp en gezelligheid!
A special thank-you goes to Seph Borrow who luckily accepted me to come and work in her lab on a 
joined interest for a couple of months. Seph, thanks for your great support and believe in me and our 
project. Working in your lab opened my eyes for possible future projects I would not have dared to 
dream of. Furthermore, I want to thank my colleagues in Seph’s group; Katia, Angharad, Tom, Ceci and 
especially Isabela who helped me enormously finding my way in NK-land. 
Verder wil ik al mijn mede-auteurs bedanken voor goede discussies en hun bijdrage aan mijn 
uiteindelijke publicaties. In het bijzonder wil ik de volgende mensen noemen. Jos van der Meer; voor 
je inhoudelijk en stijl-gerelateerde commentaar op mijn stukken en je kritische vragen tijdens de 
cytokine meetings. Leo Joosten; voor het geweldig leiden van het lab en je praktische en humoristische 
inzichten. Christine Stabell Benn and Peter Aaby for the opportunity to be, for a small part, involved in 
your impressive research about non-specific effects of vaccines. Jessica Quintin for all our collaboration 
on the trained immunity papers.  
Niemand kan zonder vrienden en ik al zeker niet. Wat jullie allemaal voor me doen en voor mij over 
hebben, vooral als ik weer eens in het buitenland verbleef (eindeloos skypen, lieve brieven/kaartjes voor 
170
de moeilijke momenten en me zelfs komen opzoeken) vind ik echt fantastisch. Altijd een luisterend 
oor, soms goede adviezen maar vooral die o zo belangrijke afleiding met de vele leuke momenten 
hebben me zoveel geholpen! Uit een grote groep vrienden heb ik uiteindelijk 2 gekozen als paranimfen, 
Bianca en Marye.
Bianca jij bent er als afvaardiging van ‘de meiden’; wij kennen elkaar al sinds het begin van de studie en 
hebben met z’n zessen zoveel meegemaakt! Ik heb jou gekozen omdat we een hele goede band hebben 
en omdat je van de vijf als enige weet hoe het voelt om te promoveren. 
Marye, sinds wij elkaar leerden kennen in Doetinchem zijn we door de vele gezamenlijke autoritjes 
hele goede vriendinnen geworden. Dat we een heel deel van de opleiding maar ook het promotietraject 
tegelijk hebben gedaan maakte dat we ook soms tegen dezelfde dingen aanliepen. En wat is het dan fijn 
daar samen over te kunnen klagen! 
Ik ben zo blij dat jullie op 22 september naast mij staan!
Marieke, nu heb je wat te laten zien als mensen vragen wat je zusje doet. Dit is het resultaat van ‘de 
onderzoekskant van de medische wereld’ ;) En misschien kun je er zelfs wel wat meer over vertellen 
na mijn lekenpraatje. Jij en Bram bedankt voor de fijne momenten in Denemarken (sinterklaas!) en dat 
jullie me hebben laten voelen wat het is om tante te worden.
Jan en Janne, bij jullie voel ik me bijna zo thuis als thuis. De treinreizen van en naar Amsterdam stonden 
misschien wel vaak in het teken van mijn promotie maar als ik bij jullie was, was er ruimte voor andere 
dingen. We staan hetzelfde in het leven en ik ben blij met mijn rol in Jonas’ leven. 
Pap en mam, zonder jullie opvoeding was dit boekje er vast ook niet geweest. Jullie hebben me geleerd 
altijd het beste uit mezelf te willen halen, door te zetten en hard te werken. En laat dat nu net het 
belangrijkste zijn om een PhD. project tot een goed einde te brengen! Bedankt voor jullie steun en 
goede voorbeeld.
171
PUBLICATION LIST
1. Kleinnijenhuis, J, van Crevel R, and Netea MG. Trained immunity: consequences for the 
heterologous effects of BCG vaccination. Trans R Soc Trop Med Hyg. 2015;109:29-35
2. Kleinnijenhuis, J,  Quintin, J, Preijers, F, Joosten, LAB, Jacobs, C et. al. BCG-induced trained 
immunity in NK cells: role for non-specific protection to infection. Clin Immunology. 2014;155:213-
9
3. Buffen K, Oosting M, Quintin J, Ng A, Kleinnijenhuis J et. al. Autophagy controls BCG-induced 
trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 
2014;10(10):e1004485
4. Kleinnijenhuis, J, Quintin, J, Preijers, F, Benn CS, Joosten, LAB et. al. Long-lasting effects of BCG 
vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate 
Immun 2014;6(2):152-8
5. Van Laarhoven, A, Mandemakers, JJ, Kleinnijenhuis J, Enaimi, M, Lachmandas, E et. al. Low 
induction of proinflammatory cytokines parallels evolutionary success of modern strains within 
the Mycobacterium tuberculosis Beijing genotype. Infect Immun 2013;81(10):3750-6
6. Kleinnijenhuis, J, vd Molen, R, Franssen, P, Berden, JH, van der Meer, JWM. et. al. Ribosomal 
P antibodies as a single serological marker in SLE: lupus in disguise. Scand J Rheumatol 
2013;42(2):165-6
7. Kleinnijenhuis, J, Quintin, J, Preijers, F, Joosten, LAB, Ifrim, DC et. al. BCG induces NOD2-
dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. 
Proc Natl Acad Sci USA. 2012;109:17537-42
8. Kleinnijenhuis, J, Songane, M, Alisjahbana, B, Sahiratmadja, E, Parwati, I et. al. Polymorphisms in 
autophagy genes and susceptibility to tuberculosis. PLos One 2012;7(8):e41618. 
9. Songane M, Kleinnijenhuis, J, Netea, MG, van Crevel, R. The role of autophagy in host defence 
against Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2012;92:388-96
10. Kleinnijenhuis, J, Oosting, M, Plantinga, TS, van der Meer, JWM, Joosten, LAB et. al. 
Autophagy modulates the Mycobacterium tuberculosis-induced cytokine response. 
Immunology.2011.134:341-8
11. Kleinnijenhuis, J, Oosting, M, Joosten, LAB, Netea, MG, van Crevel, R. Innate immune recognition 
of Mycobacterium tuberculosis. Clin Dev Immunol. 2011:405310.
12. van de Veerdonk, FL, Teirlinck, AC, Kleinnijenhuis, J, Kullberg, BJ, van Crevel, R et. al. 
Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically 
dependent on endogenous IL-1. J Leukocyte Biol 2010;88:227-232
13. Kleinnijenhuis, J, Joosten, LAB, van der Veerdonk, FL et. al. Transcriptional and inflammasome-
mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis. Eur 
172
J Immunol 2009;39:1914-22
14. Aarnoutse, RE, Kleinnijenhuis,J, Koopmans, PP, Touw, DJ, Wieling, J et. al. Effect of low-dose 
ritonavir (100mg twice daily) on the activity of CYP2D6 in healthy volunteers. Clin Pharmacol 
Ther 2005;78:664-674
15. Van Horssen, J, Kleinnijenhuis, J, Maass, CN, Rensink, AA, Otte-Höller, I et. al. Accumulation 
of heperan sulphate proteoglycans in cerebellar senile plaques. Neurobiol Aging 2002;23:537-545
16. Aarnoutse, RE, Verweij-van Wissen, CPWGM, Underberg, WJM, Kleinnijenhuis, J et. al. High 
performance liquid chromatography of HIV protease inhibitors in human biological matrices. J 
Chromatogr B Biomed Sci Appl. 2001;74(1-2):363-384    
H
O
ST
 R
ESPO
N
SE TO
 M
YC
O
BAC
T
ER
IA
: IN
N
AT
E R
EC
O
G
N
IT
IO
N
 A
N
D
 M
EM
O
RY
                   JO
H
A
N
N
EK
E  K
LEIN
N
IJEN
H
U
IS
HOST RESPONSE 
TO MYCOBACTERIA: 
INNATE RECOGNITION 
& MEMORY
JOHANNEKE  KLEINNIJENHUIS
UITNODIGING 
 
voor het bijwonen 
van de openbare verdediging  
van mijn proefschrift  
Host response to 
mycobacteria: innate 
recognition & memory 
op dinsdag 
22 september 2015  
om 14.30 uur  
Aula Radboud Universiteit 
Nijmegen 
Comeniuslaan 2 te Nijmegen
 
Receptie na afloop van de 
promotie  
’t Sfeerhuys, 
Looimolenweg 15 te 
Nijmegen 
Johanneke Kleinnijenhuis 
koninginnelaan 207  
6542ZR Nijmegen 
johanneke.kleinnijenhuis@
radboudumc.nl
Paranimfen
Bianca Snijders 
Marye Boers-Sonderen 
johannekepromoveert@gmail.com
ABOUT THE AUTHOR 
Johanneke Kleinnijenhuis was born in Den Ham on March 21th 1979. After 
completing secondary school (Augustinus College, Groningen and Menso 
Alting College, Hoogeveen)  she studied Biomedical (Health) Science at 
the Radboud University, Nijmegen from 1997-2001. She obtained research 
experience during two internships in the Radboudumc at the departments of  
Pathology and Clinical Pharmacy . In 2001 she started with Medicine and 
went abroad for two international internships during that study. The first one 
was in the Hospital Dr. Humberto Alvarado Vasquez, Masaya, Nicaragua. She 
finished her medical degree in the Sengerema Designated District Hospital, 
Tanzania in 2006. Later that same year she began her residency Internal 
Medicine at the Radboudumc (prof. dr. Jos van der Meer, Prof. dr. Jacqueline 
de Graaf, and Prof. dr. Jan Smit).  In 2008 she continued her residency at 
the Slingeland Hospital in Doetinchem (Dr. A Mudde). During that time she 
started to discuss the possibility of  doing a PhD project with Prof. Dr Mihai 
Netea which resulted in a personal grant from the Radboudumc in 2009. 
She started the project “Host response to mycobacteria; innate recognition 
and memory” in 2010 and alternated research and clinical work until 2015. 
During her PhD project she visited Seph Borrow’ group at Oxford university 
for four months to work on a joined project. From November 2012 till August 
2015 she continued her medical training as registrar infectious diseases (Prof. 
dr. BJ Kullberg) and worked during that time four months in the Academic 
Hospital Paramaribo, Suriname.
UITNODIGING  
Ter gelegenheid 
van de promotie van 
Johanneke Kleinnijenhuis  
nodigen wij u graag uit 
voor het promotiefeest  
op 22 september 
van 20.00-24.00 
in 't Sfeerhuys, 
Looimolenweg 15 
te Nijmegen 
graag vernemen we 
voor 8 september 
of  u bij het feest 
aanwezig zult zijn. 
De paranimfen
Bianca Snijders 
Marye Boers-Sonderen 
johannekepromoveert@gmail.com
